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1.1. Introduction 
 
Yearly, almost half a million people die and three to five million people become severely ill after an 
influenza virus infection 1. Furthermore, infection with influenza A viruses can occur as pandemic 
outbreaks, which spread rapidly worldwide and are usually more severe and lethal 2. Despite global 
surveillance efforts to trace circulating influenza viruses, the predictability of seasonal influenza 
outbreaks during winter seasons and the availability of fairly effective vaccines, influenza has a huge 
social and economic impact on society. Influenza vaccination is undoubtedly a cost-effective 
intervention, and the global influenza vaccine market is a multibillion dollar business 3,4. Hence, there 
are strong economical as well as medical incentives for improving currently licensed influenza 
vaccines. In addition, since their discovery in 1933, influenza viruses and their interactions with the 
vertebrate host have continued to attract the interest of researchers in virology, immunology and 
vaccinology 5. 
Hemagglutinin (HA) and neuraminidase (NA) are the two membrane glycoproteins of influenza A and 
B viruses. Both HA and NA are expressed abundantly on the surface of infected cells. On the surface 
of influenza A and B virions they form spikes that can easily be discerned in electron micrographs 6. 
HA allows the virions to bind to human airway epithelial cells via surface receptors containing sialic 
acid residues. Because of their abundance and accessibility, HA and NA draw most of the 
immunological attention in response to an infection. In accordance with Jenner’s approach, licensed 
influenza vaccines (in use since the 1940s) aim to induce HA-specific and to a lesser extent NA-
specific humoral responses in vaccines as occurs during the recovery from natural infection. 
However, the continuous antigenic variations in HA and NA, known as drift, allow the virus to bypass 
humoral immunity built up against these antigenic determinants during previous infections or in 
response to prior influenza vaccination. This antigenic drift makes annual vaccinations necessary for 
protection against influenza disease. Vaccination is effective when the vaccine antigenically matches 
the circulating virus strains. Accurate predictions of the epidemic strains that will circulate the next 
influenza season are sometimes difficult to make, and inaccurate matching might lead to failure of a 
vaccination campaign. When a new virus subtype emerges, a phenomenon called antigenic shift, or a 
virus with an HA that is antigenical profoundly different from recent seasonal strains (e.g. the H1N1 
2009 pandemic virus), little or no preexisting cross-reactive humoral immunity against HA or NA will 
be present in the majority of the population and the virus can spread worldwide. Yearly updates of 
influenza vaccines also challenge the vaccine-industry because it is difficult to produce enough 
vaccines quickly, and stockpiling is not an option. As a result, only a small part of the population can 
be actively vaccinated. Vaccines that protect against multiple strains or even subtypes of influenza 
could avoid several problems: such vaccines could be produced in advance, used in the general 
population, stockpiled, and they could provide prolonged protection. For these reasons, there is 
considerable interest in cross-protective or universal vaccines. 
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1.2. Natural pandemic immunity in humans: lessons from the past 
 
Four major pandemics have plagued man during the past century (Figure 1.1). The Spanish Flu 
(H1N1) in 1918 was by far the severest, causing 40-50 million deaths worldwide 7. One should take 
into account the lack of adequate medical supplies and the lack of antibiotics to treat the frequent 
secondary bacterial infections, but nonetheless experimental infections of mice, ferrets and 
cynomolgus macaques with reconstructed 1918 H1N1 influenza virus confirm the unusual virulence 
of this virus strain. The pandemic of 1957 (H2N2; Asian Flu) and 1968 (H3N2; Hong Kong Flu) were 
less severe, but still responsible for 1.5 and 0.5 million deaths worldwide, respectively, within a single 
flu season. Importantly, the latter two pandemics occurred after the identification of influenza virus 
as the causative agent of influenza, at which time the field of virology was already largely developed, 
and so valuable immunological and epidemiological data are available about them. For instance, the 
Cleveland Family Study performed before and during the 1957 pandemic showed that adults, who 
had been infected with the previously circulating H1N1 virus, were unlikely to exhibit H2N2 influenza 
symptoms. By contrast, children who had contracted H1N1 in previous years were far less protected 
against H2N2 infection than adults 8. This suggests that natural, recurrent pre-exposure to an H1N1 
virus over a long period of time can provide protection against a heterosubtypic strain. 
Epidemiological data from the 1968 pandemic also revealed an interesting aspect of natural 
heterosubtypic immunity. In Europe and Asia, influenza-related mortality was relatively infrequent 
during the 1968 pandemic year, but was much more frequent during the second year. It turned out 
that the 1968 H3N2 pandemic virus had retained the N2 gene of the H2N2 ascendant. The increased 
mortality observed during the 1969-1970 influenza season coincided with antigenic drift of NA of the 
H3N2 virus, making it more antigenically distinct from the NA of H2N2 compared to the prior 
(pandemic) season 9. This epidemiological observation indicates that also pre-existing anti-NA 
immunity can temper the severity of a pandemic 10. 
The latest establishment of a human-transmissible shifted influenza strain, the 2009 H1N1 pandemic 
(H1N1/09), provided more detailed information about possible natural cross-protective mechanisms. 
The most remarkable fact was the lack of intrasubtypical immunity, potentially provided by recurrent 
seasonal H1N1 vaccination or infection. It soon became clear that trivalent seasonal vaccines did not 
provide protection against pandemic H1N1/09 infection, based on classic criteria of 
haemagglutination inhibition (HI) titers 11. The same study also showed that people over 60 years old 
contain much higher HI titers compared to people under 30 years old, results which were 
corroborated by numerous other studies 12-15. These observations can be linked to the circulation of 
early 20th century H1 strains, structurally and antigenically closer related to the pandemic virus then 
more recent strains 16. Likewise, the contested vaccination campaign aimed at preventing a potential 
swine flu pandemic in 1976 did offer some protection against the H1N1/09 pandemic 17.  
So it seems that recurrent infections or vaccinations during interpandemic periods may provide some 
degree of heterosubtypic immunity that can mitigate the clinical outcome of infection with a 
subsequent pandemic influenza strain. However, there needs to be a certain degree of relation 
between seasonal/vaccination strains and the pandemic virus, be it based on conservation of HA 
and/or NA epitopes or on shared internal epitopes. However, the nature of the NA subtype of the 
influenza virus that will cause the next pandemic remains as much an enigma as that of HA, although 
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apparently NA has a slightly lower drift rate than HA 18. Are there influenza vaccine approaches that 
could mimic the level of natural cross-protective immunity induced after recurrent natural exposure? 
Are there other approaches that could lead to a pandemic influenza vaccine? The answers to these 
questions require a closer look at the conserved antigens of the influenza virus and finding ways to 
make them immunoprotective in a safe and effective way. 
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Figure 1.1. Seasonal, pandemic and zoonotic human influenza of the past 100 years. Since 1900, five pandemics have 
plagued the human population: Spanish flu (H1N1) in 1918, Asian flu (H2N2) in 1957, Hong Kong flu (H3N2) in 1958, Russian 
flu (H1N1) in 1977 and most recently Mexican flu (H1N1) in 2009. Of these, H3N2 strains related to the Hong Kong flu and 
H1N1 strains related to Mexican flu currently circulate as seasonal IAV strains in the human population. The Mexican flu 
originated from reassortment of the triple reassortant swine H1N1 strain and the Eurasian avian-like swine H1N1; the 
generated strain crossed the species barrier, establishing itself in the human population. Likewise, a number of other swine, 
equine and avian viruses have infected  individuals, but these have been restricted to small-scale zoonotic scares. 
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1.3. Heterosubtypic immunity and classical vaccines: formulation is critical 
 
Currently, licensed inactivated influenza vaccines contain three different viral strains: influenza 
A/H1N1, A/H3N2 and one influenza B strain. Vaccines are produced by growing viral seed strains, 
issued by the WHO, in embryonated chicken eggs; however, alternative production methods based 
on tissue culture methods are being explored by a number of vaccine manufacturers and research 
groups 19,20. Three main methods are available for inactivation of produced viruses. In a first method, 
virions are partially purified by zonal gradient centrifugation followed by inactivation with formalin or 
β-propiolactone. Untill the 1970s, whole inactivated virus (WIV) manufactured this way was the main 
formulation of influenza vaccines. However, although they are generally regarded as more 
immunogenic 21, WIV are also more reactogenic, particularly in children 22-24. Therefore, more pure 
formulations have been produced. In split vaccine formulations, purified virions are treated with 
detergents or ethyl ethers, leading to inactivation of the virus and disruption of the virionic integrity. 
This allows further partial purification by mainly centrifugal techniques, leading to a less reactogenic 
vaccine. If the viral surface antigens HA and NA are purified further to obtain a formulation which is 
mainly consisting of these proteins, a subunit vaccine is obtained. In all cases, each dose of vaccine 
should be normalized to contain 15µg of HA for each viral strain used. Main vaccines used today in 
the Belgian market are the split vaccines Alpharix® (GSK) and Vaxigrip® (Sanofi-Pasteur) and the 
subunit vaccine Influvac® (Abbott Biologicals). 
Despite the notion that immune protection by conventional inactivated influenza vaccines (including 
split and subunit vaccines) is highly strain-specific, these vaccines can provide more broad protection. 
A critical parameter is the preservation of the virion structure during the inactivation process, and 
whole virus vaccines, which are not often used anymore, can provide a considerable degree of 
heterosubtypic immunity, at least in animal models of human influenza 25. Formalin-inactivated virus, 
when administered intranasally without adjuvant, was superior in providing cross-protection than an 
ether-split vaccine, and even protected mice against an H5N1 challenge (A/HongKong/483/97). The 
mechanism responsible for this cross-protection is unknown but a role for mucosal IgA antibodies 
was suggested. The particulate nature of formalin-inactivated vaccines, which have a liposome-like 
structure, is more stable than ether-split vaccines, less prone to degradation, and has intrinsic 
adjuvant properties. By contrast, split vaccines are less immunogenic, especially when no adjuvant is 
included 25. A more recently evaluated procedure for virus inactivation makes use of the non-toxic 
photoactivatable alkylating membrane probe, 1,5-iodonaphtylazide (INA). This hydrophobic chemical 
targets transmembrane domains of proteins and accumulates there. Upon UV-irradiation, membrane 
proteins and lipids are covalently bound by INA. This leads to inactivation of the targeted 
transmembrane protein, but the overall structure is preserved and the virion can initiate membrane 
fusion 26. Remarkably, INA-inactivated X31 (H3N2) virus elicited protective humoral and cellular 
responses in mouse comparable to live X31 virus infection and, moreover, was protective against 
heterosubtypic (H1N1) challenge 27. These results suggest that application of whole virus vaccines 
should be considered, perhaps following improvement of currently used chemical inactivation 
procedures. Whole virus influenza vaccines, however, are not only less pure, but also usually more 
reactogenic, confirming the saying that a good immune response has its price. 
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Immunization with inactivated viruses does not elicit strong protective immunity, and high dosing is 
usually required for an effective response. Particularly, mucosal administration of non-replicating 
antigens is associated with poor immune responses. A solution to this problem could come from 
bacterial holotoxins. These represent a bacterial protein family, of which the members have been 
known since a long time as strong mucosal adjuvants. As their name implies, toxicity has been the 
main impediment to clinical application, but recent developments might have overcome this 
problem. Two different molecular approaches have been used to remove toxicity without affecting 
mucosal adjuvant activity. Bacterial holotoxins are composed of an ADP-ribosylating A subunit that is 
associated with a pentameric B-domain that binds to gangliosides present on the outer membrane of 
almost all mammalian cells. Most of the approaches that reportedly prevent toxicity of these 
bacterial holotoxins were aimed at inactivating the enzyme. For example, an E. coli heat-labile 
enterotoxin detoxified in this way, LT(R192G), was combined with inactivated H3N2 vaccine. When 
given intranasally to mice, this vaccine induced substantial heterosubtypic protection, even against 
challenge with the A/HongKong/483/97 virus (H5N1) 28. Other adjuvants that have been used mainly 
for parenteral vaccination may also function as mucosal adjuvants. For example, the synthetic toll-
like receptor 3 agonist, poly(I):poly(C(12)U), also augments immune responses directed against 
intranasally administered inactivated vaccine and provides heterosubtypic immunity in mice 29. 
From these and other studies it has become clear that the route of administration is a key factor for 
inducing heterosubtypic immunity, and the same vaccine formulation given parenterally usually does 
not give the same protection as mucosal delivery 25,28,29. Since airway mucosal sites are the entry port 
of influenza virus, protection is most likely achieved by providing a frontline defense in the 
respiratory tract in the form of local IgG and IgA antibody induction and/or cross-protective T cell 
responses. Intranasal, oral or even sublingual administration of classical vaccines as well as new, 
recombinant vaccines, with or without specific adjuvant, could become realistic alternatives for 
vaccination against influenza and other pathogens 30,31. 
Without novel generation adjuvantation systems however, the protection induced by inactivated 
viruses remains strictly strain-specific. This has been very clearly shown by the Bodewes et al. in the 
group of Guus Rimmelzwaan. Based on the premises that there is evidence that recurrent infection 
with seasonal influenza can induce heterosubtypic immunity based on cellular immunity 8,32,33 and 
that vaccination with inactivated viruses does not elicit cellular responses effectively 34, they 
designed experiments showing that inactivated virus vaccination abrogates induction of natural 
cross-immunity. Naive mice were immunized with split vaccine 35 or whole inactivated virions (WIV) 
36 based on seasonal A/H3N2 virus, or mock-immunized. Following a non-lethal A/H3N2 infection, 
vaccinated mice were found to be strongly protected from morbidity, while mock-immunized 
animals developed clear disease systems and lung virus titers. With a subsequent challenge using a 
potential lethal dose of A/H5N1 virus, previously protected mice succumbed to the infection, while 
initial mock-immunized mice showing morbidity after the A/H3N2 infection survived with reduced 
signs of morbidity. This observation could be attributed to the induction of cross-reactive cytotoxic T 
cell (CTL) responses and shifts in immunodominance of elicited responses. Together with the 
aforementioned epidemiological data, these results favor the induction of cross-reactive CTL 
responses to achieve broad protection against influenza infection. The non-neutralizing nature of 
such immunity does imply infection cannot be blocked; however, it may subside to subclinical level. 
Moreover, each infection could further boost or broaden cellular immunity to combat antigenically 
distinct strains.  
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1.4. The influenza hemagglutinin: revisiting an old foe 
 
Vaccination with inactivated virions evokes strong humoral responses that protect against 
homologous, i.e. serologically matching, virus strains. In the case of influenza, this protection is very 
narrow, and protection is lost or severely compromised when an antigenically drifted influenza virus 
infects the vaccinated host. Nevertheless, currently licensed influenza vaccines use inactivated 
virions or HA-containing subunit preparations with an antigenic profile based on strains which 
according to WHO guidelines are most likely to cause the next epidemic. Such antigenically matching 
immunity is largely confined to the viral HA. Also natural humoral immunity against influenza A and B 
viruses predominantly targets the so-called major antigenic determinants in HA 37-39. HA-specific 
antibodies can neutralize the virus by preventing it from attaching to the cell membrane 40; in 
addition, these antibodies might interfere with membrane fusion (figure 1) 41. Such immunity is often 
referred to as sterilizing immunity, based on extrapolating the in vitro activity of HA-specific 
neutralizing antibodies to influenza virus infection in vivo. Indeed, neutralizing antibodies can be 
detected and measured by a hemagglutination inhibition (HI) or a microneutralization assay. Under 
such immunological pressure, there is a strong selection of mutant viruses that avoid the virus-
neutralizing effect of HA-specific antibodies. The high error frequency of influenza virus RNA 
polymerase, along with the high degree of antigenic freedom within the immunological determinants 
of HA, allows seemingly endless cycles of such escape from immune protection. 
Though HA is an elusive antigen, it remains a relevant target of vaccination. HA-specific antibodies 
can act as gatekeepers to prevent influenza infection, because of its pivotal role in the influenza life 
cycle: attachment of the virus to the host cell, endocytosis of the virus, and fusion of the viral 
envelope with the cell membrane (figure 1) 39,42. This has been acknowledged by many, and a 
number of different strategies have been tested to exploit the HA antigen in a more structured 
manner (Figure 1.2.). But one critical aspect that should be taken into account is the presence of 
mainly conformational epitopes within the protein. This was illustrated by Green et al., who showed, 
using a HA-based peptide library, that although anti-peptide antibodies can recognize HA, anti-HA 
antibodies do not bind to the linear peptides 43. This apparent contradiction exemplifies the 
complexity of the HA molecule and the resulting difficulties to design novel HA-based vaccines with 
broader efficacy. 
 
1.4.1 Broadly reactive anti-HA responses: deconstructing the antigen 
 
Early studies, based on primary sequence analysis of the HA gene, showed that there are conserved 
regions in HA. For example, the HA2 subunit, which provides the peptide needed for membrane 
fusion and release of the viral genetic material into the cytosol 39,44-46, shows sequence and structural 
conservations even between influenza A and B 47-49. The group of Peter Palese took advantage of this 
structural conservation to investigate whether the HA2 subunit can induce protective responses. 
However, HA1 and HA2 associate tightly within the trimeric molecule. Therefore, to unmask HA2 and 
present it to the immune system, the membrane-distal HA1 subunit of HA has to be removed. In an 
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initial study 50, acid treatment combined with chemical reduction or enzymatic cleavage to release 
the HA1 part from intact virions was used to create ‘subviral particles’ containing only HA2. When 
these subviral particles were tested as vaccine antigens in rabbit, the immune sera reacted with the 
HA2 protein and subviral particles. Moreover, cross-reactivity was observed between HA2 subunits 
of the H1 and H3 subtypes. However, the antisera did not bind to intact HA-bearing viruses. In 
accordance with this, the subviral particles did not induce protective immunity against a viral 
challenge when used to vaccinate mice, indicating that reactivity against a conserved domain or part 
of HA does not guarantee immune protection. 
The value of the membrane-proximal part of HA as the basis for a vaccine might not have been 
established in early experiments, but a decade later monoclonal antibody (mAb) screenings led to a 
re-evaluation of its use. Okuno et al. set out to identify virus-specific antibodies that recognize 
different HA subtypes 51. Using a screening method designed to score in vitro inhibition of virus 
replication 52, they identified a mAb (C179) that neutralized both H1 and H2 viruses. Remarkably, 
although mAb C179 could neutralize the virus, it did not show any of the HI activity that is generally 
associated with reactivity towards the globular head of HA. Since neutralization of influenza virus by 
monoclonal antibodies can only occur in two ways, namely by blocking viral attachment to the host 
cell or by inhibition of membrane fusion 53, the lack of HI activity indicates that C179 acted by 
inhibiting membrane fusion. In mapping the binding domains of C179 mAb, Okuno et al. identified 
conserved parts in the stalk region of the protein responsible for its broad binding profile. This 
finding, along with the protective effect of passive immunization with C179 mAb against viral 
challenge 54,55, stimulated the search for a vaccine candidate that can be used for active 
immunization.  
More elegant than the chemical approach used to release HA1 50, Sagawa et al. made a genetic HA 
deletion mutant lacking the immunodominant globular head but retaining the complete HA2 domain 
and HA1-associated stem regions 56. Using an H2-derived head-less HA, they were able to induce 
protection against an H1 virus by using transfected cells as vaccine. Since heat-treated cells did not 
lead to comparable protection levels, this was the first description of a conformational epitope in 
headless HA constructs that was capable of inducing broad humoral protection. More recently, the 
group of Peter Palese also constructed similar ‘headless HA’ constructs based on direct linking of two 
cysteine residues in HA1 57. Applying their construct directly as a DNA vaccine in combination with 
purified HIV Gag-based virus-like particles (VLPs), the group demonstrated that an H1-based vaccine 
can induce cross-reactive immune sera and protection against a homologous infection. The first true 
soluble HA2-based immunogen was designed by Bommakanti et al. 58. This recombinant molecule, 
derived from A/Hong Kong/68, mimics the membrane-proximal HA part at neutral pH and can be 
solubilized after expression in E. coli. Intrasubtypic reactivity was seen against heterologous H3 
viruses, demonstrating the accessibility of the stalk of HA to neutralizing antibodies. 
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1.4.2 Digging deeper: antibodies will lead the way 
 
When discussing broad anti-HA responses, one has to keep in mind the phylogenetic grouping of the 
HA protein. Sixteen different HA subtypes have been identified so far, the large majority only present 
in bird populations 59. These subtypes can be discriminated by the binding of immune sera to the HA 
globular head in double radial immunodiffusion assays, using a set of reference sera. When basing 
vaccine design on the stalk of the protein, however, other classifications should be applied. The 
presence of a single glycosylation site at position N38 of subtypes H3, H7, H10 and H15, identified 
when scrutinizing the binding profile of another stalk-specific neutralizing antibody (CR6261) 60, along 
with other structural differences, distinguishes two groups of hemagglutinins with differing stem-
structures 61. Group 1 contains the H1-2, H5-6, H8-9, H11-13 and H16 subtypes, while group 2 
consists of subtypes H3-4, H7, H10 and H14-15. For most of the known monoclonal antibodies that 
can bind the stalk region (and deduced vaccine constructs), specificity is restricted to one of the two 
groups. This has been documented for the group 1 specific mAbs C197 51,54-56, CR6261 60,62,63 as well 
as for other murine and human mAbs 61,64,65.  
Similarly, mAbs specific for only group 2 viruses have been isolated. Serial infection of mice with 
antigenically distinct H3 viruses induced an antibody repertoire with binding profiles restricted to 
heterologous group 2 viruses 66. In this study by Wang et al., a set of H3 HA-specific mAbs that were 
isolated did not show HI activity but could prevent HA-induced cell fusion, which is reminiscent of 
HA2-specific antibodies 41. Of particular interest is mAb 12D1, which mapped to a very short region 
within the HA2 part of the protein, making it seemingly less conformationally restricted than other 
described HA stalk-specific mAbs. The epitope was reduced to the membrane-distal part of the so-
called long α-helix (LAH). The strong conservation of this region, even between the two evolutionarily 
distinct HA groups with distinct stalk structures, generated a great deal of interest in further 
validation. Even more so, the apparent inability to isolate escape viruses after 16 passages of virus in 
the presence of 12D1 is very promising from a vaccine-design point of view. 
The minimal sequence needed for optimal binding of the 12D1 mAb was pinpointed to the region of 
amino acids 76–130 of HA2, encompassing the entire long alpha helix (LAH) of HA 67. In an attempt to 
induce 12D1-like IgG responses, the LAH was synthesized, acetylated to expand the in vivo half-life, 
and coupled to keyhole limpet hemocyanin (KLH) using a tagged sequence as spacer arm. This 
prototype vaccine design proved to be effective: the vaccine was very immunogenic when used in a 
vaccination-boost scheme in mice together with Complete Freund as adjuvant, and it elicited 
antibody responses with reactivity towards the HA2 domains of H1, H2, H3, H5 and H7 subtypes. 
Challenging immunized mice with a lethal dose of H1, H3 or H5 viruses revealed a fair degree of 
protection compared to controls. Remarkably, the universal character of the LAH domain surpassed 
that of the HA2 domain when antisera raised to both were probed against a wide range of HA 
proteins. This shows that even the HA2 domain, which is antigenically subdominant to HA1, can mask 
more conserved regions within its own structure. 
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1.4.3 Prevalence of cross-reactive humoral anti-HA memory in the population 
 
Licensed influenza vaccines are poor inducers of cross-reacting antibodies. The emergence of the 
pandemic H1N1/09 provided a unique opportunity to quantify the induction of cross-reactive 
immunity by seasonal vaccination or by previous infection to this strain, antigenically new for the 
majority of the human population. Based on studies on human sera performed by the Centers for 
Disease Control and Prevention, it deemed unlikely that vaccination with seasonal trivalent 
inactivated vaccines (TIV), both adjuvanted and non-adjuvanted, or live attenuated vaccines (LAIV), 
used during the flu seasons 2006-2009, had induced a protective cross-reactive antibody response 
against H1N1/09 virus 68. Using HI and microneutralization assays, which allow determination of the 
standard correlates of protection for human influenza vaccines, it became clear that most elderly 
people (but not children or young adults) had fairly high titers of serum antibodies reacting with the 
H1N1/09 virus, regardless of their vaccination status 14,69,70. This finding may explain why fewer cases 
of laboratory-confirmed pandemic H1N1 infections were reported for this age group. Presumably, 
these cross-protective antibodies were generated during infections in early live with a virus that was 
genetically similar. 
Based on a detailed analysis of plasmablasts and monoclonal antibodies isolated from nine adult 
patients who had been infected with H1N1/09, there is some evidence that antibodies directed 
against conserved regions of HA are dominant following infection with pandemic H1N1 virus 71. 
These findings support the idea of constructing a “pan-influenza” or even “universal” vaccine that 
protects against diverse viral strains by means of neutralizing antibodies directed against conserved 
regions in HA. In this regard, it would be possible to score their effectiveness in the same way that is 
used now for the TIV, i.e. using HI and microneutralization. For neutralizing antibodies, HI is still the 
gold standard correlate of protection 72. Universal HA-based vaccines would simplify administration 
and acceptance by the FDA and would allow the pharmaceutical industry to evaluate a new vaccine 
in the existing system of scoring protective efficacy. 
 
1.4.4 The hemagglutinin fusion peptide: the weak spot of the virus 
 
The HA of influenza is a homotrimer, which binds to sialic acid receptors on the host cells, followed 
by virion internalization and acidification of the vesicle. This leads to a conformational change, 
resulting in membrane fusion and entry of the viral core into the cytosol. For this to occur, the 
mature HA (HA0) needs to be cleaved into two subunits, HA1 and HA2. The N-terminal HA1 subunit is 
larger and bears the hypervariable immunodominant regions, which are targeted by virus-
neutralizing antibodies. The C-terminal HA2 component anchors the protein in the viral or cellular 
membrane. Upon cleavage of HA0, the N-terminal part of HA2 (the fusion peptide) is freed and 
becomes available for fusion of the viral and endosomal membranes under low pH conditions 73. 
To be accessible for proteases, the HA cleavage peptide has to be exposed 74. Sequence comparison 
of this posttranslational maturation site of HA reveals that it is strongly conserved in all influenza A 
subtypes. For influenza B, which is not subdivided in subtypes but in two antigenically distinct 
 16 Chapter 1 
lineages (the B/Victoria/2/87 and B/Yamagata/16/88 lineage), the cleavage site has a high state of 
conservation across both lineages 75. The fusion peptide appears to be conserved even across 
influenza types A and B, since there are only two amino acid differences between the consensus 
sequence of types A and B 75. Two studies focused on the protective potential of interference with 
the cleavage site or fusion peptide of influenza A 75,76 or influenza B 75. In the latter study, it was 
shown that antibodies against the influenza B cleavage peptide could lead to broad-spectrum 
protection against influenza B viruses of both lineages, while partial heterosubtypic antibody-based 
protection could also be obtained with the A/H3-based vaccine against influenza A/H1 infection. 
Furthermore, partial protection was even obtained against influenza B challenge by using the A/H3 
vaccine. Of note, infection of humans or mice does not significantly elicit antibodies directed to the 
fusion peptide or cleavage site 75, reminiscent of the absence of natural M2e-specific humoral 
immunity. The structural constraints of the fusion peptide make it unlikely that immune pressure 
induced by vaccination would lead to escape mutants, as indicated by mutational studies 77. These 
considerations suggest that the fusion peptide could be a valid component for development of a 
broad-spectrum vaccine, possibly with a true cross-typic universal character.  
 
A B C D
E F G H
 
Figure 1.2. Graphical display of monomeric and trimeric HA with highlighting of cross-protective regions. Depicted are HA 
monomers (A-D) and trimers (E-H), with in orange the HA2-domain (B, F), the LAH (C, G) or the cleavage loop (D, H). 
Structures were made using the modeling software provided by the Influenza Research Database (www.fludb.org).  
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1.5. The M2 protein as vaccine target: broad protection derived from a small protein 
 
In the previous section, we described examples of broad immunity afforded by conformational parts 
of the HA protein. Although deducing the minimal sequence needed for such conformation-
dependent antigens by using reverse vaccinology can be tedious and time-consuming, it can lead to 
the identification of novel vaccine targets. When assessing the influenza A virus structure as an entire 
antigen, similar deductions can be made. The focus for humoral protection against infection is 
restricted to the three transmembrane proteins: HA, neuraminidase (NA) and M2. Of these, HA and 
NA have intricate structures and are prone to constant immunological pressure, which complicates 
the identification of cross-protective epitopes. The intravirionic dominance of HA and NA over M2 
might have safeguarded the latter from antigenic stress. Moreover, not only is the extracellular part 
of M2 much smaller than that of HA or NA, it is also much less abundant on the viral particle. The 
negligible role of M2e-specific antibodies in protection or recovery from infection is exemplified by 
the weak antibody responses against M2e following natural infection or vaccination with currently 
licensed vaccines, both in humans and animals 78-80. Nevertheless, the smallest extracellular protein 
of influenza A virus has become one of the biggest targets in the past two decades for the generation 
of a “universal” influenza vaccine. 
 
1.5.1 Physical and functional characteristics of the influenza A M2 protein 
 
Since its original description in 1981 81, several characteristics of the M2 protein have made it an 
alluring target for vaccine design. At the genetic level, M2 is expressed from RNA segment 7 along 
with the M1 matrix protein. The reading frame of M2 overlaps partially with that of M1: the latter is 
translated from the linear mRNA and the former from a spliced mRNA variant. As translation of both 
proteins is initiated at the same codon, they share the first stretch of eight amino acids. Hence, it is 
not surprising that specifically these amino acids show strong conservation. The M2 protein is further 
modified by phosphorylation and palmitoylation. The latter modification of M2 contributes to 
influenza virus virulence in vivo 82,83. M2 assembles into a membrane-spanning homotetramer 
utilizing four parallel disulfide-linked monomers 84. M2 is abundant at the surface of the infected cell, 
reaching densities close to that of HA 85, but it is scarce in virions for unknown reasons 86,87. In its 
native conformation, M2 serves many important functions in the influenza A life cycle. 
The transmembrane portion of M2 contains an HXXXW motif, which in its tetrameric conformation 
can support the transfer of protons from a low pH environment to more basic compartments 88,89. By 
allowing such passive proton transport, M2 can modulate the pH of the viral interior when it is 
present in the endosomal compartment and of the trans-Golgi network, respectively promoting or 
protecting the fusion capacity of HA 90-92. The cytoplasmic domain of M2 assists in the process of viral 
budding by interacting directly with the M1 protein 93. In conjunction with M1, M2 governs the 
general viral morphology. By association with cholesterol within the membrane, M2 can modulate 
the formation of filamentous virus particles instead of spherical particles 94,95. Also, the cholesterol-
binding M2 protein was recently shown to mediate viral budding in a manner that is independent on 
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endosomal sorting complex required for transport (ESCRT), and that the intracellular, membrane-
proximal amphipathic alpha-helix is responsible for membrane scission 96. Moreover, direct and 
indirect interactions of M2 with cellular proteins suggest additional functions for the M2 viroporin in 
regulating the influenza A virus infection cycle or modulating the anti-viral response of the host 97-99. 
Mutational studies have shown that C-terminal alterations 93-95, mutation of the transmembrane 
section 100 or removal of the M2 ectodomain 101 can have deleterious effects on M2 activity. In 
addition, deletion of the entire protein severely affects virus assembly and infectivity 94,102. This led to 
the use of M2-negative viruses rescued from M2-expressing cell lines and with a strong attenuated 
phenotype as experimental live vaccine strains 103. Thus, with the functional constraints imposed on 
the protein, M2 shows remarkable sequence conservation. The 23-amino-acid ectodomain of M2, 
termed M2e, is particularly conserved (Figure 1.3) and has drawn major attention as a vaccine target. 
The low level of sequence variation along with its high expression level and accessibility at the 
surface of infected cells define an excellent basis for cross-protective vaccine designs based on M2e.  
 
1.5.1 Strategies to render M2e immunogenic 
 
Numerous research groups have endeavored to develop an M2e-based vaccine that evokes broad 
protective responses towards influenza A viruses. Although anti-M2e responses induced by infection 
or vaccination appear to be weak in humans, different types of carriers have been used to present 
the peptide in a more immunogenic fashion to the adaptive immune system of the vertebrate host. 
Here, we will highlight a few successful examples of such M2e-vaccines. 
Initial immunogenicity studies were based on solubilization of intact full-length M2-protein 104. These 
enriched membrane preparations were tested in mice and induced a significant anti-M2e antibody 
titer. The larger part of the humoral response however was directed to the intracellular part of M2. 
When vaccinated mice were challenged with a lethal dose of a homologous or heterologous 
influenza strain, protection was observed. Since the M2-induced immunity could not be transmitted 
by transfer of serum, protection was believed to be based on cellular immunity. In a further 
development, the transmembrane section of M2 was deleted and fused to glutathione-S-transferase 
in order to obtain a less hydrophilic protein 105. Immunization of mice with these constructs led to 
high antibody titers specific for M2e, leading to enhanced viral clearance following infection with 
influenza strains of different subtypes.  
Given the small length of the M2e epitope, combined with a better understanding of how immune 
cells can be triggered, densely arrayed presentation of the antigen has been investigated rigorously. 
Fusion to certain capsid proteins derived from viruses can lead to self-assembly of uniform virus-like 
particles (VLPs), which present the antigen in an arranged fashion at high density. Neirynck et al. 
(1999) evaluated the Hepatitis B core (HBc) protein as carrier, by genetically fusing M2e to the N-
terminus of HBc 106. Immunization of mice led to long-lasting protection against influenza A virus 
infection, and this protection could be transferred to naive mice by using anti-M2e antisera. By 
adding one or two more M2e copies at the N-terminus, or inserting the epitope into the 
immunodominant loop of HBc protruding as spikes from the VLP, immunogenicity was further 
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enhanced 107. Other groups followed the reasoning of high epitope-density presentation of M2e 
using capsid proteins from animal or plant viruses or bacteriophages 108-112. Besides the antigenic           
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Figure 1.3. Alignment of M2e sequences avialable in the influenza sequence database (http://www.fludb.org) before 
February 2011.  In green the consensus sequences are shown for the indicated host, in yellow the consensus sequences for 
the indicated viral subtypes.  Residues marked in red deviate from the human consensus sequence.  For the alignments, 
8316 human, 4856 avian, 526 swine, 131 equine and 178 canine sequences were aligned. 
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display benefits of VLPs, their ordered and rigid three-dimensional structure and, in some cases, the 
potential to encapsulate nucleic acids, may bypass the need for adjuvants. Moreover, these VLPs not 
only induce strong humoral responses, but also lead to T-cell-based cellular immunity 113. 
The encouraging results obtained with M2e-based vaccines, showing broad protection against 
influenza-induced morbidity and mortality, enticed several other research groups to further explore 
M2e vaccine design. In more classical chimeric products, M2e has been chemically fused to well-
known carrier proteins, such as KLH or bovine serum albumin. Testing such constructs in animal 
models generally requires the addition of adjuvants, such as incomplete Freund’s adjuvant or alum, 
to elicit substantial antibody responses. Therefore, more elegant and easier to produce carriers for 
M2e have been tested, some of which even have been evaluated in phase I clinical trials. With the 
dawn of new-generation adjuvants, the concepts of vaccine design have changed. Recombinant 
production of antigens and immunomodulatory components allows direct linking of both for optimal 
formulations. Coupling of M2 antigens to microbial proteins 114-119, innate immune components 120 or 
synthetic lipids 121 has been proven effective in preclinical studies against a wide range of influenza A 
subtypes. The antigen-sparing qualities of such vanguard formulations further meet the 
requirements for novel cross-protective vaccines. 
Some research groups avoided the use of natural scaffold proteins and have developed instead 
synthetic constructs for presentation of the M2e 122-125. Mozdzanowska et al. (2003) coupled M2e 
peptides, along with defined T-helper epitopes, to a scaffold. The absence of a potential 
immunodominant carrier protein provided a clean model for initial dissection of the anti-M2e 
immune response. In their model of intranasal immunization, this group demonstrated a clear 
difference between the upper and lower respiratory tract with regard to the presence of anti-M2e 
antibodies. In a follow-up study 123, this was elucidated further. While parenteral immunization 
through the subcutaneous route induced protection that correlated with the presence of M2e 
antibodies in the serum, intranasal vaccination did not show such a correlation, even though it was 
superior in inhibiting viral replication in the lung. Moreover, the correlations only were valid when 
comparing antibody titers reactive with native M2 expressed on infected cells, and not with peptide-
specific titers.  
The results obtained by Mozdzanowska et al. indicated that protection elicited by a given vaccine can 
vary considerably with the route of administration, and this obscures or at least complicates the 
detection of protective correlates. Indeed, the additional effects of local immunity induced by 
intranasal immunization, both antibody and T-cell-based, are not easily quantifiable before infection. 
A second conclusion to be drawn from the study is the pivotal role of reactivity towards native M2e 
species. Titers purely based on recognition of peptidic M2e might not be indicative of a prechallenge 
protected state, since only antibodies capable of binding native M2 expressed on virions or infected 
cells can convey immunity. Based on these premises, De Fillette et al. (2008) designed a tetrameric 
presentation model closely mimicking the native M2 structure 126. M2e was fused to a tetramerizing 
form of the leucine zipper of the GCN4 transcription factor of yeast 127. Immune sera raised with this 
chimeric protein showed high specificity for cell-expressed M2, which could not be completely 
competed away using free M2e peptide. This result substantiated the merit of a quaternary 
structured vaccine. Other similar native presentation strategies are based on simultaneous 
expression of M2 and M1, with or without NP, which leads to formation of enveloped VLPs carrying 
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membrane-inserted full-length M2 128,129. Application of such VLPs not only induces anti-M2e 
immunity, but also builds a degree of cellular immunity provided by the internal proteins M1 and NP. 
 
1.5.2 Dissecting the anti-M2e response 
 
While the objective of M2e immunization has been by and large induction of antibodies, and vaccine 
efficacy has mainly been evaluated as such, the anti-M2e response is broader. The early studies with 
M2e-based vaccines showed that protection was transferrable by serum, and hence was largely 
based on induction of M2e-specific humoral immunity 106,128-131. Furthermore, both murine and 
human monoclonal antibodies can protect against lethal influenza infection 132-138. Using these mAbs, 
two immunogenic regions were mapped in M2e: they comprised the middle EVETPIRN sequence and 
the N-terminal SLLTEVET part 132,133,136. The latter is of particular interest, since this epitope is also 
present in the M1 protein and therefore highly conserved. However, although the former epitope 
can induce protective antibodies when presented with classical carrier proteins 139, this is not true for 
the M1-M2 common epitope 140. Likewise, certain mAbs and polyclonal sera show specificity for only 
native M2 on infected cells 123,126,138. Thus, not only the tetrameric presentation of M2e can form the 
basis of conformational epitopes, but also the monomeric M2e sequence seems to be more 
structured than might be expected. 
Clearly, antibodies directed to M2e can thwart influenza infection, but how do they function? 
Although they can have an effect on viral replication in vitro (e.g. plaque size reduction assays for 
some influenza A virus strains) 86, they do not display neutralizing activity. In vivo, this translates into 
immune mechanisms dependent on opsonization of infected cells and possibly virions. Downstream 
of this, effecter cells, such as natural killer cells and alveolar macrophages, kill and remove the 
antibody-opsonized infected cells by the process of antibody-dependent cell cytotoxicity (ADCC) 
131,141.  
The role of M2-protein in protection may be broader than mere humoral immunity. Also M2e-
specific T-cell-responses contribute to viral clearance in the BALB/c mouse model and most likely 
form the basis of local immunity in the lung 122,123,142,143. Furthermore, the infection-permissive nature 
of M2e antibodies may allow other anti-influenza immune mechanisms to be activated, thereby 
enforcing the induction of broad influenza immunity.  
Stand-alone M2e vaccines can provide defense against viral infection, but some groups have also 
considered a mixture of a classical vaccine with M2e antigen. This is in accordance with the concept 
of intravirionic dominance, based on the overwhelming effect of HA on the humoral immune 
response compared to other viral antigens. The dominance of HA was acknowledged by Johansson et 
al. (1987), which led to redefinition of classical vaccine concepts 144. It was found that intravirionic 
competition between dominant and subdominant antigens could be diminished when they are 
administered as separated (i.e. molecularly non-associated) antigens in one vaccine preparation 
145,146. Does this hold true for M2e-based vaccines? Wu et al. (2009) addressed this issue by 
combining a traditional split vaccine with M2e peptide 147. Using a combination vaccine together with 
aluminum salt, they could induce stronger humoral and cellular M2e responses than those obtained 
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with the classical inactivated viral vaccine alone, and immune sera were protective in passive transfer 
experiments. This enhanced M2e response also conveyed heterosubtypic immunity surpassing that 
of the classical split vaccine on its own. Similarly, Song et al. (2011) enhanced the interstrain 
protective efficacy of inactivated virus by adding M1-M2 VLPs; protection was transferable with 
serum and apparently dependent on dendritic cells and macrophages 128. Hence, apart from its own 
protective potential, under certain conditions the M2 ectodomain can improve the immunity 
provided by classical vaccines. However, in non-optimal formulations, strong epitopes of HA and NA 
antigens may still dominate the immune response, abrogating the induction of cross-protective M2e-
based immunity.  
 
1.5.3 M2e immunity: one size fits all? 
 
M2e can be regarded as universal, but this claim should only be seen as valid for a particular host 
species. Variations in M2e-sequence appear to coincide with host restriction, and mutations in the 
M-gene is one of the genes believed to be involved in adaptation of influenza virus to new hosts 148. 
When comparing sequences of different influenza subtypes within one host, it becomes clear that 
consensus sequences can be compiled. Even within the short M2e sequence, a number of key 
changes occur (Figure  1.2). On the one hand, this endorses the cross-protective potential of M2e-
based constructs for a specified host, but on the other hand interspecies variation can complicate 
rendition of reactivity towards deviating viruses 114,149, as present in any epidemic or pandemic. 
However, differences are limited and vaccines encompassing the major antigenically distinct 
sequences could overcome this hurdle. Moreover, while zoonoses of avian influenza strains are still 
of great concern, these viruses appear to be in evolutionary stasis 150. Swine viruses pose another 
potential threat, as shown by the 2009 Mexican flu pandemic. Surprisingly, the M2e sequence of this 
pandemic virus digressed to a large extent from other human-to-human transmissible strains, but 
vaccine studies utilizing 2009 pandemic strains as challenge virus have proven protection based on 
classical human or avian M2e sequences 124,128,129. 
As M2e is a very poor immunogen in natural setting, this lack of antigenic pressure probably means 
that there was no need for mutational escape. With the use of M2e-directed vaccines, the problem 
of escape might occur, but can we predict the likelihood of such an event? This issue was addressed 
by Zharikova et al. (2005) 151. Under controlled conditions, they serially infected SCID mice in the 
presence or absence of M2e-directed or control mAbs. Somewhat expected, they could select a large 
number of viruses with mutated M2e sequences. However, the identity of changes was limited to 
only one residue in the epitope, namely proline at position 10, and only two variants emerged in this 
model: proline 10 was changed to histidine or leucine. Both mutations also occur naturally, mainly in 
avian strains. The narrow window of mutational freedom points to strong conservation mechanisms, 
most likely related to the linkage of the M1 and M2 reading frames and the functional importance of 
M2. Importantly, the selection for escape mutants was not successful in in vivo experiments using 
immunity-deficient mice. In active immunizations however, the broad recognition by elicited 
polyclonal antisera would in all likeliness not be hindered by such localized mutations. 
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The mouse is the influenza animal model that is easiest to handle, and preclinical studies are 
predominantly performed in mice. How do results obtained using mice translate to other animal 
models and to humans? A number of groups have used other animals for preclinical testing of M2e 
vaccines. In a large collaborative study, Fan et al. (2004) compared their conjugate vaccine in mice, 
ferrets and rhesus monkeys 114. Protection against human influenza viruses was evident in mice and 
ferrets, and monkey sera could protect mice in passive transfer experiments. Even with failed 
recognition of avian virus M2e-peptides in vitro by mouse sera, these results are encouraging in 
translational views. However, to some extent, the choice of carrier protein can influence the overall 
immunogenicity of M2e 152, but this might not be reflected in overall anti-viral activity. In a model of 
respiratory stress in cotton rats, M2e antibodies could reduce tachypnea when transferred before 
challenge 153. Additional protective effects of M2 immunity were also seen in pigs 154. Protection with 
M2e vaccines has also been tested in birds. However, few convincing results have so far been 
obtained in avian challenge models. Fusion of M2e to the chicken complement factor C3d proved 
effective in mice, but protection of SPF chickens remained unsatisfying 120. In a related study, 
immunization with recombinant Newcastle Disease Viruses expressing HA, NA and M2 showed that 
although M2 was immunogenic, it had a negative effect on immunogenicity in general in a combined 
vaccine and showed no M2-related protection 155. These results demonstrate the need for caution 
when evaluating efficacy of novel vaccine designs, and they clearly show possible barriers in the 
compatibility of immunogens and hosts, even in inbred mouse strains 143.  
 
1.6. Can isotypic NA responses provide pandemic protection? 
 
Influenza NA is the second major glycoprotein and is targeted by immune responses induced by 
vaccination or natural infection. Like HA, NA is prone to drift and shift in influenza A viruses as a 
consequence of the natural occurrence of immunological pressure in the host 18. In vitro, anti-NA 
antibodies cannot prevent infection, but they can interfere with the enzymatic activity of NA and 
severely reduce virus progeny production 156. Anti-NA antibodies thwart the infection process 
sufficiently to slow down disease progression while allowing other immune mechanisms to become 
activated, resulting finally in viral clearance. During infection, NA on influenza virions probably also 
plays an essential role at the portal site of entry in the host by hydrolyzing structures that contain 
sialic acid in the mucus layer lining the respiratory tract 157. Therefore, it is conceivable that anti-NA 
antibodies, in particular secretory IgA, could also play a role during the early phase of infection. 
Only two NA subtypes, N1 and N2, have been introduced in the human population for a prolonged 
time. H1N1 and H3N2 human viruses have been cocirculating since 1977. Therefore, one could 
expect that the presence of only two serotypes in humans, which have been circulating for 
presumably 90 years or more, has resulted in considerable anti-NA herd immunity. A downside, 
however, is the immune dominance of HA, i.e. the skewing of the anti-influenza immune response 
towards HA during homotypic recall infections 158. Nonetheless, as mentioned above, the 1968 H3N2 
pandemic provided some evidence supporting the possibility that NA afforded heterosubtypic 
protection 9. Could a homosubtypic anti-NA response provide some defense against a pandemic 
strain? The recent threats of avian H5N1 strains as a potential pandemic precursor, for instance, 
make N1 an interesting vaccine candidate. Sandbulte et al. (2007) showed that despite the difference 
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between human and avian N1, the NA derived from human H1N1 (A/New Caledonia/20/99), 
delivered as a DNA vaccine, could partially protect mice against a lethal H5N1 challenge 159. This 
protection was apparently antibody-mediated, since passive transfer of immune serum resulted in a 
similar level of protection. This study also demonstrated that up to 20% of people have serum IgG 
titers against avian N1 that can inhibit the enzyme in vitro. This could imply that prevailing anti-N1 
immunity provides baseline protection against H5N1 infections. Unfortunately, there is no reliable 
standardization for the neuraminidase content in currently licensed inactivated influenza virus 
vaccines. Supplementation of classical inactivated vaccines with NA, or immunization with purified 
NA or DNA vectored NA, may elicit more balanced anti-NA responses and heterosubtypic protection 
160-163. These observations warrant further investigation of possible protection against pandemic 
influenza strains with an N1 or N2 make-up by vaccination with NA-vaccines. 
The introduction of the pandemic H1N1/09 virus in the human population provided a contemporary 
situation to analyze the influence of NA-immunity. The group of Richard Webby examined the effect 
that repetitive immunization with or previous exposure to seasonal influenza A/ H1N1 viruses has on 
susceptibility to H1N1/09 infection 164. Using a panel of recombinant viruses, only differing in their 
NA gene, they showed induction of anti-NA antibodies cross-reactive with H1N1/09. Moreover, sera 
taken from mice after challenge with these recombinant strains could protect naive recipient mice in 
passive transfer experiments against a potential lethal H1N1/09 infection, despite the lack of cross-
reactive HI titers. In addition, they showed that exposure to multiple seasonal H1N1 strains elicited 
H1N1/09 NA cross-reactive titers. Using convalescent sera from elderly humans immunized with 
conventional TIV vaccines, they could also detect anti-NA responses reactive with H1N1/09 164,165.  
Clearly, pandemic settings of the past do provide evidence for the merit of anti-NA responses for 
broad protection. This has instigated quite some interest in the development of vaccination 
strategies augmenting NA-specific responses. Indeed, without a clear definition of the NA content in 
conventional vaccines and the immunodominance of HA towards NA, novel formulations are 
warranted. A potential successful approach is the combination of soluble trimeric HA and tetrameric 
NA, produced by eukaryotic expression systems, to be combined as vaccine antigens. Bosch et al. 
followed this strategy in assessing protection against H1N1/09 infection in a ferret model 166. The 
addition of NA in the vaccine preparation augmented the induction of viral neutralizing titers and had 
a profound impact on antiviral immunity compared to HA-only vaccination. Specifically, NA inclusion 
decreased morbidity and lung pathology quite significantly. Moreover, the induced anti-NA 
responses were shown to be cross-reactive with other N1NA molecules, neutralizing their NA 
activity. Overall, these epidemiological and experimental data underscore the value of anti-NA 
responses in broad anti-influenza immunity. 
 
1.7. Influenza-specific CTLs: help from the inside 
 
The major structural proteins nucleoprotein (NP) and matrix protein 1 (M1) are the main candidate 
antigens to contain conserved regions. But also M2, basic polymerase 1 (PB1) and non-structural 
protein 1 (NS1), and even HA bear epitopes that are conserved across subtypes. Of note, among the 
described immune epitopes of influenza, the sequence conservation of T cell epitopes seems to be 4-
 25 Innovative and novel designs of broad influenza vaccines 
5 times greater than that of the dominant B cell epitopes 167. The reason is that the majority of 
identified antibody-interacting antigens are located in HA and NA, while most known T cell epitopes 
are present in conserved internal gene products. Many of these are cytotoxic T cell epitopes, i.e. 
linear peptides presented by MHCI molecules and recognized by a matching T cell receptor. Cellular 
immunity directed against several of these T-cell epitopes has been proven to be protective (Table 
1.1.). 
 
Table 1.1. Overview of identified MHCI and MHCII binding influenza epitopes capable of inducing cytotoxic T cells. 
 
The first evidence of heterosubtypic immunity induced by influenza infection dates back to the mid 
1960s, when Schulman and Kilbourne reported that infection of mice with one influenza A virus could 
induce protective immunity against an unrelated influenza A virus but not against a B virus 168. By 
Virus CTL type Epitope Sequence restriction ref 
IAV 
CD8 
PB1 (591-599) VSDGGPNLY A1 
177
 
M1 (58-66) GILGFVFTL A*0201 
178-181
 
M1 (128-135) ASCMGLIY B*3501 
182
 
M2 (7-15) VETPIRNEW B*44 
180,181
 
NS1 (122-130) AIMDKNIIL A*0201 
180,181,183
 
NP (44-52) CTELKLSDY A1 
177
 
NP (146-154) TTYQRTRAL B*1402 
184
 
NP (174-184) RRSGAAGAAVK B*2705 
180,181
 
NP (265-273) ILRGSVAH A3 
177
 
NP (339-347) EDLRVLSFI B*3701 
185,186
 
NP (380-388) ELRSRYWAI B*0801 
187-190
 
NP (381-388) LRSRYWAI B*2702 
187
 
NP (383-391) SRYWAIRTR B*2705 
180,181,189-192
 
NP (418-426) LPFEKSTVM B*3501 
189,193,194
 
CD4 
M1 (17-31) SGPLKAEIAQRLEDV DR1 
180,181
 
NS1 (34-42) DRLRRDQKS DR3 
180,181
 
NP (254-262) EDLTFLARSAL - 
180,181
 
IBV 
CD8 
NP (30-38) RPIIRPATL B8 
195
 
NP (85-93) KLGEFYNQM A*0201 
196
 
NP (263-271) ADRGLLRDI B8 
195
 
NP (413-421) ALKCKGFHV B8 
195
 
CD4 HA (308-320) PYYTGEHAKAIGN DR1 
195
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contrast, parenteral inoculation with inactivated virus did not have the same effect, implying that 
such cross-protection requires viral replication. A decade later, it was demonstrated that cytotoxic 
activity of T cells derived from infected mice could kill infected syngeneic cells, that this cytotoxic 
activity could also target heterosubtypically infected cells and could be boosted in mice by using 
antigenically distinct viruses 169-172. It thus seemed that cellular cytotoxicity was cross-subtype-
specific, a first indication of the broad protective potential of this immune compartment. These 
influenza-specific CTLs apparently played a role in vivo, because they are found in lungs and draining 
lymph nodes after intranasal challenge of mice, and because adoptive transfer of primed CTLs 
protects naive mice 173-176. Following these initial studies, the field of CTL-mediated anti-influenza 
immunity expanded substantially. 
 
1.7.1 Influenza-specific CTL epitopes 
 
Influenza virus NP is involved in coating of the viral RNA and assembly of the ribonucleoprotein 
complexes. These complexes play a role in nuclear transport, and possibly in transcription of viral 
genes and in replication (reviewed in 197). This multitude of functions imposes considerable structural 
constraints on the protein and leaves little room for sequence variation. Consequently, immune 
responses directed against NP epitopes are often heterosubtypic. The first evidence that 
heterosubtypic cellular cytotoxicity was directed against NP came from Townsend and Skehel, who 
showed that CTL activity coincided with the presence of NP 198. The protective potential of NP as a 
vaccine was demonstrated by using both purified NP and adoptively transferred NP-specific CTLs 
199,200. Although cytotoxic cellular anti-NP activity does not confer sterilizing immunity – in fact, it is 
infection-permissive – NP-specific CTL activity in the mouse has a beneficial effect on survival and 
lowers viral titers. Recently, a more surprising protective role for NP was reported. Carragher et al. 
used recombinant NP adjuvanted with LPS to show that humoral responses raised against NP can 
protect mice against influenza infection, as reflected in reduced morbidity and lung viral titers 201. 
This protection was antibody-dependent, since immunization of mice unable to produce antibodies 
(AID/µS mice) did not lead to reduction in lung viral titer. However, protection was also T cell-
dependent, as passive transfer of immune serum to B cell-deficient µMT mice protected the mice, 
whereas B and T cell-deficient Rag1-/- mice were not protected by passive immunization. These 
results show that non-neutralizing anti-NP antibodies, in conjunction with a responsive T cell 
compartment, can provide protection against influenza infection. 
It is important to note that influenza CTL epitopes are characterized by a hierarchy of immune 
dominance based on the magnitude of the T cell responses. This particular hierarchy depends on the 
HLA/MHC genetic background 202,203 and consequently differs between different animal models and 
between individual humans. On the other hand, this hierarchy implies that depending on the 
individual, several potentially useful viral CTL epitopes can be masked by the presence of 
immunodominant epitopes 204. Careful selection of strong CTL-inducing epitopes and their 
presentation in the absence of viral immune dominance, e.g. by using peptide-based vaccines, is 
therefore crucial for the design of a broad-spectrum vaccine based on CTL induction. A prerequisite 
for efficient cognate CD8+ T cell induction is productive processing of the epitope during infection or 
vaccination followed by MHCI-associated presentation 203,205. Besides immune dominance, HLA 
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restriction is another feature of CTL epitopes that might pose a problem for development of a broad-
spectrum CTL-based vaccine for the entire human population  202,206. Therefore, for human use, a 
CTL-based vaccine should preferably contain or code for multiple epitopes covering most of the HLA 
pool. 
Noteworthy, in silico screening for human CTL-inducing sequences revealed several putative epitopes 
that are highly conserved and are present in a diverse range of human and avian influenza isolates 
207. Some are genuine CTL-inducing T-cell epitopes in vitro and cover a wide range of human HLA 
haplotypes, providing direct evidence for the natural occurrence of cross-reactive cytotoxic T cell-
inducing determinants, even directed against a potential pandemic (avian) strain. H5N1 cross-
reactive CTLs appear to be present in healthy humans as a consequence of repeated H1N1 and H3N2 
infections, as reported by Kreijtz et al 208. The authors showed that known human CTL epitopes are 
present in a set of 900 different H5N1 viruses, although several mutations were detected. In 
addition, isolated PBMCs from healthy Dutch blood donors produced a cytotoxic reaction against 
cells presenting NP-epitopes of H5N1 (A/Vietnam/1194/04) and against H5N1-infected cells. This 
suggests that at least some humans possess memory CTLs that can cross-react with 
(heterosubtypical) divergent influenza strains. The contribution of NP-specific CTL responses to 
natural protection in humans is supported by the evolution of human influenza virus strains with 
escape mutations in NP CTL epitopes 209. However, not everyone in a population will have a frontline 
CTL memory response, because repeated viral encounters during epidemic seasons seem to be 
necessary. The above-mentioned scientific, historical and even anecdotal evidence indicates that 
CTLs could play a role in surviving a pandemic. But one important question remains: how to induce 
cross-reactive, influenza-specific CTL responses in a safe, effective and reproducible manner? 
 
1.7.2 CTL-inducing vaccines: a practical overview 
 
A vaccine inducing effective CTL responses has to cover a wide range of HLA-binding epitopes. But 
another necessary property is topological: for efficient uploading of peptides onto MHCI molecules, 
the antigen has to be processed in the cytosol of the presenting cell. This implies that the CTL 
peptides or their precursors must be delivered into the cytosol, and so the vaccine has to be 
formulated with this in mind. Four main options are available for this: the use of live, attenuated 
influenza vaccines (LAIV), recombinant viral or bacterial vectors, gene vaccination, and protein 
vaccines formulated with particular adjuvants.  
LAIV have been used in Russia for over 40 years and in the USA since 2003. They can be divided in 
two classes: cold-adapted viruses and genetically engineered viruses with attenuated features. The 
former are derived from virus that was passaged in vitro at low temperatures (25-33°C) 210. Influenza 
virus isolates selected under these conditions replicate poorly at temperatures over 35°C, and when 
they are administered to humans, they only replicate in the upper respiratory tract, without causing 
illness. Cold-adapted viruses have acquired mutations in PB1, PB2 and possibly NP and NS 211,212. 
Other mutations in the influenza genome can also attenuate the virus, and several rationally 
designed candidate live attenuated vaccine strains have been generated in this way 213-215. Use of 
these cold-adapted viruses as intranasal live vaccines provokes an immune response that provides 
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strain-matched humoral immunity (mainly HA-directed) and some CTL responses. In the mouse, 
these T-cell mediated responses provide heterosubtypic protection 216. Also for humans, cross-
reactive responses could be shown in vitro after immunization with cold-adapted viruses 217. Some 
evidence for enhanced cross-protection by live attenuated influenza vaccines was provided during 
the 2003-2004 season, during which the circulating H3N2 strain did not antigenically match the 
vaccine strain 218,219. A word of caution is that efficacy of attenuated viruses as vaccines might be 
counteracted by pre-existing (heterosubtypic) immunity, be it cell-mediated or antibody-mediated. 
However, non-sterilizing heterosubtypic immunity in children has only a limited effect on the efficacy 
of vaccination with LAIV 220,221. In adults and the elderly, however, natural infections are usually 
numerous, and pre-existing memory might pose a barrier for vaccine efficacy 222. 
Besides LAIV, other replication-competent viruses have been employed as vectors for influenza 
antigens, including Fowlpox virus, Newcastle disease virus (NDV), human and non-human 
Adenovirus, and Vaccinia virus. Initial, proof-of-concept findings were established mainly by using HA 
expressing viral vectors. Replication-deficient Adenoviral vectors offer immune protection against 
highly pathogenic H5N1 virus challenge in mice and poultry, including protection against antigenically 
distinct H5N1 virus challenge 223,224. Such vaccines, and in particular live recombinant NDV and 
Fowlpox vectors, could be useful to protect against potential pandemic strains in animal reservoirs of 
influenza, such as poultry 225. However, hurdles that have to be overcome are cost-effectiveness, 
biocontainment, pre-existing vector immunity and regulation of the use of genetically modified 
organisms. 
A surprisingly simple way to present processed antigens to the T cell receptor in the context of MHCI 
is the use of DNA vaccines. The first evidence that a DNA-vaccine strategy can provide protective 
immunity was reported by Ulmer et al., who showed that intramuscular delivery of an NP-expression 
plasmid could induce CTLs and protect mice against homo- as well as heterosubtypic influenza virus 
challenge 226. This fascinating finding became the starting point for many studies investigating the 
protective potential of DNA vaccines, including their efficacy against H5N1 challenge 227. Although 
the protective potential of DNA vaccines cannot be disputed, and clinical trials have been done, their 
immunogenicity in humans remains feeble. Factors that determine the immunogenicity of DNA 
vaccines include the route and mode of administration, the CpG content of the plasmid backbone, 
codon optimization of the DNA sequence of the vaccine antigen, and formulation with adjuvants 228. 
Despite many scientific and technological advances in the use of DNA vaccines, the potential for 
genomic integration and disruption of normal cellular homeostasis remain an important concern in 
consideration of clinical application of this method. 
Recombinant protein vaccines are in principle safe, easy to handle, and can be formulated accurately 
and reproducibly. Compared to conventional influenza vaccines, which are based on virus growth, 
the process of producing recombinant influenza antigens requires less strict biocontainment. On the 
downside, injected protein antigens engage mainly the extracellular face of the immune 
compartment, and only some adjuvants or formulations can promote their uptake into the cytosolic 
route, with subsequent processing by the proteasome and uploading on MHCI molecules. One such 
example is the use of ISCOMs, or immune-stimulatory complexes, consisting mainly of Quil A,  that 
form micelles in solution; Quil A is derived from the tree Quillaja saponaria 229. ISCOMs are 
hydrophobic, and the presence of a hydrophobic domain in antigens, such as the transmembrane 
domain of HA, promotes their incorporation into the ISCOM particle 230. ISCOM-formulated vaccines 
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can elicit high titers of serum antibodies and induce CTLs, both in the systemic and in the mucosal 
compartments of the immune system 231-235. A second example is ASO4 (Adjuvant System 04), 
developed by GSK, which is based on the addition of the LPS derivative MPL (3-O-desacyl-4-
monophosphoryl lipid A) to particulate aluminium salt adjuvant 236. The specific stimulation of TLR4 
by MPL activated the Th1-arm of the immune response, evoking broad humoral and cellular 
responses to soluble exogenous antigen. 
In general, natural and vaccine-induced CTL responses against influenza have shown protection in 
several animal models. However, evidence for CTL-based protection by influenza vaccines in humans 
is still sparse. Several vaccine types that induce CTLs are in phase I clinical trials 237, and the results 
may provide more insight into cellular immunity and help define correlates of protection for CTL-
inducing vaccines. Quantifying CTL responses in a clinical laboratory is technically demanding and 
poses yet another hurdle for implementation of CTL-based vaccines. However, future technical 
developments could make CTL tests fast and cost-effective. In the following part of this review, we 
will focus on approaches that rely on antibody-mediated protection to induce heterosubtypic 
protection. 
 
1.8. Concluding remarks 
 
With conventional vaccines aiming at inducing homotypic anti-HA responses, induced immunity will 
be very strong against homologous strains. However, drifted epidemic strains could easily evade this 
immunity, bringing down vaccine effectiveness and heightening the disbelief in its efficacy. Pandemic 
strains will completely circumvent seasonal vaccine induced immunity, requiring timely responses on 
the spot. However, a great number of novel strategies have been explored the past few decades in 
eliciting broad anti-influenza responses; a general overview of these is given in Figure 1.4. Many of 
these are scrutinized in clinical trials 237; time will tell which strategy proves the most efficient. 
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HA NA M2 M1
NP PA
PB1
PB2
NS1 NS2
(NEP)
VRNP
Conserved T cell epitopes for induction of CTLs
Anti-M2e antibodies can convey ADCC
Anti-NA antibodies provide homo(sub)typic immunity
Anti-HA antibodies provide homo(sub)typic immunity
HA2, LAH and cleavage loop can induce broad (neutralizing) antibody responses  
Figure 1.4. Concise overview of novel strategies for broad influenza vaccine development. 
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2.1. Introduction 
 
The Orthomyxoviridae family of RNA viruses comprises at least five different genera 1. Next to 
Isavirus and Thogotovirus, these include the influenza A, B and C viruses.  They are all characterized 
by a negative-stranded, segmented single-stranded RNA genome. The influenza viruses are 
subdivided in types A, B and C based on the degree of antigenic similarity of their nucleoprotein (NP) 
and matrix protein 1 (M1), which show no cross-reactivity across the three types. Influenza B (IBV) 
and influenza C viruses are human pathogens, although in rare cases infections have been identified 
in other animals 2,3. In contrast, influenza A viruses (IAV) circulate in a vast animal reservoir. IAV are 
subdivided based on the similarity of the major surface glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA). To date, 16 different HA subtypes and nine NA subtypes have been identified 4. 
All of these can be found back in the avian reservoir of IAV strains. Additionally, certain strains can be 
readily detected in equine (H3N8, H7N7), swine (H1N1, H1N2, H3N1, H3N2 and H2N3) and 
occasionally canine, feline and other mammalian species. This large group of hosts, combined with 
the segmented genome, can result in co-infection of an individual host, with mixing of gene 
segments as a consequence. In rare cases, this will yield a gene constellation with intragenic 
compatibility, resulting in a replication-competent virus with dramatically altered antigenic 
characteristics compared to these of influenza viruses that circulate in human. If this does occur, it 
can lead to a pandemic or panzootic with profound effects 5. In recent human history, five major 
pandemics have occurred: the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2), the 1968 Hong 
Kong flu (H3N2), the 1977 Russian flu (H1N1) and most recently the 2009 Mexican flu (H1N1). During 
interpandemic periods, strains related to the previous pandemic circulate further as epidemic strains, 
diversifying under immunological pressure. Currently, the descendants of the Hong Kong and 
Mexican flu roam in the human population. These not only continue to drift antigenically, but could 
also feed future pandemic strains. Indeed, molecular characterization of the Mexican flu virus has 
shown that it is a reassortant virus composed of genes derived from both the Spanish flu and the 
Hong Kong flu 6. 
With a constant threat imposed by zoonotic transfers of IAV, or emergence of pandemic strains, a 
major focus has been put on broad IAV vaccine development 7. However, IBV also causes epidemics. 
Even with a lack of a comprehensive animal reservoir, and no distinction of HA and NA subtypes, the 
situation is getting precarious. Since the 1970s, two antigenically distinct lineages have been 
recognized, prototyped by B/Victoria/02/1987 and B/Yamagata/16/1988 8. This has imposed a great 
amount of pressure on conventional trivalent vaccination strategies that are based on inactivated 
viruses (TIV or trivalent inactivated vaccine) of A/H1N1, A/H3N2 and a single IBV strain. Over the past 
decade, frequent mismatches have occurred between vaccine and circulating IBV strain with regard 
to lineage selection (Table 2.1). In fact, in five out of eleven seasons, the selected vaccine strain was 
of the opposite lineage as the epidemic strain. Clearly, novel strategies need to be addressed to avoid 
future problems. In this chapter, the biological and epidemiological properties of IBV will be 
discussed, leading to front-line approaches based on these characteristics for broad influenza B 
vaccine development. 
 
 
  
Table 2.1. Overview of European circulating strains and IBV vaccine strains, illustrating recurrent mismatches of IBV lineage selection. Data is based on information from 
the European Influenza Surveillance Network (www.ecdc.europa.eu), complete until the 2009-2010 season. *, pandemic H1N1 / seasonal H1N1; 
+
, pandemic H1N1 only, 
replacing seasonal H1N1 circulating before 2009. 
Season 
Prevalence (%) IBV lineage prevalence IBV vaccine strain Dominating circulating IBV strain 
Mismatch 
A 
(Untyped) 
A/H1 A/H3 B Untyped Yam Vic Prototypical strain Lineage Prototypical strain Lineage 
2000-2001 48,9 32,9 0,8 17,4 - - - B/Beijing/184/93 Yam B/Beijing/184/93 Yam No 
2001-2002 47,9 4,0 26,8 21,3 91,8 1,7 6,5 B/Sichuan/379/99 Yam B/Hong Kong/330/01 Vic Yes 
2002-2003 24,0 7,0 25,0 44,0 51,5 5,3 43,2 B/Hong Kong/330/2001 Vic B/Hong Kong/330/01 Vic No 
2003-2004 56,4 0,4 42,3 0,9 84,5 9,5 6,03 B/Hong Kong/330/2001 Vic B/Shanghai/361/2002 Yam Yes 
2004-2005 39,3 6,6 37,1 17,0 69,8 17,1 13,0 B/Shanghai/361/2002 Yam B/Shanghai/361/2002 Yam No 
2005-2006 28,9 7,2 5,9 58,0 69,2 3,1 27,7 B/Shanghai/361/2002 Yam B/Malaysia/2506/2004 Vic Yes 
2006-2007 48,3 3,6 45,3 2,8 65,7 5,8 28,5 B/Malaysia/2506/2004 Vic B/Malaysia/2506/2004 Vic No 
2007-2008 26,5 32,1 1,4 40,2 75,6 24,1 0,3 B/Malaysia/2506/2004 Vic B/Florida/4/2006 Yam Yes 
2008-2009 23,0 3,0 55,0 19,0 34,5 2,3 63,2 B/Florida/4/2006 Yam B/Brisbane/60/2008 Vic Yes 
2009-2010 5,0 
93,8 / 
0,2* 
0,05 1,0 87,9 3,0 9,1 B/Brisbane/60/2008 Vic B/Brisbane/60/2008 Vic No 
2010-2011  (80)
+ 
 (20)    B/Brisbane/60/2008 Vic B/Brisbane/60/2008 Vic No 
2011-2012 - - - - - - - B/Brisbane/60/2008 Vic - - - 
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2.2. The biology of influenza B virus 
 
Like IAV viruses, the genome of IBV is divided in eight segments. However, despite considerable 
biological similarities, a number of features differentiate the two viruses. On the whole, the length of 
the genome of IBV is appr. 1kb larger than that of IAV (14.6kB vs. 13.6kb). This is largely due to the 
much longer 3’ and 5’ non-coding regions flanking the IBV coding sequences 9,10. These non-coding 
regions contain complementary sequences, forming a basis for viral RNA (vRNA) secondary structure 
formation 11,12, promoter regions essential for replication and transcription 13,14 and packaging signals 
for virion formation 15. For IAV, the eight segments code for up to 12 different proteins; in the case of 
IBV, 11 open reading frames (ORF) have been identified (Table 2.2). IAV has two genus-specific 
proteins, which have only recently been identified: PB1-F2 16,17 and N40 18, both encoded by the PB1 
segment. IBV contains one protein with no known homologue in IAV: the tetrameric membrane 
protein NB, encoded by segment 6 19. In the next part of this review, proteins with a distinctive 
biological role for IBV as compared to IAV will be discussed. 
 
Table 2.2. Overview of the IAV and IBV encoded proteins. The coding strategy used to express multiple 
proteins from a single genomic segment is indicated. 
Segment Virus Proteins Coding strategy 
1 IAV/IBV PB2 - 
2 
IAV PB1 / PB1-F2 / N40 Overlapping reading frames 
IBV PB1 - 
3 IAV/IBV PA - 
4 IAV/IBV HA - 
5 IAV/IBV NP - 
6 
IAV NA - 
IBV NA/NB Overlapping reading frames 
7 
IAV M1/M2 M1 colinear mRNA; M2 spliced mRNA 
IBV BM1/BM2 
Biscistronic mRNA; start-stop pentanucleotide 
sequence (UAAUG) 
8 IAV/IBV NS1/NEP (NS2) NS1 colinear mRNA; NEP spliced mRNA 
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2.2.1. The NB protein 
 
The presence of the coding sequence for the NB protein was first described by Shaw et al. in 1983, by 
careful examination of the nucleotide sequence of segment 6 of IBV 19. NB had not been previously 
detected in radiolabeling experiments using 35S-Met, since NB only contains one methionine residue : 
the initiator methionine, which is posttranslationally removed. In a later study, Williams and Lamb 
showed that NB was a membrane associated disulfide linked oligomeric protein, with an N-terminal 
ectodomain containing two glycosylation sites used for the addition of complex-type poly-N-
lactosaminoglycans 20,21. Later, two groups independently reported that NB is present in virions as an 
oligomer, adopting a similar Nout-Cin orientation as in infected cells 
22,23.  
The NB ORF, initiated by the first AUG codon in the segment, overlaps almost completely with that of 
NA. The NA ORF starts at the eighth NB-coding nucleotide (AUGAACAAUG, with the NB start codon 
underlined and the NA start codon bold) 19. Although ribosomal control of viral gene expression is 
often used to control relative protein expression levels, NB and NA are expressed in equal amounts in 
infected cells, suggesting an equal preference of ribosomes to initiate translation from either AUG-
codon 24. However, in purified IBV virions, much lower amounts of NB than NA are found back, 
reminiscent of the relative distribution of M2 in IAV virus particles versus infected cells 22,23,25. 
The strong similarities with the M2 ion channel of influenza A virus, i.e. membrane association, 
orientation and oligomeric structure 26,27, led to the hypothesis that NB was the biological 
counterpart of M2 for IBV, serving as a passive proton channel. Initial data using viral expressed NB 
or synthesized NB transmembrane peptides reconstituted in lipid bilayers revealed cation gating 
activity, although proton-selectivity could not be certified 28-30. Moreover, this activity could be 
blocked with amantadine, also capable of blocking M2 activity 31. However, amantadine could not 
inhibit IBV infectivity, contradicting the functional equivalence of M2 and NB. Indeed, construction of 
recombinant IBV strains lacking NB expression showed no need for NB activity in in vitro systems, 
although the protein does promote efficient replication in vivo in mice 32. As of yet, no exact ion-
selectivity or function has been attributed to this IBV specific protein. However, since circulating IBV 
retain NB expression the protein is most likely important in the viral life cycle. 
 
2.2.2. The BM2 protein 
 
Currently, the BM2 protein, encoded by RNA segment 7 alongside the matrix M1 protein, is the 
accepted biological counterpart of the M2 ion channel of IAV. Surprisingly, the ORF for the protein 
was already described in 1982, i.e. before the identification of the NB ORF 33. Immediately it was 
clear that it represented a conserved feature of the virus, since alignment revealed high homology 
between different IBV strains 33-35. It was not until 1990 that a protein could be assigned to the ORF, 
which was designated BM2 36. Using antiserum raised with bacterial expressed BM2, Odagiri et al. 
could show that BM2 is a phosphorylated membrane-associated protein which is incorporated into 
virions 37. Later studies identified BM2 as an oligomeric transmembrane protein with Nout-Cin 
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orientation 38-40. This entails that BM2, like M2 and NB, is a type III transmembrane protein lacking a 
cleavable signal sequence. 
On the functional level, BM2 fulfills the role of M2 in IAV replication, although some dissimilarities 
are observed 41. Paterson et al. first recognized the similarity in the transmembrane section of M2 
and BM2, in that both contain the motif HXXXW, essential for M2 proton conductance 38,42,43. The 
assumption that BM2 was the pH-modulating channel of IBV was confirmed by electrophysical 
measurements in cellular systems 44. Precise modeling of the pore of the BM2 ion channel explained 
the inability of amantadine to block IBV replication: while the hydrophobic pore of the M2 
transmembrane section allows association with amantadine, the hydrophilic BM2 pore does not 
accommodate binding of the drug 41,45-47. An additional but essential role in IBV virion formation was 
attributed to BM2. The cytoplasmic tail of BM2 ensures membrane association of M1 and 
incorporation of vRNP in viruses, leading to virion formation; truncation of this domain yields 
improper formed virus particles 48-50. A similar function can be assigned to the M2 protein for IAV, 
which has been shown to fulfill a protagonistic role in the budding process by executing membrane 
scission of newly formed virions 51-53. The non-redundant function of BM2 in the IBV life cycle is 
exemplified by the fact that BM2-negative viruses are not viable and can only be rescued by 
complementation of the BM2 functions e.g. by growth of BM-deficient IBV in stable BM2 expressing 
cells 54. 
The specific coding strategy employed by IBV RNA segment 7 is quite intriguing. It utilizes a stop-start 
pentanucleotide (UAAUG), in which the start codon of the BM2 ORF is downstream of but overlaps 
with the stop codon (UAA) of the M1 ORF. Expression of BM2 is assured by termination/re-initiation 
events, circumventing direct recruitment of ribosomes and the need of sequences to do so. The 
biological significance of such a coding strategy is often related to expression levels. Generally, the 
second ORF will only be translated to a level of 10% compared to the first ORF, as indeed is the case 
for BM2 (reviewed in 55). Molecular analysis has revealed that the minimal upstream nucleotide 
sequences that are needed for efficient BM2 expression include the 3’-end 45 nucleotides of the M1 
ORF 56. Such sequences have been termed TURBS (termination upstream ribosome binding site) and 
they interact directly with ribosomal RNA and eukaryotic initiating factor eIF3 55,57. The precise and 
compact organization of coding sequences demonstrated by such an assembly of ORFs emphasizes 
the highly evolved viral strategies used for genomic condensation and protein expression regulation. 
 
2.2.3. The BNS1 protein 
 
The influenza NS1 proteins serve as antagonists of innate immunity to give the virus the upper hand 
at the early stage of infection. As for AM2 and BM2, the gross function of ANS1 and BNS1 is similar. 
Both proteins possess an N-terminal dsRNA binding domain and can interact with PKR to limit dsRNA 
related immune responses 58. However, both proteins also exert distinct functions within their 
respective viral life cycle. ANS1 can specifically retain poly(A)-mRNA in the nucleus and prevent pre-
mRNA splicing to create a nuclear pool of capped mRNA by inhibiting CPSF30 and PABPII function 59. 
BNS1 in its turn binds ISG15 (interferon stimulated gene 15), an antiviral ubiquitin-like protein 
upregulated by IFN type I induction, thus prohibiting its conjugation to target proteins 60. ISGylation is 
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a modification with broad implications in immunity and cellular processes, and related research has 
only scratched the surface of its biological and anti-infectious role 61. Most interestingly, two recent 
publications have identified the specificity of BNS1 to be restricted to human and non-human 
primate ISGylation 62,63. The domain of ISG15 bound by BNS1 shows species-specific conservation 
motifs, forming the basis for the restricted antagonism 64. This specific interaction is one of the first 
indications for the confined host range of IBV. 
 
2.3. Epidemiological characteristics of influenza B virus 
 
Since the 1970s, two antigenically distinct IBV lineages are acknowledged, denoted by their 
prototypical strains B/Victoria/02/1987 and B/Yamagata/16/1988 8,65,66. During the 1980s, B/Victoria 
strains dominated, after which strains of both lineages co-circulated in the human population 8. This 
has led to the creation of reassortant viruses, bearing genetic constellations containing gene 
segments of both lineages. Such viruses possess adaptive benefits and can be detected all over the 
globe 8,67-74. Specifically, recombinant viruses bearing a Victoria HA gene and a Yamagata NA gene 
appear to have quite some epidemic power, pointing to an important role for NA in creating IBV 
diversity 69-74.  
The HA of IBV is characterized by four antigenic sites: the 120-loop, the 150-loop, the 160-loop and 
the 190-helix, all of which show positive selection of specific residues 75-77. This selective pressure is 
mainly induced by antibody responses evoked by infection or vaccination, similar to IAV. Specific 
sites can be attributed to either lineage: the 150-loop appears to contain a conserved neutralizing 
epitope for Yamagata strains 78, while the 160-loop is more specific for Victoria strains 79. The  latter 
site is characterized by amino acid deletions in the Yamagata lineage, and as such it has been 
postulated that immunological pressure on this site in Victoria strains initiated the emergence of the 
Yamagata lineage 78,79. The evolutionary path followed by either lineage nowadays is dictated by 
infection and vaccination-induced herd immunity, exerting differential pressure on both lineages, 
and co-circulation with IAV 75,80. Additional to antigenic drift and insertion-deletion mechanisms, 
reassortment between both lineages can benefit IBV greatly by creating genetic diversity, often 
related to NS1 gene usage 81,82. Accordingly, groups of strains can be differentiated within each 
lineage, differing in gene constellation 80. The precise effect of specific IBV genes on replication 
efficiency and transmissibility remains unknown and could provide a wealth of information and could 
lead to formulation of novel IBV vaccines or therapeutics. 
The epidemiological significance of the antigenic distinctiveness of the two influenza B lineages has 
been illustrated by a number of studies. Two concomitant studies by the same research group using 
conventional TIV vaccinated children aimed to investigate the effect of spacing between a prime and 
booster immunization 83,84 (summarized in Table 2.3). The timing of their study combined the 
2003/2004 and 2004/2005 influenza seasons, which were characterized by a dual change in 
composition. The A/H3N2 strain was changed from A/Panama/2007/1999 to A/Wyoming/03/2003 (a 
A/Fujian/411/2002-like strain) and the IBV strain was adapted from B/Hong Kong/330/2001-like 
viruses (belonging to the Victoria-lineage) to B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like virus, 
belonging to the Yamagata-lineage). In both studies one group of children was immunized according 
to a conventional scheme, i.e. twice one-month apart, with the 2004/2005 TIV vaccine. A second 
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group of children was primed with the 2003/2004 vaccine either in the fall 83 or in the spring 84 of 
that season and boosted the next fall with the 2004/2005 vaccine. Quite striking results were seen 
when evaluating the serological responses of the two groups (scored by hemagglutination inhibition 
titers; HAI). Titers for A/H1N1 were similar in both groups, as would be expected from the inclusion 
of the same strain in both vaccines. The deviating A/H3N2 strains also elicited protective titers 
(HAI≥32) in a high percentage of both groups (70% and 84% for differential immunized children, 83% 
and 91% for identically immunized children). For IBV, the situation was completely different. Giving 
the same vaccine twice (in a short period of time) yielded protective titers in 88% and 86% of 
vaccinated children in both studies. However, the distinct vaccines could only induce protective titers 
against the novel B/Shanghai/361/2002-like virus in 39% or 27% of vaccinees, underlining the 
antigenic distinctiveness of strains belonging to the Victoria- or Yamagata-lineage. In a study utilizing 
MF59 adjuvanted TIV vaccines for immunization of elderly people in the 2007/2008, similar 
observations were made: a mismatch between the B/Malaysia/2506/2004-like vaccine strain 
(Victoria lineage) and the circulating B/Florida/04/2006-like strain (Yamagata lineage) could not 
prevent an outbreak of IBV in vaccinated people 85. 
 
Table 2.3. Overview of the results obtained by Englund et al. (2006) and Walter et al. (2006), scrutinizing the 
boosting effect of distinct IBV strains in children. Groups of children were either primed with the 2003/2004 
inactivated influenza vaccine, containing A/Panama/2007/1999 (H3N2) and B/Hong Kong/1434/2002 (Victoria-
lineage) or with the 2004/2005 vaccine, containing A/Wyoming/03/2003 (H3N2) and B/Jiangsu/10/2003 
(Yamagata-lineage), and boosted with the 2004/2005 vaccine. Boosting efficacy was evaluated by the induction 
of hemagglutination inhibition (HAI) titers ≥32. 
Virus Priming strain Booster strain HAI titer ≥32 Ref 
A/H3N2 
A/Panama/2007/1999 A/Wyoming/03/2003 
84% 83 
70% 84 
A/Wyoming/03/2003 A/Wyoming/03/2003 
91% 83 
83% 84 
IBV 
B/Hong Kong/1434/2002 (Vic) B/Jiangsu/10/2003 (Yam) 
27% 83 
39% 84 
B/Jiangsu/10/2003 (Yam) B/Jiangsu/10/2003 (Yam) 
86% 83 
88% 84 
 
Very clear evidence for antigenic individuality of the Victoria and Yamagata lineage has come from 
clinical trials using live attenuated influenza viruses (LAIV), formulated as trivalent vaccines. Belshe et 
al. organized all available data from such trials performed using successive LAIV immunization in 
children aged 0.5-6 years 86. In strain-matching situations, the effectiveness of vaccination reached 
86%. However, when circulating strains drifted from the vaccine strain (but both of the same 
lineage), this diminished to 55%. In situations where the vaccine and epidemic strain were from 
opposite lineages, effectiveness of vaccination was further reduced to 31%, leading to a lack of 
protection in vaccinees. Similar observations were made by Ohmit et al., who performed a study in 
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adults using LAIV in the 2004/2005 season when vaccine and epidemic strains did not match 87, and 
by Skowronski et al., who determined vaccine effectiveness in the 2005/2006 season in Canada when 
both the A/H3N2 and IBV vaccine strain did not match the circulating strain 88.  
Overall, the biological and epidemiological data discussed here indicate the need for better tactics to 
combat IBV epidemics. Indeed, in instances a mismatch occurs between vaccine strain and circulating 
strain, excess morbidity can be observed in vaccinated populations. This has been evidenced by a 
number of reports describing IBV outbreaks in closed environments during the 2007/2008 season 
85,89. This is especially worrying for high-risk groups, such as the elderly and people with underlying 
medical conditions. Moreover, it should be noted that IBV induces higher morbidity in children as 
compared to adults, and is more often associated with severe complications as compared to IAV 82,90-
95. Although very little data is available comparing influenza A and B infections directly in children 96, 
one study showed influenza B infection predisposes infected children to develop myositis six times 
more than influenza A infection does 97. 
 
2.4. Novel influenza B vaccination strategies 
 
Conventional TIV vaccines, containing a single IBV strain from one selected lineage, are not effective 
against IBV infection. This is clearly illustrated by the mismatch of 5 out of eleven selected vaccine 
strains with circulating strains (Table 2.1). Additionally, for reasons not quite clear yet, the 
immunogenicity of IBV in TIV vaccines is reproducibly lower than for IAV, inducing lower geometric 
mean titers (GMT) and HAI titers 85,98. Without a doubt, novel frontline strategies for inducing IBV 
immunity are clearly warranted. The most straightforward answer to the problem is inclusion of 
strains of both lineages in vaccine preparations, thus creating quadrivalent vaccines. However, this 
would impose a tremendous amount of pressure on manufacturing capacity, which would require re-
organization of production systems 99. Alternatively, frontline adjuvantation system might broaden 
the antibody responses to B/HA antigens in such a way that they become cross-reactive for strains of 
both lineages 100. Such strategies are supported by data showing that immunization with TIV vaccines 
can induce cross-lineage reactive antibodies if the subject has been primed by infection or TIV 
vaccination, although these generally do not reach theoretical protective levels 101-104. 
It is widely accepted that inactivated virus vaccines elicit a more restricted immune response as 
opposed to infectious virus. Hence, a great deal of effort has been put in development of live 
attenuated influenza vaccines (LAIV). One such approach is based on cultivation of viruses at 
decreasing temperatures, leading to the accumulation of mutations restricting efficient growth at 
higher temperature. Such cold-adapted strains display a temperature-sensitive attenuated growth 
phenotype in vivo 105-108. Recently, the group of Jonathan McCullers performed a direct comparison 
of inactivated IBV and LAIV in inducing (homotypical) protection in mice and ferrets 109. They 
concluded that LAIV is superior to inactivated virus in the animal models tested. However, clinical use 
of LAIV has shown that lineage mismatch is still an issue 86,87.  
Other LAIV formats for IBV have been developed preclinically. Based on a strategy employed for IAV, 
deletion, mutation or truncation of the BNS1 gene induces severe attenuation of viral growth in IFN-
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competent cells and mice 110-113. Infection of mice with such strains induces an immune response that 
is protective against a subsequent lethal challenge with homologous or heterologous IBV 112. 
Whether this also translates into broad protection for humans still needs to be addressed.  
A third method of inducing attenuation is by mutating the maturational cleavage site of the HA. By 
changing the basic residue responsible for cleavage of HA0 into HA1 and HA2 to Ala or Val, the 
specificity for trypsin-like proteases is changed to elastase-dependent cleavage 114,115. Recombinant 
viruses can be grown efficiently in vitro to similar titers as wild type virus, by inclusion of elastase 
instead of trypsin in culture media, but these viruses display a very low infectivity in vivo, restricted 
to a single or at most a few replication cycles. By administering high viral doses, protective immune 
responses can be evoked in homologous settings 114,115.  
A last format used for attenuation of influenza is chimerization by mixing IAV and IBV genes. 
Introduction of the B/HA gene in the IAV genetic background rendered the virus crippled in vitro and  
in vivo, but allowed the induction of very broad effective immunity active against lethal IAV 116 and 
IBV 117 infection. Analysis of the breadth and type of immunity induced by such attenuated strains, or 
LAIV in general, is warranted to optimally induce antiviral activity. Additionally, alternative 
approaches inducing attenuation, such as deletion or modification of the BM2 or NB protein 32,49,54, 
also deserve further investigation to obtain broader immunity inducing LAIV. 
A select number of research groups have endeavored to develop a recombinant protein approach to 
combat IBV infection. Most noteworthy, Bianchi et al. fused the maturational cleavage sequence of 
HA  of IBV (B/HA0) to OMPC (outer membrane protein complex) as immunogen for immunization of 
mice 118. A potential lethal infection with B/Ann Arbor/04/55 (pre-dating lineage separation), B/Hong 
Kong/330/01 (Victoria lineage) or B/Jamanashi/166/98 (Yamagata lineage) showed induction of 
protective responses with the B/HA0-vaccine. This immunity was Fc-mediated, showing no direct 
neutralization effect on IBV replication. Quite strikingly, because of conservation of the maturational 
cleavage site across IAV and IBV, immunization with a similar vaccine based on the AH3/HA0 
cleavage site also could afford protection against A/H1N1, A/H3N2 and  IBV infection 118, showing an 
ultimate universal profile of protection. Most recently, Wang et al. reported on the development of 
BM2e-specific antibodies 119. These are able to protect MDCK cells from cytopathic effects induced by 
IBV to a certain extent. Additionally, they are able to reduce but not neutralize replication of IBV in a 
plaque size reduction assay, reminiscent of M2-specific antibodies and IAV replication 25. 
 
2.5. Concluding remarks 
 
The antigenic situation of IBV is troublesome, to say the least. The constant co-circulation and 
reassortment of the Yamagata and Victoria lineage of IBV hinder effective vaccination with 
conventional TIV. Indeed, a mismatch in 5 out of the last eleven seasons highlights a major problem 
in the current vaccination policy. The easiest and fasted way of avoiding future problems is upgrading 
current vaccines (be it inactivated or live attenuated) from trivalent to quadrivalent, although this 
might create logistic and manufacturing problems. Alternative approaches should aim at inducing 
cross-lineages responses, which can be achieved by certain LAIV strains inducing cellular immunity or 
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cross-reactive antibody responses, novel adjuvantation systems, or consensus IBV sequences such as 
the maturation cleavage site of HA and BM2e. Of these, only temperature-sensitive cold-adapted 
LAIV viruses have been tested clinically and are used currently in the human population (Flumist, 
MedImmune Inc.). Clinical data from seasons with a vaccine mismatch indicate a lack of high cross-
lineage protection induced by these 86. Further investigation in immune responses elicited by (live) 
vaccination and infection might avoid this and afford the broad IBV immunity so desperately needed 
through identification of cross-protective viral features. 
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Aims and objectives 
 
As discussed in Chapter 2, the current situation of IBV vaccination and circulation does not fulfill the 
requirements needed for a reliable immunization strategy. Since the 70s, IBV has evolved into two 
antigenically distinct lineages (Victoria and Yamagata lineage) showing little or no cross-immunity 1,2. 
This entails that vaccination with trivalent inactivated vaccines, containing a single IBV strain 
belonging to one of the two lineages, does not induce protective responses against strains of the 
opposite lineage. Consequently, in the recent past a mismatch has occurred between vaccine and 
circulation strain in no less than 5 out of eleven influenza seasons. This inevitably resulted in a lack of 
protection of vaccinated people 3-5, elevating influenza-associated disease in vaccinated people, 
limiting herd immunity for non-vaccinated people and bringing discredit to the merit of general 
influenza vaccination. Novel strategies to induce cross-reactive IBV immunity, encompassing strains 
of both lineages, are needed. A small number of research groups have endeavored to do so, although 
little in vivo evidence for cross-lineage protection has been generated as yet 5-10. In light of this, we 
set out to develop next-generation cross-reactive IBV vaccine designs. 
In a first part of the research, the immunogenic and protective potential of a number of conserved 
features of IBV was assessed. Alignment of the sequence of selected extravirionic antigens, namely 
the NB and BM2 ectodomain (termed NBe and BM2e, respectively) and the maturational cleavage 
site of HA (termed B/HA0), instigated the development of chimeric proteins based on consensus 
sequences of these three antigens. A number of different protein carriers were chosen to render the 
small antigens immunogenic, and were combined with different expression systems. The rationale 
for this was to present the selected antigens in a manner mimicking their natural structure, adopted 
during infection, as much as possible. To assure such a conformational mimickry, and to evaluate the 
assembly of the proteins in general, in vitro experiments were designed to identify the molecular 
characteristics of the chimeric proteins. In a next phase, the in vivo immunogenicity and protective 
nature of the induced response of the cross-reactive IBV vaccine candidates was tested. To this end, 
the vaccine candidates were combined with different adjuvants and used to immunize mice. 
Serological analysis of evoked immune sera was done in several manners to tax the recognition of 
viral proteins. Finally, challenge of immunized mice with mouse-adapted IBV strains of both lineages 
formed the ultimate test to determine the merit of the selected antigens in general and the design of 
our cross-reactive vaccine candidates specifically. 
Performing experiments with NBe-based proteins led to the serendipitous identification of an NBe-
encoded T cell epitope, specific for the H2b-background of C57Bl/6 mice. In a second part of the 
research, the induction and antiviral activity of such cellular responses was examined in-depth. 
Specifically, the relation between proteinaceous and viral induction of NBe-specific T cells was 
scrutinized, as a model for boosting primed cellular immunity by natural IBV infection. 
Overall, the main objective of this research, scrutinizing conserved features of IBV in eliciting cross-
reactive protection, was to contribute to the strategic development of novel frontline influenza 
vaccines. Additionally, we hope to obtain further insight in influenza immunity and the cross-talk 
between immunization and infection in inducing cross-reactive immunity to IBV. Eventually, this 
might lead to the adaptation of new antiviral tactics to prevent or  treat influenza infection. 
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3.1. Introduction 
With the appearance of two antigenically distinct lineages of influenza B virus in the past three to 
four decades, classic trivalent vaccines have been shown to be inappropriate for optimal protection 
against influenza B. Numerous mismatches between the selected vaccine strain and epidemic 
circulating strain have already occurred, leading to excessive infection rates and associated morbidity 
in the (vaccinated) population 1. Most of these mismatches are the mere consequence of predicting 
circulation of a B virus strain belonging to the opposite lineage, or of co-circulation of viruses 
belonging to both lineages. Hence, a number of authors have already pushed the idea forward of 
including viruses of both lineages in tetravalent influenza vaccine preparations 1,2. Alternatively, 
attention has been drawn towards new prophylactic treatments of influenza B virus infection in 
humans, using novel immunization strategies or conserved viral features. In this chapter, we describe 
the first in-depth analysis of the potential merit of the ectodomains of the NB and BM2 
transmembrane protein of influenza B in vaccination strategies. Here, we will focus on the 
construction, expression, purification and in vitro characterization of proteins based on selected 
conserved features fused to appropriate carrier proteins.  
 
3.2. Results and discussion 
 
3.2.1 Vaccine basis, construction and expression 
 
a) Selected influenza B derived epitopes for cross-protective vaccine development 
 
Influenza B viruses contain a number of conserved viral features which can serve as a basis for a 
broad vaccine design. In this PhD study, three epitopes were selected to form the basis of a broadly 
protective influenza B vaccine (Fig. 3.1).The first of these received the most attention, namely the 
ectodomain (NBe) of the NB ion channel. NB is a tetrameric transmembrane protein, encoded by 
segment 6 by a open reading frame overlapping with that of neuraminidase (NA). NB serves an as yet 
unidentified  but seemingly indispensable in vivo role in the influenza B virus life cycle 3,4. NBe forms 
the N-terminal region of the protein, comprising a total of 18 amino acids. It shows a high degree of 
conservation, based on the alignment of 854 NBe-sequences obtained from influenza B strains 
isolated between 1940 and April 2011 (Fig. 3.1A). Of note, this short sequence contains two sites (N3 
and N7) for the addition of N-linked glycosyl-structures, which are used in  NB protein expressed by 
infected mammalian cells 5,6.  
A second epitope  that was studied, is the ectodomain (BM2e) of the selective proton channel BM2. 
This protein is the biological counterpart of the M2 proton channel of influenza A virus and shares a 
number of features illustrating this. Like the NB protein, both M2 and BM2 are type III 
transmembrane proteins, with an N-terminal ectodomain and lacking a secretion signal 5,7. The 
transmembrane section of both proteins contains the conserved HXXXW motif, responsible for 
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selective passive transport of protons across lipid membranes 7,8. BM2 or M2 is necessary for 
efficient in vivo replication of influenza B or A virus, respectively 9,10. The BM2e, however, is 
significantly shorter than M2e, comprising only 8 amino acids compared to 23 for M2e. These 
however are highly conserved among all sequenced influenza B isolates (Fig. 3.1B). Quite recently, 
Wang et al. described the isolation of BM2e-specific monoclonal antibodies and their successful use 
in in vitro inhibition of influenza B infection 11, enforcing its potential use in cross-protective influenza 
B vaccine development. 
A third epitope scrutinized here is the cleavage peptide of the influenza B hemagglutinin (HA). For HA 
to obtain its membrane fusion activity, the protein needs to be cleaved at residue R329. This 
transforms the precursor HA, termed HA0, into two chains, covalently linked by cysteine bridges, 
termed HA1 and HA2. HA1 comprises the globular head of the protein, bearing the main antigenic 
sites responsible for the induction of anti-HA neutralizing humoral responses. The HA2 segment 
contains the stem region, in recent years shown to be minor immunogenic in natural infectious 
settings but an interesting candidate for a broadly protective vaccine for influenza A viruses 12-15. In 
addition, the N-terminus of HA2  forms the fusion peptide, responsible for membrane insertion and 
fusion of the viral and host cell membranes, a step that is essential for delivery of the influenza 
genetic material into the cytoplasm 16. To be accessible for proteases, the cleavage peptide forms a 
loop protruding from the stem structure 17. This loop is likely also exposed to the host’s adaptive 
immune system. Moreover, the structural and biological constraints impose a strong conservational 
pressure on the primary sequence of the exposed loop (Fig. 3.1C). On these premises, Bianchi et al. 
explored the natural immunogenicity of the influenza A and B HA cleavage peptide (termed A/HA0 
and B/HA0) and demonstrated protection against viral challenge following immunization of mice 
with conjugate vaccines comprising the maturational cleavage loop of HA 18. With conservation of the 
cleavage loop sequence even crossing the A/HA – B/HA barrier, they were able to show protection 
against influenza A/H1, A/H3 and B viruses when using a fusion loop conjugate derived from A/HA3 
based vaccine. 
 
A B
C
 
 
Figure 3.1. Conservation of selected influenza B 
derived epitopes used in this research. For the 
sequence analysis, all sequences available in the 
Influenza Research Database (www.fludb.org) from 
1940 until April 2011 for NBe (A; n = 854), BM2e (B; n = 
381) or the B/HA0 cleavage loop (C; n = 662) were 
aligned. X-axes indicate the consensus amino acid 
sequence, the Y-axes show the relative conservation of 
each amino acid residue. 
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b) Selected carrier proteins 
 
To render small linear polypeptides immunogenic, they need to be linked to a scaffold that facilitates 
their presentation to the immune system. In most cases, these carriers are protein-based, with a 
potential adjuvant function and or helper T cell epitopes. The fusion of an immunogen to a carrier 
can also be designed in such a way that it provides conformational mimicry of the epitope that is 
naturally produced. In their natural conformation, NBe and BM2e are presented on the infected cell 
or viral surface in a tetrameric fashion. As a whole, the tetrameric assembly might form a 
conformational epitope able to elicit tetramer-specific antibodies. Assuming this, a second carrier 
chosen for fusion with NBe and BM2e is a tetramerizing mutant form (tGCN4) of the leucin zipper of 
the GCN4 transcription factor of yeast 19. It has been successfully used in combination with M2e, 
showing induction of tetrameric M2e-specific antibodies and protection against a potential lethal 
influenza A infection 20. The construction and assembly of tGCN4-based immunogens used in this 
research is depicted in Figure 3.2. For the BM2 ectodomain, two different constructs were made 
differing in the length of BM2e (Fig. 3.2A and C). In a first, only the 5 first amino acids of BM2e were 
used, linked to tGCN4 by a Gly-Gly linker. A second BM2e-based tetramer used the full 8 amino acids 
of the BM2 ectodomain fused directly to tGCN4, mimicking the natural BM2 structure as close as 
possible regarding implantation of the ectodomain on the tetramer 21.  
 
NBe tGCN4GG GG 3xFlag
BM2e tGCN4GG
NBe
tGCN4
Flag
L I L I L I L I LKQ EDK EE LSK YH ENE AR KKL GEtGCN4
MDYKDHDGDYKDHDIDYKDDDDK3xFlag
MLEPFBM2e
MNNATFNYTNVNPISHIRNBe
MLEPFQILBM2e(QIL)
BM2e(QIL) tGCN4
M2e-tGCN4
NBe-tGCN4-Flag
BM2e-tGCN4
BM2e(QIL)-tGCN4
A
C
B
tGCN4GGM2e
MSLLTEVETPIRNEWGCRCNDSSDM2e
tGCN4 GG 3xFlagTGCN4-Flag  
Figure 3.2. Construction and make-up of tetrameric tGCN4-based chimeric vaccines. A. Amino acid sequences of the 
different ectodomains used in this research (top four), the tGCN4 scaffold and the triple Flag-tag added for solubility of 
NBe-tGCN4. For the tGCN4-sequence, residues forming the hydrophobic interface responsible for tetramerization are bold 
in red. B. Schematic representation of the tetrameric NBe-tGCN4-Flag chimeric protein. C. Build-up of all bacterial 
expressed tGCN4-based proteins used in this research. 
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For presenting NBe, the ectodomain is linked to tGCN4 by a Gly-Gly linker (Fig. 3.2C). This fusion 
however turned out to be almost completely insoluble (see further). The addition of a triple Flag-tag 
improved solubility tremendously, allowing successful production and purification of the resulting 
chimeric protein NBe-tGCN4-Flag. As control for tGCN4-based immunizations, M2e-tGCN4 was used. 
For detection of tGCN4-specific antibody titers in immunization experiment, tGCN4-Flag without an 
additional N-terminal sequence was produced. 
For a stable, repetitive and high-density presentation of immune epitopes, we used the core protein 
(HBc) of Hepatitis B virus 22-24. It is a well-evaluated carrier protein, that has already been successfully 
used with a wide variety of antigens 23,24. Of these, the fusion of M2e of influenza A virus with HBc 
has been extensively evaluated by our research group 25-28. As scaffold protein, it is used in different 
conformations, based on the presence or absence of the protamine-like nucleic acid binding C-
terminal regions. It has been shown that the presence of trace amounts of nucleic acids inside HBc-
particles (derived from the organism used for production 29) adds on to the adjuvant effect of the 
protein 30. Here, however, the truncated form of HBc was used (149 amino acids in length) to avoid 
issues with complexity of the vaccine preparations. A C-terminal cysteine-residue was added to 
increase stability of particle formation. This approach allows properly folded HBc-monomers to 
dimerize and self-assemble into particles containing 180 or 240 monomers upon expression (Fig. 
3.3B) 31.  
Two of the selected influenza B epitopes were combined with C-terminally truncated HBc particles 
(HBc149) lacking the nucleic acid binding domain (Fig. 3.3A). The NBe-epitope was fused N-terminally 
to HBc-sequence (replacing amino acids 1-4) or inserted into the immunodominant loop (replacing 
amino acids 78-82), protruding as spikes from assembled particles formed by two adjacent -helices 
in the dimer 24. The N-terminal fusion yielded particle 1651; the particle with NBe inserted into the 
loop was termed 1646. A third construct combined the presence of NBe and M2e into one particle. In 
this construct, NBe was fused N-terminally to particle 1817 containing 2 M2e-copies 26. In this 
particle, the most HBc-proximal M2e-copy contains its natural cysteine-residues, while these are 
removed in the more distal copy. It is expected that the remaining cysteines within M2e stabilize 
particle formation additionally 26. The resulting construct was termed NM2H (NBe-2M2e-HBc), which 
showed improved solubility over other NBe-HBc fusions tested (data not shown) and would display 
NBe N-terminally (as in natural expressed NB) extending from the particle. Moreover, with the 
combination of NBe and M2e, this vaccine could be protective against influenza A and B viruses. All 
of these construct contain an additional cysteine-residue C-terminally of HBc (position 150), 
mimicking the cysteine-residue in full-length HBc at position 183, which should further assist in 
particle formation by cross-linking HBc-dimers to each other 26,32. 
The second epitope used in combination with HBc is the B/HA0 cleavage sequence (for structural 
information, see Fig. 1.2D and H, p16). Conformationally, this is a loop sequence, and hence was 
introduced in the immunodominant loop of HBc. To overcome problems with solubility, this chimeric 
protein was produced by a dual expression system combining unsubstituted HBc and B/HA0-HBc, 
yielding particles with mixed free and substituted loops termed 3004. An overview of all HBc-
constructs used in this thesis is given in Table 3.1. 
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PAKLLKER’GFFGAIAGFLEB/HA0
MNNATFNYTNVNPISHIRNBe
A
B
N-terminus
Immunodominant 
loop
 
Figure 3.3. Construction and make-up of Hepatitis B core (HBc) protein based vaccines. A. Amino acid sequences of the 
influenza B epitopes used for fusion to HBc, NBe (top) and the B/HA0 cleavage loop (bottom). The apostrophe in the B/HA0 
sequence indicates the cleavage site. B. Assembly of HBc-particles. Properly folded HBc monomers combine into dimers, 
which assemble into particles consisting of 180 or 240 monomeric building blocks. The spikes in the particle are formed by 
two adjacent -helices of monomers in the HBc-dimer. Specific sites in monomers used for insertion of antigens are 
indicated by the red arrows. Pictures based on 
33
 
 
Table 3.1. Overview and description of HBc-based IBV vaccine candidates used throughout this thesis. 
Shortname Construct  Specifications 
1646 NBe-HBc(149)  
NBe sequence inserted in the immunodominant loop 
of HBc(149) 
1651 NBe-HBc(149)  NBe fused N-terminally to HBc(149) 
1817 M2e2-HBc(149)  Two copies of M2e fused N-terminally to HBc(149) 
NM2H NBe-M2e2-HBc(149)  One copy of NBe fused N-terminally to 1817 
3004 B/HA0-HBc(149)  
B/HA0 cleavage loop inserted in HBc(149), produced 
as mixed substituted/unsubstituted HBc-particles 
 
During infection, the NB protein is expressed as a glycoprotein, with addition of complex-type poly-
N-lactosaminoglycan structures on two sites in NBe 6. To assess whether glycosylated NBe-based 
vaccines can offer protection against influenza B infection, two different strategies were employed. 
In a first approach, NBe-tGCN4 was produced in a yeast expression system. In this instance, the 
protein was soluble without the Flag-tag (see further).  
In a second approach, cellular expressed and membrane-associated NBe-based proteins were 
utilized. In our hands, full-length NB protein expression by transfection of mammalian cells is not 
high-yielding, both by transient transfection or stable transduction, when analyzed by western blot 
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(data not shown). Full-length M2 and BM2 proteins however were efficiently expressed in 
mammalian cells that had been transfected with the corresponding expression plasmids (see 
further). For these reasons, ectodomain swaps were performed, in which the BM2- or M2-
ectodomain was replaced by the NB-ectodomain and vice versa (Fig. 3.4). The influence of 
glycosylation on expression and immunogenicity was taxed through mutation of these (N3Q and 
N7Q), either separately or together (Fig. 3.4C). To ease detection, a single Flag-tag was added C-
terminally of these chimeric constructs.  
For all constructs, a silent mutation was introduced in the NBe-sequence, deleting the startcodon of 
the downstream open reading frame of NA (ATGAACAATGCT  ATGAACAACGCT). This was done to 
avoid potential problems with translation initiating at this second AUG-codon. 
 
Ectodomain
TM
domain
Cytoplasmic
domain
Single 
Flag-tag
LVVAASIIGIL LIL IL HLFFKCIYRFFKHGLKRGPSTEGVPESMREEYRKEQQSAVDSDDSHFVSIELEH W DM2
DYKDDDDKGTFlag-tag
MNNATFNYTNVNPISHIRGSVNBe(WT)
MLEPFQIBM2e
Ectodomain Transmembrane - cytoplasmic domain
C D
MN ATFNYTNVNPISHIRGSVQNBe(GM1)
MNNATF YTNVNPISHIRGSVQNBe(GM2)
MN ATF YTNVNPISHIRGSVQ QNBe(GM1+2)
MSLLTEVETPIRNEWGCRCNDSSDPM2e
LSICSFILSAL FMA TIGHLNQIKRGVNMKIRIKGPNKETINREVSILRHSYQKEIQAKETMKEVLSDNMEVLSDHIVIEGLSAEEIIKMGETVLEIEELHH WBM2
IITICVSFTVILTIFGYIAKIFTNRNNCTNNAIELCKRIKCSGCEPFCNKRGDTSSPRTGVDIPSFILPGLNLSESTPNNB
B
A
AS Flag-tag
 
Figure 3.4. Construction and make-up of chimeric transmembrane proteins. A. General structure of transmembrane 
proteins, consisting of an ectodomain combined with a transmembrane and cytoplasmic domain. A C-terminal Flag-tag, 
following a Ala-Ser (AS) linker, allows easy detection of the proteins. B. Amino acid sequences of M2, BM2 and NB protein. 
For M2 and BM2, the amino acids responsible for proton-selective gating are shown bold and in blue. C. Sequences of the 
ectodomains used for domain-swapping in expression of chimeric transmembrane proteins and the single Flag-tag for 
detection. For the NBe-sequences, glycosylation mutants (GM), with removal of the first (GM1), the second (GM2) or both 
(GM1+2) N-glycosylation sites, are shown with altered residues in bold and red. D. Cartoon representation of membrane-
associated chimeric proteins. 
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c) Expression and purification of chimeric proteins 
 
 For initial expression, purification and structural tests of M2e-, NBe- and BM2e-tGCN4 fusion 
proteins, tags were introduced C-terminally. These include both a hexahis-tag (His6) and a triple Flag-
tag. Expression of all these constructs was optimized using E. coli B strains (BL21 CodonPlus) and 
transcriptionally controlled by the pL-promotor. To avoid unwanted expression under non-optimal 
conditions, potentially leading to counter selection or mutation, the pICA2 repression plasmid was 
used (Fig. 3.5) 20. In this system, a temperature sensitive variant of the cI-repressor 34 assures 
silencing of pL-promotor based transcription at temperatures below 30°C; repression can be lifted by  
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Figure 3.5. E. coli based expression of tGCN4-based proteins. A. Vector map of the pICA2 repression plasmid, used in the 
bacterial expression system for the production of tGCN4-based proteins. B. Schematic representation of the bacterial 
expression system used here. When incubating cultures below 30°C, in trans expression of the temperature-sensitive cI(ts) 
will block pL-promotor driven expression of the protein of interest (top). Increasing the cultivation temperature to 42°C will 
lead to inactivation of cI(ts) and expression of the protein of interest (bottom). The pICA2 repression plasmid also codes for 
the P22 anti-repressor, which can hetero-oligomerize with the cI-repressor and inactivate it as such. Expression of this anti-
repressor is under control of a hybrid promotor containing Lac-repressor sites, which are bound by the LacI-repressor, also 
encoded by pICA2. Addition of lactose-analogues such as IPTG will alleviate LacI-based repression, lead to anti-repressor 
expression and block cI repression (middle). C. Expression tests of NBe-tGCN4 proteins without tag (left), with a His6-tag 
(middle) or with a triple Flag-tag (right), analyzed by SDS-PAGE and Coomassie-staining after sonication of bacterial cultures 
(see Material and Methods). 1 = gel marker with mass in kDa, 2 = non-induced sample, 3 = IPTG-induced sample (30°C), 4 = 
temperature-induced sample (42°C); S = supernatant after sonication, P = pellet after sonication. D. Overview of all BM2e- 
and NBe-tGCN4 proteins expressed after temperature induction of bacterial cultures. 1 = gel marker with mass in kDa, 2 = 
non-induced sample, 3 = BM2e-tGCN4, 4 = BM2e-tGCN4-His, 5 = BM2e-tGCN4-Flag, 6 = NBe-tGCN4, 7 = NBe-tGCN4-His, 8 = 
NBe-tGCN4-Flag; S = supernatant after sonication, P = pellet after sonication. 
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raising cultivation temperature to 42°C. The system also allows induction at lower temperatures, for 
instances in which problems are anticipated with solubility of the expressed protein due to high 
induction temperature. The anti-repressor from the Salmonella specific bacteriophage P22 35, able to 
hetero-oligomerize with the cI-repressor and inactivating it as such, is under control of a hybrid 
promotor containing Lac-repressor sites (pN25/02). In cis expression of the lac-repressor prevents 
expression of this cI-antirepressor. Addition of non-metabolizable lactose-analogues, such as 
isopropyl--D-1-thiogalactopyranosid (IPTG), blocks repression of the pN25/O2 promotor by the Lac-
repressor, leading to expression of the cI-antirepressor and freeing of the pL-promotor (Fig. 3.5B).  
The results of expression tests of NBe-tGCN4 are shown in Figure 3.5C. Untagged and  His6-tagged 
NBe-tGCN4 chimeric protein resulted in insoluble recombinant proteins  upon induction, as does. The 
addition of the highly charged triple Flag-tag improves solubility significantly. Hence, this format was 
purified and used for further in vitro and in vivo analysis. For BMe-based proteins, the presence or 
absence of a tag did not alter solubility tremendously, since all combinations show high expression of 
soluble protein (Fig. 3.5D). Tagless BM2e-tGCN4 was purified and used for downstream analyses. As 
induction method for all tGCN4-proteins, temperature induction was chosen. Higher incubation 
temperatures did not affect solubility greatly here, but did lead to slightly lower culture densities and 
hence lower amounts of endogenous proteins in the lysates after sonication. 
Purification of tGCN4-based proteins exploits their physicochemical properties as much as possible. 
The heat-stability of the tGCN4-tetramer 19 and the lack of effect of temperature-induction on 
solubility of the proteins, tempted us to assess the effect of heat-treatment on the protein samples 
for purification purposes. Incubating samples directly after sonication for 30 minutes at 65°C resulted 
in denaturation of most of the endogenous proteins, without affecting the solubility of the tGCN4-
based proteins (Fig. 3.6A). This highly effective first step in the purification process was therefore 
applied before further chromatographical steps.  
The purification process of NBe-tGCN4-Flag is illustrated in Figure 3.6. Following induction, sonication 
and heat precipitation, the mixture was centrifuged and filtered to remove insoluble particles. In the 
next step, the protein sample was applied to a SourceQ anion exchange column, with the main 
purpose being the removal of nucleic acids in the lysate. NBe-tGCN4-Flag eluted in two different 
peaks (Fig. 3.6C), most likely differing in overall charge. Applying the first peak on a gel filtration 
column after concentration (Fig. 3.6D) resolved two species that differ in size. Analyzing the second 
peak from the anion exchange chromatography on the gel filtration column showed presence of 
solely the first protein species with high molecular weight (MW; data not shown). Although not so 
outspoken for other chimers, tGCN4-proteins seem to behave as a mixture of different species with 
distinct size and charge. A potential explanation is association of some of the tGCN4 chimeric 
proteins with bacterial endogenous proteins, as previously seen for M2e-tGCN4 20, although other 
explanations such as multimerization of tetramers cannot be ruled out. For further analyses, only 
protein corresponding to peak 2 of the gel filtration, with an estimated molecular mass 
corresponding to that of the tetramer, was retained for further analysis. 
The yield for each protein after expression and purification illustrates the power of the bacterial 
expression system used. On average, M2e-tGCN4 and NBe-tGCN4-Flag purification resulted in 10-20 
mg per liter of bacterial culture (shake flasks), while for BM2e-tGCN4 proteins this reached 30-100 
mg per liter of culture. tGCN4-Flag purification yielded 300-600mg per liter of bacterial culture. 
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Figure 3.6. Purification of tGCN4-based proteins. A. Effect of heat-treatment (30min, 65C) of sonicates of tGCN4-Flag (left), 
BM2e-tGCN4 (middle) and NBe-tGCN4-Flag (right). Directly after sonication, lysates were centrifuged or heat-treated before 
centrifugation, followed by analysis of soluble and insoluble fractions through SDS-PAGE and Coomassie staining. Arrows 
indicate bands corresponding to tGCN4-proteins. 1 = gel marker, 2 = samples after sonication without heat-treatment, 3 = 
samples after sonication and heat-treatment; S = supernatant, P = pellet. B. Flow chart showing the different steps used for 
purification of tGCN4-proteins. C. Anion exchange profile and SDS-PAGE analysis of relevant samples of NBe-tGCN4-Flag 
purification. Elution peaks and corresponding fractions containing NBe-tGCN4-Flag are indicated. D. Gel filtration profile 
and SDS-PAGE analysis of relevant samples of NBe-tGCN4-Flag purification. Elution peaks and corresponding fractions 
containing NBe-tGCN4-Flag are indicated. 
 
HBc-particles were expressed and purified using the same bacterial system relying on pL-promotor 
driven transcription and pICA2-encoded repression as was used for the tGCN4 fusions. In this 
instance, we opted for IPTG-based induction at lower cultivation temperatures, since induction at 
elevated temperatures led to higher amount of insoluble material (data not shown). After sonication 
and centrifugation, the cleared lysates were treated with (NH4)2SO4 (30% saturation) to specifically 
 
78 Chapter 3 
precipitate large proteins such as HBc-particles. Pellets were resuspended and dialyzed extensively, 
followed by fractionation by anion exchange chromatography. In a final gel filtration step on a 
Sephacryl S400 column, particles were selected on size and the solution buffer was changed to PBS 
for in vitro use. This protocol was applied for purification of 1646, 1651 and NM2H. A number of 
particles, namely  3004, 1817 and unsubstituted HBc, were produced and purified by Acambis Inc. 
(Cambridge, MA). 
For expression of N-glycosylated NBe-proteins, eukaryotic expression systems have to be used. The 
recombinant transmembrane proteins were expressed by transfection of mammalian cells (HEK293T, 
CHO, NIH3T3). Plasmids used for expression are pCAGGS based, relying on transcription from a 
constitutive chicken β-actin/rabbit β-globin hybrid promoter. For vaccination studies, transfected 
cells as such were used as immunogen. Glycosylated NBe-tGCN4 (gNBe-tGCN4) was produced by 
stable transformation of  Pichia pastoris strains with methanol inducible expression plasmids. Two 
different strains of Pichia were used: the wild-type strain GS115 and a glyco-engineered strain (KE3) 
producing only proteins bearing a Mannose5-glycostructure 
35,36. As analyzed on SDS-PAGE, the 
majority of yeast-produced gNBe-tGCN4 however did not show glycosylation (Fig. 3.7). Remarkably, 
in contrast to bacterially expressed NBe-tGCN4, solubility does not seem to be a problem in the 
Pichia pastoris expression system. Most likely reasons for this are the lower expression levels 
combined with secretion of the protein in the yeast expression system. Additionally, low-grade 
glycosylation of only a single monomer in the tetrameric structure might increase solubility as such. 
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Figure 3.7. Cation exchange purification of gNBe-tGCN4 produced by wild type GS115 and glycomutant KE3 P. pastoris 
strains. SDS-PAGE analysis of samples from purification of gNBe-tGCN4 produced by wild type GS115 (A & C) and glyco-
engineered KE3 (B & D)  P. pastoris. Culture supernatants containing secreted gNBe-tGCN4 were concentrated and applied 
to a cation exchange column. The triangle depicts the elution phase with increasing salt concentrations. Presence of 
proteins was analyzed by Coomassie staining (A & B) or Western blot using tGCN4-specific rabbit serum (C & D). 1 = gel 
marker with mass in kDa, 2 = culture supernatant, 3 = concentrated culture supernatant, 4 = concentrate diluted in sample 
buffer, as applied on the column, 5 = flow-through fraction, 6 = wash fraction, triangle = elution with increasing ionic 
strength; NG = unglycosylated NBe-tGCN4, gNG = glycosylated gNBe-tGCN4. 
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Purification of gNBe-tGCN4, secreted by methanol-induced yeast cultures, started with concentration 
of the cell-free culture media by filtration or fractional (NH4)2SO4-precipitation (specific precipitation 
between 40% and 80% (NH4)2SO4). Because of the predicted overall positive charge of the protein at 
neutral pH (pI = 7,69), the concentrate was applied to a cation exchange column (Fig. 3.7). Analysis of 
the elution fractions on SDS-PAGE clearly shows gNBe-tGCN4 produced by wild type yeast shows a 
more dispersed glycosylation pattern compared to the Mannose5-strain produced protein. Although 
not resembling the natural glycosylation state, the more uniform character of the Mannose5-bearing 
gNBe-tGCN4 was selected for further analysis. Final purifications steps, gel filtration and 
concentration, were similar to E.coli produced tGCN4-protein purification. 
 
3.2.2 In vitro characterization of tGCN4-based cross-reactive influenza B vaccine candidates 
 
The quintessential property of the tGCN4-scaffold is its ability to tetramerize spontaneously, and thus 
present linked epitopes in a tetrameric fashion. To evaluate the quaternary structure of purified 
proteins, a number of in vitro tests were performed to assess the MW of these. N-terminal 
sequencing by Edmann-degradation showed that the primary sequence of the monomers was as 
expected (data not shown). For NBe-tGCN4-Flag, on average 80% of the protein retained the 
initiating methionine. Likewise, the majority of  BM2e-proteins did not show cleavage of this residue. 
This last result was confirmed by mass-spectrometric determination of the MW of tagged and 
untagged BM2e-tGCN4 proteins, as described before 20. Ionization led to disruption of the tetrameric 
structure, allowing detection of the MW of monomers only. These, however, did confirm the 
presence of the initiating methionine and showed that the monomers are intact. For BM2e-tGCN4 
(theoretical mass of 4438.22Da), the detected mass was 4438.2Da; for BM2e-tGCN4-His6 (theoretical 
mass of 5375.17Da), this was 5375.3Da; for BM2e-tGCN4-Flag (theoretical mass of 7339.15Da), a 
mass of 7326.6Da (with somewhat lower resolution) was detected. 
 
a) Size-exclusion and native PAGE yield molecular weights corresponding to that of tetramers 
 
The final step of purification of tGCN4-based proteins is gel filtration, achieving both size exclusion 
and productive buffer exchange. Additionally, calibration of the specific column used can generate 
information about the size and oligomeric state of the proteins. For gel filtration of the tGCN4-
proteins, a Superdex75pg column was used, calibrated using a combination of bovine serum albumin 
(66 kDa), ovalbumin (43 kDa), chymotrypsinogen A (29 kDa) and RNase A (13.7 kDa). Figure 3.8A 
shows the calibration profile. Overlaying this profile with those of the tGCN4-proteins (Fig 3.8B-F) 
indicates that these are in an oligomeric state with molecular sizes agreeing with a tetramic 
structure. 
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Figure 3.8. Gel filtration profiles of tGCN4-bases proteins using a calibrated column reveal that they adopt an oligomeric 
state. A. Gel filtration profile of a mixture of proteins with known sizes applied to the Superdex75pg column. This mixture 
includes BSA (66kDa), ovalbumin (43kDa), chymotrypsinogen A (29kDa) and RNase A (13.7kDa). B-F. Overlay of profiles 
from the calibration (A; in red) with that of (in black) tGCN4-Flag (B), BM2e-tGCN4 (C), BM2e(QIL)-tGCN4 (D), NBe-tGCN4-
Flag (E) and gNBe-tGCN4 (F). Peaks containing the protein of interest are indicated; other peaks correspond to 
contaminating proteins or UV-absorbing molecules in general (cf. Fig.3.6D). 
 
A second method to determine the oligomeric state of native proteins and their approximate 
molecular weight is native gel electrophoresis, based on the methods of Bryan and Davis 37,38 (Fig. 
3.9). In this approach, proteins of interest together with a number of reference proteins are loaded 
on a series of native polyacrylamide gels with increasing acrylamide concentration. Based on the 
mobility (measured as ratio-to-front or Rf values) of a set of reference agents, a standard curve can 
be drafted showing the relationship between MW and the effect of gel density on the Rf value. From 
this, the molecular size of the proteins of interest can be deduced. Three different tGCN4-based 
proteins were evaluated in this way (Fig. 3.9D). For all of these, deduced MW are in agreement with 
theoretical numbers for tetrameric forms of the protein. 
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Figure 3.9. Native PAGE approach to determine the molecular size of selected tGCN4-based proteins. Reference proteins 
and selected tGCN4-proteins were analyzed on native gels with different gel percentages. A. Coomassie stain of a 9% native 
gel. 1 = BSA (monomer, bottom; dimer, top), 2 = ovalbumin, 3 = carbonic anhydrase, 4 = -lactalbumin, 5 = tGCN4-Flag, 6 = 
BM2e-tGCN4, 7 = BM2e(QIL)-tGCN4, 8 = NBe-tGCN4-Flag, 9 = M2e-tGCN4. B. Graph showing the relationship between gel 
concentration and mobility of the proteins (measured as ratio-to-front or Rf values), showing a linear relationship with 
negative slope. C. Standard curve showing the relationship between the size (MW) and slope of the mobility graph depicted 
in B. D. Deduced MW of native tGCN4-proteins based on the standard curve depicted in C and slopes of the mobility graphs 
depicted in B. 
 
b) Cross-linking experiments reveal tetrameric and intermediate structures 
 
To visualize tetramers or oligomeric structures in general, tGCN4-protein solutions were treated with 
two different homobifunctional cross-linkers, bis(sulfosuccinimidyl)suberate (BS³) and dithiobis-
(succinimidyl)propionate (DSP). Both react with primary amino-groups, but the spacer arm of DSP 
contains a reducible disulfide-bridge. Cross-linked samples were analyzed by SDS-PAGE in the 
presence or absence of -mercapto-ethanol in the loading buffer, to assure effects seen on gel are a 
consequence of the cross-linking. Results of two independent cross-linking experiments are shown in 
Figure 3.10. In a first set-up, BM2e-tGCN4 was treated with both cross-linkers at two different 
concentration (Fig. 3.10A and B). In the absence of reducing agents, all treated samples show a main 
species running at just under 14kDa (Fig. 3.10A). With the theoretical MW of tetrameric BM2e-tGCN4 
being 17.75kDa, this result is in line with the expected, since cross-linking might compact the 
structure to a certain extent and render it somewhat more mobile than expected. DSP-treated 
samples seem to have higher mobility than BS³-treated samples; this can be explained by the 
difference in MW of both cross-linkers, with the larger BS³ (572.43Da) increasing the size of the 
 
82 Chapter 3 
structure more than the smaller DSP (404.42Da). Also note the presence of other bands in treated 
samples, corresponding to sizes of intermediate monomer, dimer and tetramer structures. With the 
addition of reducing agents (Fig. 3.10B), BS³-treated samples behave the same, while DSP cross-
linked species all fall back to the size of the monomer. 
In a second experiment (Fig. 3.10C and D), BM2e(QIL)-tGCN4, M2e-tGCN4 and NBe-tGCN4-Flag were 
treated with BS³ or DSP cross-linkers under the same conditions and analyzed in a similar manner. In 
the absence of reducing agents (Fig. 3.10C), the majority of cross-linked samples show mobility 
corresponding to that of tetramers. Note the uncross-linked M2e-tGCN4 sample (lane 3a) behaves as 
a dimer, indicating the influence of M2e-encoded cysteine-residues on the organization of the 
structure. Under reducing conditions (Fig. 3.10D) , BS³-treated samples behave similarly, while DSP-
treated proteins show more species of lower complexity (monomer, dimer and trimer). A third 
experiment, with equivalent results, is described further (Fig. 3.14). Overall, these cross-linking 
experiments show that tGCN4-proteins can be fixed in a complex with a size corresponding to that of 
the expected tetramer. 
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Figure 3.10. Cross-linking experiments show tetrameric and intermediate structures of tGCN4-proteins. Selected tGCN4-
proteins were treated with two homobifuncional cross-linkers, BS³ and DSP, of which DSP has a reducable disulfide bridge 
in its spacer arm. Analysis of cross-linking was done on SDS-PAGE with or without the addition of -mercapto-ethanol as 
reducing agent. A-B. Cross-linking of BM2e-tGCN4 with two concentrations of cross-linker and analysis under non-reducing 
(A) or reducing (B) conditions. M = gel marker with mass in kDa, UC = uncross-linked sample, BS
3
 = BS
3
-treated sample, DSP 
= DSP-treated sample. C-D. Cross-linking of BM2e(QIL)-tGCN4, M2e-tGCN4 and NBe-tGCN4-Flag and analysis under non-
reducing (C) or reducing (D) conditions. M = gel marker with mass in kDa, BG = BM2e(QIL)-tGCN4, MG = M2e-tGCN4, NGF = 
NBe-tGCN4-Flag; U = uncross-linked sample, B = BS³-treated sample, D = DSP-treated sample. 
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3.2.3 Characterization of HBc-based proteins 
 
To assess the assembly of HBc-based vaccine candidates, i.e. VLP formation, a number of assays were 
performed. Initial proof for multimerisation of HBc-proteins comes from the gel filtration profiles of 
the final purification step. Comparison of the profiles of the gel filtration run of NM2H and 1651 with 
a calibration run is shown in Figure 3.11. The size exclusion column used was a Sephacryl S400 
column, with a range of separation between 10kDa and 5MDa. The expected particle size of 
unsubstituted HBc149 VLP is appr. 3-5MDa, entailing these and any antigen-bearing particles will 
elute shortly after the void volume of the column. For calibration, a mixture of bovine thyroglobin 
(670kDa), bovine -globulin (158kDa), chicken ovalbumin (44kDa), horse myoglobin (17kDa) and 
Vitamin B12 (1.35kDa) was used (Biorad Gelfiltration Standard). As can be deduced from the profile 
overlay, both 1651 and NM2H show a single peak larger than 670kDa, close to the void volume. This 
suggests that both proteins behave as particulate antigens. 
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To assure the particulate proteins form VLPs and are not just aggregates, two additional tests were 
done. A first is based on separation of large (negatively charged) proteins using agarose gels. Full-
length HBc-proteins (183 amino acids; HBc183) will spontaneously form particles with the ability to 
retain nucleic acids by binding of these through a C-terminal protamine-like domains. Truncated 
forms of HBc (149 amino acids; HBc149) loose this property. A third form of VLPs is constituted of 
HBc-monomers with an intermediate protein length (163 amino acids; HBc163), retaining part of the 
nucleic acid binding domain. These different particles can easily be visualized by agarose gel 
electrophoresis, followed by Ethidium Bromide (EtBr) in case nucleic acids are retained by the 
particles or Coomassie staining. If VLP formation is complete, HBc proteins will stain as a discrete 
band on Coomassie gel, and stain with EtBr if they contain nucleic acid binding motifs C-terminally. 
Additionally, because of the stabilizing role of disulfide bridges in particle formation 32, reduction of 
these VLPs by agents such as -mercapto-ethanol (BME) is expected to abolish particle formation. 
Figure 3.12 depicts an agarose gel analysis of different HBc proteins in the absence or presence of 
BME. Both unsubstituted HBc163 and M2e3-HBc163 run as a defined species visualized by Coomassie 
Figure 3.11. Gelfiltration profiles illustrate 
the particulate nature of HBc proteins. The 
profiles of a calibration run (dashed red) and 
gel filtration of 1651 (solid blue) and NM2H 
(solid block) are shown, overlayed with each 
other. For the calibration run, proteins and 
their MW corresponding to each peak are 
indicated. 
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staining; additionally, both contain nucleic acids since particles in the gel can be stained with EtBr. 
With the addition of BME, only M2e3-HBc163 particles can be disrupted, indicating that substitution 
of HBc has an effect on general stability of the formed VLP. HBc149 and HBc183 proteins, provided as 
certified VLPs by Acambis Inc. (Cambridge, MA), lost their particulate integrity upon extended 
storage at -20°C, as apparent by staining as a smear on gel with Coomassie. Addition of BME however 
does focus these proteins into a single band, most likely corresponding to reduced monomers 
derived from dissociated particles. The NM2H hybrid also shows a profile corresponding to a broken-
down particle, with no defined staining in the absence of BME and appearance as a single band with 
higher mobility in the presence of BME. 1646, 1651 and 3004 are not visualized on gel because of low 
protein concentration; in other instances, staining of single bands has been possible (data not 
shown). 
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Figure 3.12. Agarose gel electrophoresis distinguishes particles formed by HBc proteins. Different HBc proteins were 
loaded on a 2% agarose gel in the absence or presence of the reducing agent -mercapto-ethanol (BME) as indicated. After 
electrophoresis, gels were stained with EtBr (A) to reveal particles containing nucleic acids, or with Coomassie (B) to stain 
proteins. M = DNA marker, 1 = HBc149, 2 = HBc163, 3 = M2e3-HBc163, 4 = HBc183, 5 = 1646, 6 = 1651, 7 = 3004, 8 = NBe-
M2e2-HBc. 
 
A second method to evaluate VLP formation is based on light scattering induced by particles. The 
technique, called dynamic light scattering (DLS), essentially measures the Brownian movement of 
particles in solution and relates this to their size. By measuring the fluctuation in light scatter that 
particles in solution induce over time, the so-called translational diffusion coefficient of those 
particles, representing the velocity of the Brownian movement, can be determined. Based on this 
measurement, and taking into account the temperature and viscosity of the solution, the 
hydrodynamic diameter of the particles in solution can be calculated. Because DLS assumes particles 
measured are spherical in size, the diameter of the particles obtained by this technique will be 
equivalent to that of a sphere with the same diffusion coefficient. In initial measurements, the 
intensity of scattering is determined in relation to the size of the particles in solutions, giving an 
intensity-size distribution. However, because larger particles scatter light more than smaller particles, 
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the relative presence of larger particles will be strongly favored this way (intensity correlates with d6, 
with d the diameter of the particle). By converting intensity signals in volume occupied by the 
particles (volume-size distribution, correlating with d3), a closer approximation of the relative 
prevalence of particles of different sizes is obtained. 
As a control, a validated HBc VLP was taken along, namely 1604 26, consisting of a single M2e-copy N-
terminally fused to the short (149 amino acids) HBc protein. The particulate nature of three HBc-
chimeras was assessed here: an M2e-HBc fusion with full length HBc (183 amino acids; M2e-HBc183), 
the 3004 B/HA0-HBc protein and the NBe-M2e2-HBc fusion. The expected diameter for an HBc-
particle is appr. 30nm, which is detected by dynamic light scattering for the 1604 particle (Fig. 3.13). 
Note that in both the intensity-size and  volume-size distributions a single peak is observed, 
indicating that the protein behaves as a single-size complex. For the three test-particles, other peaks 
in the intensity-size distribution can be seen. For M2e-HBc183 and the B/HA0-HBc proteins these 
resemble high-order complex, most likely aggregates of particles (Fig. 3.13A, C). These however have 
a relatively low prevalence in the mixture, as illustrated by the disappearance of the peaks through            
. 
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Figure 3.13. Dynamic light scattering (DLS) shows NBe-M2e2-HBc does not behave as a VLP. DLS measurements were done 
for different HBc-particles. Shown is the hydrodynamic diameter or size of illuminated proteins in function of relative 
intensity of scattering (A, C, E) or relative volume (B, D, F). Profiles for M2e-HBc183 (A, B), B/HA0-HBc (C, D) and NBe-M2e2-
HBc (E, F) are represented by dashed lines and overlaid with the profile of 1604 particle (full line). 
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conversion to volume-size distribution (Fig. 3.13B, D). For NBe-M2e2-HBc protein, a small peak 
corresponding to a diameter of 50nm can be seen (Fig. 3.13E); however, conversion into a volume-
size distribution reveals the presence of a single major species with a size under that of a particle 
(Fig. 3.13F). Together with the above data, this shows the NBe-M2e2-HBc protein does not behave as 
a particle, but as a dimer or aggregates/complexes thereof. Other HBc-based proteins used in this 
research, including the B/HA0-HBc (3004) chimera, do form particles. 
 
3.2.4 Characterization of glycosylated proteins 
 
a) P. pastoris produced gNBe-tGCN4 
 
As described above (see 1.3), SDS-PAGE analysis of yeast-produced gNBe-tGCN4 indicates that the 
majority of monomers are non-glycosylated (Fig. 3.7). Evidence on the glycosylation state of 
tetramers comes from the profile and size exclusion analysis by gel filtration. As shown in Figure 3.14, 
no dissociation of glycosylated and non-glycosylated tetramers can be seen. The profile shows only 
one main peak containing gNBe-tGCN4 (peak 2), with analysis of fractions confirming co-elution of 
glycosylated and non-glycosylated species.  
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Figure 3.14. Gel filtration profile and molecular characterization of gNBe-tGCN4 reveal the presence of glycan structures. 
A-B. Gel filtration profile of gNBe-tGCN4 purification (A) and concomitant analysis of fractions on Western blot probed with 
anti-tGCN4 rabbit serum (B). NG = NBe-tGCN4 running at the MW of non-glycosylated protein, gNG = NBe-tGCN4 with 
indication of glycosylation. Elution peaks and corresponding fractions containing gNBe-tGCN4 are indicated. C-D. Cross-
linking of tGCN4-proteins with BS
3
, analyzed by SDS-PAGE and Coomassie-staining (C) or Western blot (D) with detection 
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using rabbit anti-tGCN4 serum, reveals structures corresponding to dimers, trimers and tetramers. For gNBe-tGCN4, higher 
structures run as a smear on gel, not discerning discrete multimeric species. M = gel marker (mass in kDa), GF = tGCN4-Flag, 
BG = BM2e-tGCN4, BGQIL = BM2e(QIL)-tGCN4, NGF = NBe-tGCN4-Flag, MG = M2e-tGCN4, gNG = gNBe-tGCN4; U = uncross-
linked, C = BS
3
 cross-linked. 
 
Because of the predicted positive charge of gNBe-tGCN4 at pH below 7.4, native gel electrophoresis 
to determine the MW of the native protein is not straightforward. As an alternative, fixation of the 
native multimeric structure with the homobifunctional BS3 cross-linker was performed. Analysis on 
SDS-PAGE through Coomassie staining (Fig. 3.14C) and Western blot detected with rabbit anti-tGCN4 
serum (Fig. 3.14D) revealed clear mono-, di-, tri- and tetrameric structures for all bacterial produced 
tGCN4-proteins. For gNBe-tGCN4 however, monomers are clearly distinguishable, but higher 
structures form a smear on gel, compatible with oligomers with mixed glycosylation state and mixed 
size  of glycosyl-structure. 
To ascertain the identity of the glycosyl-structure on gNBe-tGCN4, DNA sequencer-assisted 
fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) analysis was performed 39. gNBe-
tGCN4 produced by both wild type GS115 and glyco-engineered KE3 P. pastoris were analyzed. Little 
glycosyl-structures were detected on wild type produced protein, and structures detected mainly 
existed of phosphorylated structures (data not shown). KE3 produced gNBe-tGCN4 is expected to 
contain structures not more complex as GlcNAc2-Man5 ((N-Acetyl-Glycosamine)2-Mannose5). 
However, both GlcNac2-Man5 glycans and a higher order structure can be discerned. The precise 
identity of the latter structure is as yet undetermined.  
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Fig. 3.15. DSA-FACE analysis ofglycan structures 
on gNBe-tGCN4. The top panel shows the 
profile of a maltodextrose reference; the 
numbers indicate the number of glucose units 
present in oligomers corresponding to the 
indicated peaks. The middle panel shows the 
analysis of KE3 P. pastoris produced gNBe-
tGCN4, showing two glycan-peaks. Of these, the 
first corresponds to Man5-GlcNAc2, the second is 
as yet unidentified. The bottom panel shows 
reference glycans (Man5-9-GlcNAc2) derived from 
bovine RNaseB. 
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b) Expression of membrane-bound NBe-M2 chimers 
 
pCAGGS-based plasmids were created for cellular expression of transmembrane Flag-tagged full-
length NB protein. However, in our hands, expression levels of NB-Flag protein were near to 
undetectable by Western blot analysis (data not shown). For this reason, chimeras were created 
replacing the ectodomains of well-expressed BM2 and M2 proteins by that of NB (see 3.2.1b, Fig. 
3.4). As additional testing ground, mutations were introduced deleting the glycosylation sites (here 
termed G1 and G2) in the NBe-sequence (N3Q and N7Q), alone or combined (Fig. 3.4). SDS-PAGE 
analysis of lysates from transiently transfected HEK293T cells clearly shows the influence of 
introduction of these mutation, both for NBe-M2 and NBe-BM2 combinations (Fig. 3.16). Proteins 
bearing the wild-type NBe-sequence clearly show three bands on immunoblot, corresponding to 
unglycosylated (UG), single glycosylated (G1/2) and double glycosylated (G1+2) monomers. Although 
natural glycosylation has been shown to be of the complex type 6, no great amounts of high MW 
NBe-based proteins were observed in gel analyses. As for gNBe-tGCN4, unglycosylated monomers 
are readily detectable on Western blot. Also striking, the chimeric proteins show similar properties as 
the protein providing the transmembrane and cytoplasmic domains. For example, NP40-based lysis 
of transfected cells will solubilize M2-based proteins completely, while BM2-based proteins will 
remain associated with cellular structures, regardless of the ectodomain. 
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Figure 3.16. SDS-PAGE and Western blot analysis of eukaryotic cell expressed chimeric transmembrane NBe-proteins. 
HEK293T cells were transfected with pCAGGS-based vectors coding for different Flag-tagged M2- and BM2-based NBe-
bearing proteins. NP40-detergent lysed cells were analyzed by SDS-PAGE and Western blot. These were detected using 
rabbit anti-Flag and anti-rabbit-HRP antibodies. Different NBe-ectodomains expressed are: WT = wild type sequence, 
WTsilent = wild type sequence with silent mutation deleting neuraminidase initiating codon (N3: AATGCT  AACGCT), GM1 = 
glyco-mutant 1 (N3Q), GM2 = glyco-mutant 2 (N7Q), GM 1 + 2 = glyco-mutant 1+2 (N3Q + N7Q). Control proteins are full-
length Flag-tagged BM2-protein (BM2) and M2-protein (M2). S = supernatant after lysis, P = pellet after lysis. 
 
A more detailed expression profile of chimeric transmembrane proteins was obtained by 
immunofluorescence staining. For this, HEK293T cells were transfected with pCAGGS-vectors 
encoding the different chimeras. After fixation and permeabilization, stainings were done with a 
rabbit anti-Flag antibody and a mouse serum raised against the NBe-, BM2e- or M2e-ectodomain. 
These were obtained by immunizing mice with the different prokaryotic expressed and purified 
tGCN4-proteins. Figure 3.17 shows the results for NB-based proteins. Although full-length NB is 
hardly detectable when analyzing transfected cell lysates (obtained under similar conditions as for 
these stainings) on SDS-PAGE, clear Flag-staining and ectodomain detection is visible here. Serum 
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raised against NBe-tGCN4-Flag can clearly stain both wild type (NBe(WT)) and mutated NBe (lacking 
both glycosylation sites; NBe(GM1+2)). Is should be noted that using triple Flag-tagged NBe-tGCN4-
Flag for raising the immune serum did not evoke antibodies cross-reactive with the single Flag-tagged 
transmembrane proteins, since control settings did not show cross-reactivity of this serum with other 
non-NBe bearing Flag-tagged proteins (data not shown). 
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Figure 3.17. Immunofluorescence staining of HEK293T cells transfected with different NB-based proteins. Cells were 
transfected with pCAGGS-based vectors encoding the indicated ectodomains (M2e, NBe(WT), NBe(GM1+2)) fused to the NB 
transmembrane and cytoplasmic domain. Transfected cells were fixed, permeabilized and stained with rabbit anti-Flag and 
mouse antisera raised against the corresponding ectodomains using tGCN4-based proteins (see text). Antibody binding was 
visualized by secondary staining with anti-mouse-AlexaFluor488 and anti-rabbit-AlexaFluor568 antibodies. Cells were 
mounted using Vectashield containing DAPI for nuclear counterstain. Pictures shown are representative for each setting. 
Control settings using mock-transfected cells or secondary stain only were negative (data not shown). 
 
Stainings of cells expressing proteins with BM2- or M2-basis (i.e. transmembrane and cytoplasmic 
domain) are shown in Figure 3.18. Corresponding with the Western blot analysis (Fig. 3.16), M2- and 
BM2-based proteins show a distinct localization pattern, in that BM2-proteins locate to perinuclear 
membranes (most likely Golgi-membranes), while M2 is more surface-expressed. Like for NB-fusions, 
antiserum raised with M2e-tGCN4 or NBe-tGCN4-Flag can clearly stain M2e- or NBe-fusions, both 
wild type and glycomutant for the latter. BM2e-tGCN4 antiserum however does not seem to contain 
anti-BM2e antibodies. Under certain conditions however, staining of IBV proteins with BM2e-tGCN4 
antiserum can be seen (see Chapter 4). 
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Figure 3.18. Immunofluorescence staining of HEK293T cells transfected with different M2- and BM2-based proteins. Cells 
were transfected with pCAGGS-based vectors encoding the indicated ectodomains (M2e, NBe(WT), NBe(GM1+2), BM2e) 
fused to the BM2 (left) or M2 (right) transmembrane and cytoplasmic domain. Transfected cells were fixed, permeabilized 
and stained with rabbit anti-Flag and mouse antisera raised against the corresponding ectodomains using tGCN4-based 
proteins (see text). Antibody binding was visualized by secondary staining with anti-mouse-AlexaFluor488 and anti-rabbit-
AlexaFluor568 antibodies. Cells were mounted using Vectashield containing DAPI for nuclear counterstain. Pictures shown 
are representative for each setting. Control settings using mock-transfected cells or secondary stain only were negative 
(data not shown). 
 
To attest cellular expressed transmembrane proteins are in their native tetrameric organization, cell 
lysates were treated with the BS3 cross-linker. Western blot analysis of treated samples, detected 
with rabbit anti-Flag serum, is shown in Figure 3.19. This confirms that monomers can be fixed 
together in structures with mobility on gel corresponding to dimers and multimers. For multimeric 
species, no discrete forms can be found for NBe-based proteins, as compared to e.g. M2-Flag, 
pointing to tetramers with mixed glycosylation state, as seen for gNBe-tGCN4 (Fig. 3.14). However, 
the complex nature of the cell lysates could influence the formation of homologously cross-linked 
oligomeric proteins. 
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Figure 3.19. Cross-linking of cell-expressed viral and chimeric proteins shows the presence of higher oligomeric 
structures. Lysates of HEK293T cells transfected with pCAGGS vectors encoding different Flag-tagged transmembrane IAV 
and IBV proteins, or chimeric derivatives thereof, were treated with the BS
3
 cross-linker. Samples were analyzed on 
Western blot through detection with rabbit anti-Flag antiserum. M = gel marker (mass in kDa), 2 = BM2-Flag, 3 = M2-Flag, 4 
= NB-Flag, 4 = NBe(WT)-M2-Flag, 5 = NBe(GM1)-M2-Flag, 6 = NBe(GM2)-M2-Flag, 7 = NBe(GM1+2)-M2-Flag; U = uncross-
linked sample, C = cross-linked sample. 
 
Overall, these experiments show that NBe-proteins can be expressed successfully in cellular systems 
and assume their natural confirmation. Glycosylation of the NB ectodomain is evident from the 
Western blot analysis, clearly showing use of both sites individually or combined. Glycosylation of 
one site happens independently of the other, indicated by presence of monoglycosylated protein by 
mutation of either site. Removal of both sites also does not influence expression or transport to the 
cell surface, as described before 6. Likewise, adopting a tetrameric structure is not dependent on 
glycosylation status for NBe (Fig. 3.19). The presence of both non-, mono- and double glycosylated 
monomers in tetramers, comparable to gNBe-tGCN4 expression (Fig. 3.7), makes it probable that 
tetramers consist of monomers with mixed glycosylation state, as confirmed by cross-linking (Fig. 
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3.19). In contrast to described data for naturally expressed NB 6, no evidence is seen for the addition  
of complex type carbohydrates, such as poly-N-lactosaminoglycans to the NBe-fusion constructs 
described here. However, the native conformation of glycosylated NBe-based proteins, as achieved 
by transfection of mammalian cells, formed the basis for assessing the in vivo protective effect of 
transfected cells as such. These cellular vaccines could lead to a proof-of-principle regarding 
protection against influenza B infection by using glyco-NBe proteins (see Chapter 4).  
 
3.2.5 Generation and validation of NBe-specific monoclonal antibodies (mAbs) 
 
a) Generation of NBe-directed mAbs 
 
A good way of taxing the accessibility of antigens in their native (cell-associated) conformation, is by 
means of monoclonal antibody (mAb) binding assays. To develop NBe-specific mAbs, mice were 
repeatedly immunized with the NM2H protein. After three consecutive immunizations, splenocytes of 
mice were used for fusion with myeloma cells to obtain hybridomas. On a regular basis, growing 
clones were tested for production of specific antibodies; an example of screening is shown in Figure 
3.20A. After scaling up and further screening, five clones were retained for further use: the NBe-
specific 11B1, 11H5, 12A7 and 15G5 and (as control) the HBc-specific 20C3. After 1-2 rounds of 
subcloning (through single-cell titration), monoclonal hybridomas were obtained which were used 
for large-scale production of mAbs. Titration of the purified mAbs showed that only 15G5 mAb had a 
significant affinity for NBe; the three other NBe-directed mAbs only reacted moderately with NBe-
peptide coated on ELISA-plates (Fig. 3.20B). The concentration giving appr. 50% maximal binding in 
NBe-peptide ELISA was 197.28ng/mL for 15G5. The HBc-specific 20C3 mAb showed a higher affinity 
with its ligand (Fig. 3.20C), with a 50% maximum binding dose in HBc-ELISA of 20.01ng/mL. ELISAs 
using different substituted HBc-particles for coating revealed that 20C3 mAb is directed towards the 
immunodominant loop of the protein (data not shown). Reactivity of 15G5 mAb and 20C3 mAb 
towards different HBc- and NBe-HBc proteins in Western blot is shown in Figure 3.20D. Because of 
incomplete denaturation and reduction, both monomeric and dimeric HBc-species are visible in this 
figure. 20C3 mAb reacts with all HBc-proteins, except with 1646, the NBe-HBc chimeric protein 
bearing NBe in the immunodominant loop of HBc, confirming that this loop contains the 20C3 mAb 
epitope. Concomitantly, 15G5 mAb shows clear reaction with NBe-HBc fusions (1646, 1651, NM2H). 
Because of the low affinity of other NBe-directed mAbs, focus remained on 15G5 mAb. Similar set-
ups to develop mAbs directed to BM2e, B/HA0 or glycosylated NBe were performed numerous times, 
without any success of isolation of such specific mAbs or surviving hybridoma clones. 
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Figure 3.20. Development and validation of NBe-specific monoclonal antibodies (mAbs). Splenocytes of mice immunized 
with the chimeric NM2H protein were used for the production of hybridomas secreting antibodies specific for HBc and NBe. 
A. Example of screening of hybridomas using HBc- and NBe-specific ELISAs. Clones which were selected based on their 
specificity and growth are circled in red. B-C. NBe- (B) and HBc-specific (C) ELISAs using purified mAbs at a starting 
concentration of 3mg/mL to detect specificity and affinity of the selected mAbs. D. Different HBc- and NBe-HBc-proteins 
(1µg each) were analyzed on Western blot with detection using the NBe-specific 15G5mAb (10µg/mL; left) or the HBc-
specific 20C3mAb (1µg/mL; right). 1 = HBc (149 amino acids), 2 = 1646 (NBe-HBc, NBe in the loop), 3 = HBc (163 amino 
acids), 4 = 1651 (NBe-HBc, NBe N-terminal), 5 = NBe-M2e2-HBc , 6 = HBc (183 amino acids), 7 = gel marker with mass in 
kDa. 
 
 
 
 
94 Chapter 3 
b) In vitro validation of native NB-binding by NBe-mAbs 
 
Binding to native structures by 15G5 mAb was evaluated in a number of in vitro assays. In a first 
approach, cellular expressed Flag-tagged NBe-chimeric transmembrane proteins were immuno-
precipitated. Lysates of transfected HEK293T cells were incubated with 15G5 mAb, 20C3 mAb 
(negative control) or mouse anti-Flag mAb (mFlag, positive control). After pull-down of antibody-
antigen complexes with Protein G beads, bound (eluted: EL) and unbound (UB) fractions were 
analyzed on Western blot by means of rabbit anti-Flag detection. As antigen, the NBe-M2 fusion 
protein was used, both with wild type NBe-sequence and the mutant sequence lacking both 
glycosylation sites. Figure 3.21A shows the result of the transfection and lysis, with clear presence of 
three distinct NBe-M2 bands in the wild type (WT) setting (corresponding to non-, mono- and double 
glycosylated NBe-M2) and a single band in the mutant setting. To assure that the immuno-
precipitation was technically sound, the antibody bands of precipitating mAbs were also detected in 
Western blot (Fig 3.21B). The results of the pull-down are shown in Figure 3.21C-D. The control 
settings behave as expected: 20C3 mAb (and beads alone) do not bind any antigen, while mouse 
anti-Flag is able to precipitate the majority of NBe-M2-Flag protein. The 15G5 mAb can pull down a 
large part of the NBe-based proteins, irrespective of their glycosylation state. This might entail the 
binding site of 15G5mAb does not include the most N-terminal sequence containing the glycosylation 
sites, or that NBe-M2 tetramers are mixed in nature, with a part being non-glycosylated and 
accessible for 15G5 mAb. In the latter case, the relatively conservative nature of the N3Q and N7Q 
mutations might not influence the binding of 15G5 mAb dramatically, allowing association with this 
variant practically as efficient as wild type NBe.  
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Figure 3.21. Immuno-precipitation (IP) of NBe-M2 proteins with 15G5 mAb. Lysates of transfected cells, expressing wild 
type (WT) or glyco-mutant (Mutant; lacking both glycosylation sites) NBe-M2-Flag, were incubated with the NBe-specific 
15G5mAb, the HBc-specific 20C3 or mouse anti-Flag (all 10µg). After overnight incubation, antigen-antibody complexes 
were pulled down using Protein G beads. After centrifugation, unbound species and beads were separated and processed 
for analysis on Western blot. A control setting without the addition of antibody, to assess sticking of antigen to the beads, 
was also included (Beads). A. Western blot of the lysates of transfected cells, detected with rabbit anti-Flag. The arrows 
indicate bands corresponding to (non-, mono- and double glycosylated) NBe-M2-Flag proteins. SN = soluble fraction 
(supernatant) after lysis (used for the IP assay), P = insoluble fraction (pellet) after lysis. B. Western blot analysis after pull-
down, with detection of antibody bands of the mAbs used for the IP. UB = unbound species, EL = eluted species from beads; 
IgH = antibody heavy chain, IgL = antibody light chain. C-D. Detection of precipitated wild type NBe-M2-Flag (C) or glyco-
mutant NBe-M2-Flag (D) antigen by detection with rabbit anti-Flag. The arrows indicate bands corresponding to (non-, 
mono- and double glycosylated) NBe-M2-Flag proteins. UB = unbound species, EL = eluted species from beads. 
 
A second approach to detect native NBe-binding by 15G5 mAb is immunofluorescence staining of 
influenza B (B/Memphis/12/97 and B/Harbin/7/1994) infected MDCK cells. Stainings were done 
before fixation on live cells at 37°C, to retain native structures for optimal access of 15G5 mAb as 
much as possible. As controls, influenza A/California/4/2009 (i.e. pandemic H1N1 2009) infected cells 
were taken along, as well as an M2e-specific mAb. After incubation with mAbs, cells were washed, 
fixed and permeabilized, followed by staining of the influenza expressed M1 protein using a 
polyclonal goat antiserum and secondary staining. Results of the live staining are shown in Figure 
3.22. Even with some background staining of influenza A infected cells with 15G5 mAb (third panel 
row), clear staining of influenza B infected cells is evident (top two panel rows). Using an M2e-
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specific mAb, M2-protein expressed during influenza A infection can nicely be visualized (last panel 
row), with almost no reaction towards influenza B infected cells (second to last panel row). Since viral 
expressed NB or M2 protein was stained pre-fixation, the ectodomain stainings reveal proteins 
expressed on the cell surface and line the entire surface of the infected cell. In the case of M2e-
specific staining, it is very clear antibody-antigen complexes are internalized during incubation, giving 
a speckled staining pattern. For the anti-NBe stain, this is less clear, although surface staining of 
infected cells was clear for IBV-infected cells. 
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Figure 3.22. Immunofluorescence staining of infected MDCK cells using NBe- and M2e-directed mAbs. MDCK cells were 
infected with B/Memphis/12/97, B/Harbin/07/94 or A/California/04/09 as indicated. 16h after infection, cells were washed 
and incubated with NBe-specific 15G5mAb (10µg/mL) or an M2e-specific (1µg/mL) for 2h at 37°C. After extensive washing, 
cells were fixed, permeabilized and stained with goat anti-M1 antiserum. Shown are representative pictures for each 
condition. 
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Taken together, these stainings and the ones discussed earlier (see 3.2.4b, Fig. 3.17), along with the 
pull-down results, show that NBe-directed antibodies can react with (native) membrane-associated 
NBe-proteins. Because of clear presence of non-glycosylated monomeric NBe-proteins in our in vitro 
models of transfection and no clear indication about the glycosylation state of the NB protein during 
in vitro infection, the exact influence of NBe-glycosylation on antibody recognition is still largely 
undetermined. Nonetheless, these results do indicate that a certain level of NB protein remains non-
glycosylated and shuttles to the plasmamembrane of infected (or transfected) cells in, presumably, 
tetramers with a mixed glycosylation state. It thus remains warranted to investigate the in vivo 
protective effect of (glycosylated) NBe-based vaccine candidates, next to BM2e- and B/HA0 chimeric 
proteins. 
 
3.3. Material and methods 
Construction of expression plasmids 
Construction of 1646, 1651 and 3004 HBc particles was performed by Acambis Inc. (Cambridge, MA) using the 
Lac-promoter driven pKK223-3 expression vector (Amersham Pharmacia) 
26
. For construction of NBe-M2e2-HBc, 
the NBe-sequence was fused to the coding sequence of 1817 
26
 by PCR methods. The entire sequence was 
recloned in the pLT32H vector using the NdeI and HindIII restriction sites 
40
, leading to pL-promotor driven 
expression in bacterial systems. Construction of tGCN4-Flag and NBe-tGCN4-Flag expressing vectors was done 
as previously described 
20
. Briefly, overlapping oligonucleotides (Invitrogen) were used to create the coding 
sequences for the tetramerizing tGCN4 leucine zipper variant 
41
, the NB ectodomain and the triple Flag-tag. 
Using classical cloning techniques based on restriction enzyme digestion and PCR, the three domains were 
fused in frame and inserted in the pLT32H expression vector using the NdeI and HindIII restriction sites. 
For secreted expression by P. pastoris, the pPIC9 expression plasmid was used. The NBe-tGCN4 coding 
sequence was picked up by PCR from the bacterial pLT32H expression plasmid and cloned in frame with the 
alpha mating factor secretion signal. For this, the forward primer included the XhoI restriction site 
(underscored) before the Kex2 and Dipeptidase cleavage sites and the NBe-sequence (italic) starting at amino 
acid 2  (5’-CCCCTGCAGAAAAGAGAGGCTGAAGCTAACAATGCTACCTTCAACTAT-3’), while the reverse primer 
introduced a stop codon after the tGCN4-sequence (italic) and allowed insertion at the EcoRI site (underscored; 
5’-CCCGAATTCCTATTCGCCCAGCAGTT-3’). 
 
Expression and purification of chimeric tGCN4-proteins 
For expression of tGCN4-proteins, BL21 CodonPlus (Stratagene) bacteria, bearing the pICA2 repression plasmid 
20
, were transformed with the tGCN4-protein expressing pLT32H vectors. Inductions were done by diluting a 
40mL bacterial culture, grown overnight at 28°C in Luria Broth (LB), 1/50 in 2L of LB. Cultures were grown 
further at 28°C until they reached an optical density at 600nm of 0.5-0.8. At this point, the cultivation 
temperature was raised to 42°C, leading to denaturation of the temperature-sensitive cI
ts
-repressor 
34
, 
expressed by pICA2, liberating the pL-promotor and leading to expression of the chimeric tGCN4-proteins. After 
4h of induction, bacteria were collected by pelleting the culture through centrifugation (10 min, 4°C, 6000g). If 
needed, bacterial pellets were stored dry at -20°C until use. 
To purify the chimeric tGCN4-proteins, bacterial pellets were resuspended in 1/10 of the original volume using 
50mM Tris/HCl pH8.0 + 150mM NaCl (4°C). Bacteria were disrupted by sonication and immediately treated for 
30min at 65°C to precipitate contaminating bacterial proteins, relying on the heat-resistant properties of the 
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tGCN4 leucin zipper 
41
. Next, denatured proteins and bacterial debris were removed by centrifugation (1h, 4°C, 
20.000g) and filtered through a 0.45µm filter. Using an Akta purification station, cleared lysates were applied 
on a SourceQ anion exchange column, followed by a linear gradient elution using 50mM Tris pH8.0 + 1M NaCl, 
going from 0% to 100% elution buffer. Elution fractions were analyzed through SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE); fractions containing the protein of interest were pooled and concentrated using 
Vivaspin columns (GE Healthcare) with a 5 kDa cut-off. Samples were loaded on a calibrated Superdex 75 prep-
grade gel filtration column (120mL) and eluted with PBS. Fractions containing tGCN4-proteins of the desired 
size and purity (cf. Fig. 3.6) were pooled and concentrated using Vivaspin columns (5 kDa cut-off) to a 
concentration of 1-30 mg/mL without losing solubility. Protein solutions were batched out and stored at -80°C. 
 
Expression and purification of chimeric HBc-proteins 
Expression of HBc-based proteins was done using the same expression system as for tGCN4-proteins, with the 
exception induction was done using 1mM IPTG at 28°C for 4h. Expression of 1646, 1651 and 3004 relied on lac-
promoter driven expression; for the NBe-M2e2-HBc protein this was pL-promoter driven. Both systems rely on 
repression by pICA2 and allow de-repression by the addition of IPTG. 
HBc-proteins were purified as follows. Bacterial pellets were resuspended in 1/10 of the original volume using 
50mM Tris/HCl pH8.0 + 150mM NaCl (4°C). Bacteria were disrupted by sonication, bacterial debris was 
removed by centrifugation (1h, 4°C, 20.000g) and the supernatant was filtered through a 0.45µm filter. Next, 
NH4(SO4)2 was added to the protein mixture to a final concentration of 30% (w/v) and incubated overnight at 
4°C. Next, the precipitated HBc-proteins were pelletted by centrifugation (1h, 4°C, 20.000g) and dialyzed 
extensively against 50mM Tris/HCl pH 8.0 + 150mM NaCl. Using an Akta purification station, resolubilized 
proteins were applied on a SourceQ anion exchange column, followed by a linear gradient elution using 50mM 
Tris pH8.0 + 1M NaCl, going from 0% to 100% elution buffer. Elution fractions were analyzed through SDS-
polyacrylamide gel electrophoresis (SDS-PAGE); fractions containing the protein of interest were pooled and 
concentrated using Vivaspin columns (GE Healthcare) with a 100 kDa cut-off. Samples were loaded on a 
calibrated Sephacryl S400 gel filtration column (120mL) and eluted with PBS. Fractions containing HBc-proteins 
of were pooled, concentrated using Vivaspin columns (100 kDa cut-off) and stored in batches at -80°C. 
 
Expression and purification of gNBe-tGCN4 by Pichia pastoris 
To achieve expression by P. pastoris strains (GS115 and KE3), yeast cells were made competent as follows. A 
saturated culture of cells grown at 30°C was diluted in 500mL YPD medium, based on density (OD600) and a 
doubling time of 2h at 30°C, to achieve an OD600 of appr. 1.4 after overnight incubation at 30°C. The next day 
cells were pelleted by centrifugation for 10’ at 1500g. Pellets were resuspended in 100mL YPD + 20mL HEPES 
(1M, pH 8) containing 2.5mL 1M DTT and incubated for a further 15’ at 30°C. After addition of 250mL sterile 
water, cells were pelleted by centrifugation (10’, 1500g, 4°C). Pellets were resuspended in 250mL ice-cold 
sterile water, pelleted again (10’, 1500g, 4°C) and washed once more in 125mL ice-cold sterile water and next 
20mL ice-cold 1M sorbitol. After a final pelleting step (10’, 1500g, 4°C), cells were gently resuspended in 1mL 
20mL ice-cold 1M sorbitol and kept on ice. 
For transformation, 40µL competent cells was mixed with 4µg SalI linearized pPIC9-NBe-tGCN4 in a sterile 
electroporation cuvette. Immediately after electroshock (1.5kV, 25µFad), 1mL YPD was added to the cells and 
incubated at 30°C for 2h. Next, cells were plated on RDB-plates lacking His for selection of transformants and 
incubated at 30°C. Twelve colonies were picked, replated on RDB minus His plates to obtain single-cell colonies, 
and used for expression analysis. 
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Expression by P. pastoris, based on the AOX1 promoter, was achieved by inoculating a single-cell colony in 
BMGY medium. After overnight incubation at 30°C, OD600 was measured, cells were harvested by centrifugation 
(5’, 3000g) and resuspended in BMMY medium to achieve a density of OD600 of 1. Cultures were induced for 
48h, with addition of 0.5% methanol appr. every 12h. Finally, cultures were centrifuged, supernatants were 
collected and filtered and protease inhibitors (Complete ultra protease inhibitor tablets, Roche) were added. 
Purification of gNBe-tGCN4 of P. pastoris culture medium started with differential (NH4)2SO4 precipitation at 
4°C. First, the (NH4)2SO4 concentration was elevated to 40% by adding solid (NH4)2SO4, followed by pelleting of 
insoluble material (1h, 20000g, 4°C). Next, the (NH4)2SO4 concentration was further elevated to 80%. Insoluble 
material was collected by centrifugation (1h, 20000g, 4°C), resolubilized and dialyzed extensively to 50mM 
malonate pH 6.2 + 50mM NaCl using Vivaspin columns (5kDa cut-off; GE Healthcare). Using an Akta purification 
system, the dialyzed material was applied to a SP cation exchange column, followed by a linear gradient elution 
using 50mM malonate pH 6.2 + 1M NaCl, going from 0% to 100% of elution buffer. Elution fractions were 
analyzed through SDS-polyacrylamide gel electrophoresis (SDS-PAGE); fractions containing the protein of 
interest were pooled and concentrated using Vivaspin columns (GE Healthcare) with a 5 kDa cut-off. Samples 
were loaded on a calibrated Superdex 75 prep-grade gel filtration column (120mL) and eluted with PBS. 
Fractions containing gNBe-tGCN4 of the desired size and purity were pooled and concentrated using Vivaspin 
columns (5 kDa cut-off) to a concentration of 1-2 mg/mL without losing solubility. Protein solutions were 
batched out and stored at -80°C. 
 
Construction and expression of chimeric transmembrane proteins 
The cDNA coding for M2, BM2 and NB was obtained by reverse transcription using RNA prepared from 
A/Puerto Rico/8/34 or B/Memphis/12/97 virus-infected MDCK cells. Exchange of the ectodomains was done by 
fusion PCR, using oligonucleotides spanning the ectodomain on the one hand and transmembrane regions on 
the other. All coding sequences were cloned into the pCAGGS vector, allowing constitutive expression driven by 
the chicken β-actin/rabbit β-globin hybrid promoter. A single Flag-tag was introduced C-terminally to allow 
detection. 
For transfections tests, HEK293 T cells were seeded at 2 x 10
5
 cells in a 6-well plate in complete DMEM medium 
(DMEM + 10% FCS + L-Gln + sodium pyruvate + penicillin/streptomycin). 16h later, cells were transfected with 
1µg plasmid DNA using calcium phosphate precipitation. 24h later, cells were lysed and analyzed by SDS-PAGE 
followed by Western blotting. Flag-tagged proteins were visualized using rabbit anti-Flag antibody detection, 
combined with alkaline phosphatase labeled goat anti-rabbit-AP secondary antibody and NBT/BCIP substrate 
(Roche) for detection. 
 
Mass spectrometry 
Mass spectrometry analyses were performed at the Department for Medical Protein Research (VIB, Ghent). A 
1μl sample containing 0.3μg of protein was mixed with 1μl of saturated α-cyano-4-hydroxycinnamic acid that 
had been diluted 5-fold, and 0.5μl of this mixture was dried on the MALDI target of an Ultraflex mass 
spectrometer (Bruker Daltonics, Bremen, Germany). Before measurement, the target was briefly rinsed with 10 
mm ammonium citrate. MALDI mass spectra were generated by accumulation of 200 laser shots on the best 
target spots. 
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Native PAGE 
The molecular weights of the M2e- and BM2e-tGCN4 proteins were estimated using a modification of the 
methods of Bryan and Davis 
37,38
. Briefly, the chimeric protein and molecular weight standards were resolved 
by gel electrophoresis using various polyacrylamide concentrations. Electrophoretic mobility (Rf) was 
determined in each gel relative to the tracking dye, and 100 log (Rf x 100) values were plotted against the 
percent gel concentration for the reference proteins as well as M2e- and BM2e-tGCN4. The slope for each 
protein was determined and the logarithm of the negative slope was plotted against the logarithm of the 
molecular weight of each standard protein. This produces a linear plot from which the molecular weight of an 
unknown protein can be deduced. 
 
Cross-linking experiments 
All cross-linking experiments were performed as previously described 
20
. Briefly, stock solutions of 50mM BS
3
 
(bis(sulfosuccinimidyl)suberate; Pierce) in water and 25mM DSP (dithiobis(succinimidylpropionate); Pierce) in 
DMSO were prepared freshly prior to use. These were diluted to 5 mM final concentration in PBS containing 
10µg of the different tGCN4-proteins or 20µL lysates of transfected cells (equivalent to appr. 10
5
 transfected 
cells). Cross-linking reaction was allowed to continue for 1h at room temperature, after which the reactions 
were stopped by adding 50 mM Tris, pH 6.8. When DSP and BS
3
 were both used, samples were divided in two 
and boiled in non-reducing (50 mM Tris pH 6.8, 10% Glycerol) or reducing (50 mM Tris pH 6.8, 10% Glycerol, 
20mM β-mercapto-ethanol) sample buffer, followed by analysis on SDS-PAGE and Coomassie-staining or 
Western blot analysis using rabbit anti-Flag (Sigma) or hopuse-made rabbit anti-tGCN4 serum. 
 
HBc structural analyses 
The efficiency of particle formation and the presence of particle-bound nucleic acids were analyzed by agarose 
gel electrophoresis. VLPs (5μg) were diluted in sample buffer (5% glycerol, 0,05% bromophenol blue) with or 
without the addition of 250mM β-mercaptoethanol and incubated for 2h at room temperature. Samples were 
loaded on a 2% agarose gel (Ultrapure agarose, Invitrogen) and run for 2h at 80V in TAE buffer. The gel was 
stained with ethidium bromide for nucleic acids and with Coomassie brilliant blue for proteins.  
The dynamic light scattering (DLS) analysis was performed at the Faculty of Pharmaceutical Sciences. Briefly, 
protein solutions (in PBS) were diluted to contain 10mM salt and measured and analyzed on a polystyrene 
standard calibrated Zetasizer Nano S instrument (Malvern Instruments, Worcestershire, UK). 
 
Immunofluorescense stainings 
For immunofluorescence assays, HEK293T or MDCK cells were seeded on aceton-treated coverslips in 24-well 
plates at a density of 2 x 10
4
 cells/well in complete DMEM. 16h later, HEK293T cells were transfected with 
250ng pCAGGS-based constructs; MDCK cells were washed once with serum-free DMEM and infected with a 
MOI 3 A/Puerto Rico/8/34 or B/Memphis/12/97. 24h later, cells were fixed with 4% paraformaldehyde and 
permeabilized for 5 min using 0.05% Triton X-100 in PBS + 20 mM Glycine. After blocking for 1 h using a 1% 
(w/v) PBS-based BSA solution, cells were stained with rabbit anti-Flag (HEK293T cells) or goat anti-M1 serum 
(MDCK cells) and the indicated murine antisera or mAbs at the indicated dilution or concentration. Secondary 
staining was done using goat anti-rabbit Alexa-fluor-647 conjugated antibody and goat anti-mouse Alexa-fluor-
488 antibody (Invitrogen) for HEK293T-stainings or donkey anti-rabbit Alexa-fluor-647 conjugated antibody and 
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donkey anti-mouse Alexa-fluor-488 antibody (Invitrogen) for MDCK stainings. Cells were mounted with 
Vectashield containing DAPI for nuclear counterstain before microscopic analysis. 
 
Development of NBe-specific monoclonal antibodies (mAbs) 
To obtain NBe-specific mAbs, mice were immunized three times three weeks apart with the NM2H-protein 
(10µg) emulsified in Montanide ISA-720. Three week after the third immunization, mice were boosted a final 
time. Five days after this boost, splenocytes were isolated from the mice by gentle homogenization of the 
spleen in PBS, followed by red blood cell lysis using hypotonic ammonium chloride buffer. Next, cells were 
resuspended in RPMI +  0.5% FSC + penicillin/streptomycin and mixed with SP2/0-Ag14 myeloma cells in a ratio 
of 5:1 (splenocytes : myeloma cells). The cells were pelleted together (10min, 300g) and 1mL PEG-1500 (Roche) 
was added slowly under gentle mixing. Next, 10mL RPMI +  0.5% FSC + penicillin/streptomycin was added 
gently drop-by-drop to dilute the toxic PEG-1500. Fused cells were washed three times and resuspended in 
complete RPMI (RPMI + 10% FCS + L-Gln + sodium pyruvate + penicillin/streptomycin) containing 10% BM-
Condimed-H1 (Roche). Cells were rested for 5h at 37°C and 5% CO2, after which  HAT selection (hypoxanthine – 
aminopterine – thymidine; Roche) was added and cells were seeded in 96well plates (200µL of 10
5
 cells/mL). 
For the next two weeks, medium was replaced every 4-5 days and well were visually inspected for growth.  
After a selection period of two weeks, growing clones showing production of NBe- or HBc-specific antibodies 
were transferred to sequential larger culture vessels (96well – 24well – 12well – 6well – 75cm
2
 flask – 175cm
2
 
flask). For subcloning, cells were seeded at a density of 0.3cells/100µL in 96well plates, after which growth of 
subclones was monitored daily and productive and growing clones were expanded. 
For purification of mAbs, a HiTrap recombinant Protein A MabSelect Sure column (GE Healthcare) was used 
according to the manufacturers protocol using an Akta purification station. 
 
Pull-down experiments 
For pull-down experiments, 50µL of cell lysate (corresponding to appr. 2x10
5
 transfected cells) was incubated 
with 10µg of the indicated antibodies overnight in 500µL immunoprecipication (IP) buffer (10mM Tris/HCl 
pH7.4 + 150mM NaCl + 0.5% NP40 + 0.5% Triton X-100). 20µL of washed Protein G beads (GE Healthcare) was 
added to the antigen-antibody mixture and incubated for an additional three hours. Next, beads were 
collected, washed three times with IP buffer and treated with 50µL Laemmli buffer (50mM Tris pH6.8, 10% 
Glycerol, 100mM -mercapto-ethanol). To analyze the unbound fraction, the 500µL solutions after 
precipitation were TCA-precipitated and resuspended in 50µL Laemmli buffer. For gel analysis, equivalent 
fractions were loaded, i.e. 25µL cell lysate, 25µL unbound fraction and 25µL eluted fraction. 
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4.1. Introduction 
In the previous chapter, the design and molecular characterization of broadly reactive IBV virus (IBV) 
vaccine candidates was described. Based on the combination of selected conserved IBV epitopes and 
carrier proteins, the rational design of these proteins is presumed to be efficient in eliciting immune 
responses against the presented epitopes. To evaluate this, and to assess the protective efficacy of 
elicited responses, mouse experiments were performed. These are based on a mouse model of IBV 
infection, a direct translation of that for influenza A virus infection. The immunogenic and protective 
capacity of HBc- and tGCN4-based broadly reactive IBV vaccines was assessed, using combinations 
with different adjuvants and challenge with different influenza B viruses. The merit of the selected 
epitopes derived from IBV, as construed from our mouse model, is discussed. 
 
4.2. Results 
 
4.2.1 The IBV mouse model 
 
Compared to the influenza A virus (IAV) mouse model, this small animal model for IBV is more 
constrained because of the humanized phenotype of IBV 
1,2
. In general, to obtain an influenza virus 
strain that replicates productively in the mouse lung and induces morbidity and mortality, primary 
human isolates are passaged in mice. For this, mice are infected with a virus suspension, and three 
days later the lungs are isolated, homogenized and resuspended. The soluble fraction will contain 
viruses selected on their ability to replicate successfully in the mouse lung environment. This 
selection procedure is repeated numerous times (in general, 5-30 times), until morbidity and 
mortality are observed. For most selected strains, this process is biphasic. In initial passages, the viral 
titer recovered from the lung homogenates drops drastically, through elimination of most (>99%) of 
the original viruses which are unable to replicate in the mouse lung environment. After initial 
passages, lung virus titer will typically incline again, through productive infection and replication of 
selected ‘adapted’ viruses 
3,4
. 
Mouse-adaptation of in-house available IBV strains (B/Harbin/07/94, B/Yamagata/16/88, B/Lee/40) 
was attempted several times in this research. However, after initial passages (1-10 rounds of 
infection), no virus was recovered from lung homogenates, as determined by titration on MDCK cells 
(data not shown). Even in settings with immunosuppression, exogenously induced by γ-irradiation of 
mice or use of inhibitors  of sugar-binding proteins present in the lung, such as the polysaccharide 
mannan 
5,6
, no successful recovery of virus was achieved. Therefore, research groups with published 
use of mouse-adapted IBV strains were contacted to obtain validated strains for in vivo use. A first 
viral strain obtained this way was B/HongKong/5/72, described by the group of Dr. Robert Sidwell 
(Utah State University, Logan, UT, USA) 
7
. A second strain was kindly provided by Dr. Jonathan 
McCullers (St. Jude Children’s Research Hospital, Memphis, TN, USA), and was prepared specifically 
during research into mouse-adaptation of IBV 
8
. In our Balb/c mouse model, the LD50-dose for 
B/Memphis/12/97 is appr. 1.25x10
6
 pfu and 8x10
6
 pfu for B/Hong Kong/5/72. A third strain used for 
initial (failed) mouse-adaptation and vaccine strain as inactivated virus is B/Harbin/7/94. 
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Figure 4.1 shows antigenic analysis of the IBV strains used here, compared to the reference strains of 
both lineages, i.e. B/Victoria/2/87 and B/Yamagata/16/88. Alignments were done using sequences 
available in the Influenza Sequence Database (www.fludb.org). Based on hemagglutinin (HA) 
sequences (nucleotides 481-501) 
9
, viruses can be attributed to one of both lineages. This way, the 
B/Harbin/7/94 and B/Memphis/12/97 can be identified as Yamagata-type viruses, while the B/Hong 
Kong/5/72 virus belongs to the Victoria-lineage (Fig. 4.1B).  
Certain regions within the HA structure correspond to the antigenic sites responsible for neutralizing 
anti-HA responses and escape from homotypic immunity by mutation. Four major antigenic regions 
have been identified within the HA1-region, all in close proximity of each other, thus forming one 
continuous antigenic site 
10
. These have been termed according to their location and structure: the 
120 loop (residues 70-77 and 115-130), the 150 loop (residues 141-153), the 160 loop (residues 161-
169) and the 190 helix (residues 192-202). Mutation of even a single residue in one of these sites, 
naturally or by reverse genetics, has been shown to abolish binding of monoclonal antibodies or 
antisera, and endow the naturally mutated strains with epidemic power 
10-14
. The protruding 160 
loop is specifically prone to insertion-deletion mutations, altering the antigenic site drastically 
12,15
. 
The 190 helix contains a site (residues 194-196) allowing removal or introduction of an N-
glycosylation site, influencing the epidemic and antigenic features of the virus 
16,17
. As can be 
deduced from Figure 4.1C, a number of residues are specific for either lineage of IBV 
10
. 
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Figure 4.1. Classification and epitope sequences of the influenza B viruses used in this study. A-B. IBV used in this study 
(non-mouse-adapted B/Harbin/07/94 and mouse-adapted B/Memphis/12/97 and B/Hong Kong/05/72) can be attributed to 
one of the two lineages of IBV (Yamagata and Victoria lineage, with their prototypical strains B/Yamagata/16/88 and 
B/Victoria/02/72, respectively) according to specific antigenic sites. Shown in (A) are nucleotides 481-501 of the 
hemagglutinin (HA) gene with corresponding amino acid sequence. Based on these sequences, the B/Harbin/07/94 and 
B/Memphis/12/97 viruses can be assigned to the Yamagata-lineage and B/Hong Kong/05/72 to the Victoria-lineage (B). C. 
Amino acid sequences of antigenic determinants in HA1 for the viruses mentioned in (A). Residues distinctive for viruses of 
either lineage are shown bold in red. Boxed residues represent the presence of a N-glycosylation site altering the 
antigenicity of the virus. D. Amino acid sequences of selected conserved epitopes of IBV for the viruses mentioned in (A). 
Residues deviating from consensus sequences used in the construction of broad vaccine candidates are shown bold in red.  
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Alignment of the selected regions used for vaccine design shows complete conservation of the 
B/HA0- and BM2e-sequences (Fig. 4.1D). The NBe-sequence however deviates from the consensus-
sequences for both mouse-adapted strains used. The B/Memphis/12/97 NBe-sequence differs at 
only one membrane-proximal residue (S15P). Therefore, it is unlikely that this variation will interfere 
greatly with potential antibody binding. For B/Hong Kong/5/72 however, three mutations can be 
observed, Y8C, V11I and S15T, spread over the sequence. These could potentially evade binding by 
NBe-specific antibodies. Sequencing of the NB open reading frame confirmed the presence of these 
mutations (data not shown). 
 
4.2.2 Validation of broad HBc-based IBV vaccines 
 
a) NBe-HBc fusions, 1646 and 1651 
 
In a first experiment scrutinizing HBc-based vaccination to achieve immune protection against IBV 
infection, two recombinant NBe-HBc fusions, 1646 (with the NBe-sequence in the immunodominant 
loop of HBc) and 1651 (with NBe fused N-terminally to HBc), were used to immunize mice (see 
3.2.1b) . As negative controls, unsubstituted HBc-particles were used alongside a buffer-only (PBS) 
treated group. As positive control, groups of mice were immunized with heat-inactivated IBV 
belonging to either lineage, i.e. B/Harbin/7/94 (Yamagata-lineage) and B/Hong Kong/5/72 (Victoria-
lineage). Since the challenge virus was B/Hong Kong/5/72 in this set-up, the former inactivated virus-
immunized group represents a heterologously vaccinated group, while the latter is a homologous 
(strain-matching) combination. Immunizations were given intraperitoneally (i.p.) using 10µg of 
protein (1µg for inactivated viruses) adjuvanted with LTR192G, a detoxified mutant of the heat-labile 
enterotoxin of E. coli as adjuvant 
18
. Three immunizations were given, three weeks apart. The 
challenge with B/Hong Kong/05/72 virus was done twelve weeks after the third immunization. 
Two weeks after each immunization, blood was drawn to evaluate the humoral responses in peptide- 
or protein-specific ELISA. Antibody titers specific for NBe-peptide, HBc-protein and the two 
inactivated viruses are shown in Figure 4.2. Mice clearly seroconvert towards NBe, with a slight Th2-
skewing based on higher IgG1-specific titers. No anti-NBe serum IgG responses were observed 
following immunization with inactivated viruses. Immunization with 1646, carrying NBe in the 
immunodominant loop, elicited higher anti-NBe responses than 1651, with NBe N-terminal of HBc. 
Conversely, anti-HBc titers are higher in the 1651 immunized group compared to the 1646 group, 
indicating that a large part of HBc-specific antibodies are directed towards the aptly named 
immunodominant loop. Anti-virion ELISAs show that cross-reactive antibodies are induced, but 
homologous immune responses supersede heterologous responses by at least a factor ten. 
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Figure 4.2. Serum antibody titers in vaccinated Balb/c mice . Groups of 9 (1646, 1651, HBc), 7 (PBS) or five (inHK, inHarbin) 
mice were immunized three times three weeks apart intraperitoneally with LTR192G-adjuvanted proteins (10µg) or 
inactivated B/Hong Kong/05/72 (inHK) or B/Harbin/07/94 (inHarbin) virus. Two weeks after each immunization, blood was 
drawn for serological analysis of antibody endpoint titers in pooled sera through ELISA. Shown are NBe-peptide specific (A, 
B), HBc-protein specific (C, D) and virus-specific (E, F) antibody titers. For the latter, ELISA plates were coated with 
inactivated B/Hong Kong/12/72 (B/HongKong) or inactivated B/Harbin/07/94 (B/Harbin) virus. Both IgG1-specific (A, C, E) 
and IgG2a-specific (B, D, F) titers were assessed. 
 
Twelve weeks after the last immunization, mice were challenged with 4LD50 of the mouse-adapted 
IBV/Hong Kong/5/72 strain. The challenge results are shown in Figure 4.3. Clearly, immunization with 
inactivated viruses only provides protection in the homologous setting using inactivated B/Hong 
Kong/5/72 (inHK), leading to 100% survival and no signs of morbidity. Heterologous vaccination with 
inactivated B/Harbin/7/94 (inHarbin) offers no protection from mortality. Both negative control 
groups (HBc, PBS) also show no protection. Most interestingly, NBe-HBc vaccination can offer 
protection when the NBe-epitope is presented N-terminally on HBc (1651), saving 33% of mice from 
mortality. Statistically, inactivated B/Hong Kong/5/72 vaccination protects significantly compared to 
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all other groups (Kaplan-Meier analysis; p<0.05 compared to 1651, p<0.01 compared to inHarbin, 
p<0.001 compared to 1646, HBc, PBS). Protection by 1651 vaccination is statistically significant 
compared to 1646 immunization (p<0.05). Even with overall morbidity, measured by relative weight 
loss, being relatively high, it can be concluded that NBe-HBc based immunization using the 1651 
particle can offer protection against a potential lethal IBV infection, even with a difference of three 
amino acids between the NBe-sequence of the vaccine and the challenge virus. 
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Figure 4.3. Protection in NBe-HBc (1646 and 1651) immunized mice against IBV/Hong Kong/05/72 challenge. Mice (n = 9, 
1646, 1651, HBc; n = 7, PBS; n = 5, inHK, inHarbin) were vaccinated as described in Figure 4.2. Twelve weeks after the third 
immunization, mice were challenged with a potentially lethal dose (4LD50) of IBV/Hong Kong/05/72. A. Relative survival 
after challenge. Kaplan-Meier analysis shows significant differences between inHK and all other immunized groups and 
between 1651 and 1646 immunized mice. *, p<0.05; ***, p<0.001. B. Relative body weight after challenge; group average 
+SD. 
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b) NBe-M2e2-HBc (NM2H) and B/HA0-HBc (3004)  fusion 
 
The third NBe-HBc fusion, based on coupling of the NBe-sequence N-terminally to a HBc-particle 
bearing two M2e-sequences (NBe-M2e2-HBc, NM2H), did not show particle formation in in vitro 
testing. However, because of its potential to provide heterotypic (i.e. against IAV and IBV) protection, 
the non-particulate protein was used in a challenge experiment using potentially lethal IAV and IBV 
infections. In a first set-up, groups of mice were immunized three times three weeks apart with the 
NM2H hybrid, 1817 particle (M2e2-HBc, the base on which NBe was grafted to construct NM2H), 
unsubstituted HBc or buffer only (PBS). Immunizations were done with 10µg protein per dose, 
adjuvanted with Montanide ISA-720 
19
, a metabolizable water-in-oil mixture used for subcutaneous 
immunizations. Three weeks after the last immunization, mice were challenged with mouse adapted 
X47 virus, a recombinant strain based on the internal genes of A/PuertoRico/8/34 and the 
hemagglutinin and neuraminidase of A/Victoria/3/75, or mouse-adapted IBV/Memphis/12/97. 
However, the latter challenge was unsuccessful because of low virulence of the IBV/Memphis/12/97 
virus stock used at that time (data not shown); hence, only results for the influenza A part of the 
experiment are shown.   
Two weeks after each immunization, and two weeks after the challenge, blood was drawn for 
preparation of sera and analysis of antibody responses in ELISA. Figure 4.4 shows IgG1- and IgG2a-
specific antibody responses, as determined in NBe-peptide, M2e-peptide and HBc-protein ELISA. 
Clearly, despite lack of evidence for particle formation for NM2H, mice immunized with this protein 
seroconverted for NBe, M2e and HBc. A minor difference compared to 1817 particle immunization 
however is the more Th2-skewed immune response the NM2H protein evokes, with higher IgG1 titers 
and lower IgG2a titers raised against M2e and HBc. However, a role for the presence of the NBe-
epitope on its own in eliciting this effect cannot be excluded. 
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Figure 4.4. Antibody titers in mice vaccinated with different HBc-constructs and challenged with A/X47 virus. Mice (n = 9 
for all groups) were immunized three times three weeks apart with 10µg NM2H (NBe-M2e2-HBc), 1817 (M2e2-HBc), HBc or 
PBS emulsified in Montanide ISA-720 and injected subcutaneously. Three weeks after the last immunization, mice were 
challenged with a potentially lethal dose (4LD50) of A/X47 virus. Two weeks after each immunization and after challenge 
blood was drawn from (surviving) mice for serological analysis of antibody endpoint titers in pooled sera by ELISA. Shown 
are NBe-peptide specific (A, B), M2e-peptide specific (C, D) and HBc-protein specific (E, F) antibody titers. Both IgG1-specific 
(A, C, E) and IgG2a-specific (B, D, F) titers were assessed. ND = not determined (no surviving mice). 
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Figure 4.4. Continued. 
 
Challenge results after infection with X47 virus are shown in Figure 4.5. Using a potentially lethal viral 
dose of 4LD50, all HBc-immunized mice and almost 90% of buffer-treated mice succumbed to the 
infection. In contrast, immunization with NM2H or 1817 fully protected mice from lethality and limit 
edmorbidity strongly, allowing recovery starting day 6 post-infection. Additionally, each group 
contained three immunized mice that were infected with a sublethal (0.4LD50) influenza A/X47 dose. 
These mice were sacrificed day 6 post-challenge for preparation of lung homogenates and titration of 
lung virus titers. As depicted in Figure 4.5C, the two M2e-immune groups (NM2H and 1817) contain 
significantly less virus in their lungs as do the negative control groups (HBc and PBS; one-way Anova, 
p<0.001). In conclusion, despite the lack of particle formation, the NM2H protein is very 
immunogenic, with a slightly higher Th2-skewing than its particulate counterpart (1817), and is able 
to convey protection against a potentially lethal IAV infection to a similar extent as 1817. 
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Figure 4.5. Protection of mice vaccinated with different HBc-constructs after a potential lethal influenza A/X47 virus 
challenge. Mice (n = 9 for all groups) were treated as described in Figure 4.4. Challenge results after a potential lethal 
infection (4LD50) of A/X47 virus. A. Relative survival rate of challenged mice. Kaplan-Meier analysis: ***, p<0.001. B. 
Relative body weight of infected mice; group averages +SD. C. Three mice in each group were challenged with a sublethal 
influenza A/47 dose (0.4LD50). Six days later, mice were sacrificed for preparation of lung homogenates and titration of the 
lung virus dose. Shown is the average TCID50 titer (calculated log-value) ±SD. 
 
To assess protection against IBV infection, the experiment was repeated. In this instance, mice were 
immunized with the NM2H protein and the 3004 particle, displaying the B/HA0 cleavage sequence in 
the immunodominant loop of HBc. As negative controls, immunizations with unsubstituted HBc 
particles and buffer (PBS) were performed. As in the initial set-up, vaccinations were adjuvanted with 
Montanide ISA-720 and administered subcutaneously. Mice were immunized three times, three 
times apart, with 10µg of protein per dose (7.5µg for the 3004 particle). Using serum from blood 
samples taken two weeks after each immunization and after the challenge, IgG1 and IgG2a antibody 
titers directed against NBe, M2e, HBc and inactivated virions were determined in ELISA (Fig. 4.6). 
Antibody titers induced by the NM2H protein against NBe, M2e and HBc appeared to be even higher 
in this experiment than in the formerly discussed set-up. Also here, Th2-skewing by this protein is 
evident when comparing anti-HBc titers induced by NM2H and 3004. To detect B/HA0-specific 
responses induced by 3004, cellular ELISAs were carried out using fixed influenza A or B infected cell 
monolayers (Fig. 4.6G-H). NM2H-specific antisera clearly react with IAV infected cells, corresponding 
with the presence of anti-M2e antibodies. However, no reaction is seen with IBV infected cells, 
despite the clear presence of anti-NBe antibodies in peptide ELISA. 3004-specific antisera on the 
other hand do react with IBV infected monolayers. With a lack of reaction with HBc-antisera, these 
data show the induction of B/HA0-specific antibodies which are able to bind infected cells. This 
finding was further confirmed by immunofluorescence staining of B/Memphis/12/97 infected cells 
with sera of mice taken after the second boost or the challenge (Fig. 4.7).. 
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Figure 4.6. Antibody titers in mice vaccinated with different HBc-constructs and challenged with B/Memphis/12/97 virus. 
Mice (n = 12 for all groups) were immunized three times three weeks apart with 10µg NM2H (NBe-M2e2-HBc), 3004 (B/HA0-
HBc), HBc or PBS emulsified in Montanide ISA-720 and injected subcutaneously. Three weeks after the last immunization, 
mice were challenged with a potential lethal dose (4LD50) of B/Memphis/12/97 virus. Two weeks after each immunization 
and after challenge blood was drawn from (surviving) mice for serological analysis of antibody endpoint titers in pooled sera 
through ELISA. Shown are NBe-peptide specific (A, B), M2e-peptide specific (C, D), HBc-protein specific (E, F) and infected 
cell specific (G, H) antibody titers. For the latter, monolayers of MDCK cells were infected with influenza A/PuertoRico/8/34 
or B/Memphis/12/97 virus (MOI 3), fixed after 24h of incubation and processed further using the standard ELISA protocol. 
Both IgG1-specific (A, C, E, G) and IgG2a-specific (B, D, F, H) titers were assessed. ND = not determined (no surviving mice). 
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Figure 4.7. B/HA0 antiserum reacts with IBV infected MDCK cells in immunofluorescence staining. MDCK cells were 
infected with B/Memphis/12/97 virus (MOI 3) overnight, fixed and permeabilized. Cells were stained with mouse serum 
(1/300) taken after the second boost with 3004 particles or after the B/Memphis/12/97 challenge (green) and with goat 
anti-M1 antiserum (red). Representative pictures for each condition are shown. Control stainings using A/PuertoRico/8/34 
or non-infected cells were negative. 
 
Three weeks after the third immunization, mice were challenged with 4LD50 of mouse-adapted 
B/Memphis/12/97. All groups showed severe morbidity and high mortality rates (Fig. 4.8). With only 
25% survival in the 3004 immunized group and 17% in the NM2H group, no significant protection was 
seen (3004 vs HBc, p=0.064; NM2H vs HBc, p=0.060; Kaplan-Meier analysis). As a second read-out, 
viral replication in the lungs of infected mice was analyzed. To this end, two groups of three mice in 
each immunized group were challenged with 0.4LD50 B/Memphis/12/97 and sacrificed three and four 
days after challenge. This shorter infection period as compared to IAV infections was used to 
encompass the ideal timing to detect replication in the lungs of infected mice (data not shown). As 
depicted in Figure 4.8C, titers are significantly higher on day 3 in the PBS group (p<0.05; one-way 
Anova) but do not differ significantly on day 4 (p=0.076; one-way Anova). Looking at the differences 
between pulmonary virus levels on day 3 and day 4 post-challenge, the decline is only significant for 
the 3004 particle immunized and PBS-only treated mice (p<0.01, two-sided t-test). Overall, despite 
the induction of NBe-peptide reactive antibodies in the NM2H-immunized group and B/HA0-specific 
antibodies reactive with infected cells in the 3004-vaccinated mouse group, no clear protective effect 
of either vaccination strategy against a potentially lethal IBV infection can be seen, although anti-
B/HA0 antibodies inhibit viral replication slightly. 
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Figure 4.8. Protection of mice vaccinated with different HBc-constructs after a potentially lethal infection with 
B/Memphis/12/97 virus. Mice (n = 12 for all groups) were treated as described in Figure 4.6. Challenge results after a 
potentially lethal infection (4LD50) with B/Memphis/12/97 virus. A. Relative survival rate of challenged mice. B. Relative 
body weight of infected mice; group averages +SD. C. Two groups of three mice in each group were challenged with a 
sublethal IBV/Memphis/12/97 dose (0.4LD50). Three and four days later, mice were sacrificed for preparation of lung 
homogenates and titration of the lung virus dose. Shown is the average TCID50 titer (calculated log-value) ±SD. **, p<0.01. 
 
 
4.2.3 Protection provided by tGCN4-based broad IBV vaccine candidates 
 
The second carrier protein used to display conserved IBV regions in a potentially immunogenic 
manner is tGCN4, the tetramerizing leucine zipper of the GCN4 transcription factor of yeast 
20,21
. In a 
first in vivo experiment, immunogenicity and protective capacity against B/Hong Kong/5/72 infection 
of BM2e-tGCN4 and NBe-tGCN4-Flag was assessed. As negative control, adjuvanted buffer-only (PBS) 
immunizations were included. An additional group received inactivated B/Memphis/1/97 virus, to 
assess heterologous protection provided by this strain belonging to the Yamagata-lineage against the 
Victoria-like B/Hong Kong/5/72. Two different adjuvants were used for all treatments: Montanide 
ISA-720 and Alhydrogel, an aluminum salt based adjuvant. Antibody titers two weeks after each 
immunization and after the challenge are shown in Figure 4.9. In general, the tGCN4-carrier appears 
to be highly immunogenic in Balb/c mice (Fig. 4.9A, B), giving endpoint titers of over 10
7
 after three 
immunizations. Immune responses are slightly Th1-skewed, with higher IgG1-specific titers than 
IgG2a-titers. Montanide ISA-720 adjuvanted proteins elicit higher antibody responses than 
Alhydrogel adjuvantation. Clear anti-NBe responses can be seen in peptide ELISA (Fig. 4.9C, D). Serum  
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Figure 4.9. Antibody titers in mice vaccinated with different tGCN4-constructs and challenged with B/Hong Kong/5/72 
virus. Groups of mice were immunized three times three weeks apart with 10µg BM2e-tGCN4 or NBe-tGCN4-Flag (n = 9), 
1µg heat-inactivated B/Memphis/12/97 (n = 5) or PBS (n = 9), adsorbed to Alhydrogel and injected ip. or emulsified in 
Montanide ISA-720 and injected sc. Three weeks after the last immunization, mice were challenged with a potentially lethal 
dose (4LD50) of B/Hong Kong/5/72. Two weeks after each immunization and after challenge blood was drawn from 
(surviving) mice for serological analysis of antibody endpoint titers in pooled sera by ELISA. Shown are tGCN4-Flag specific 
(A, B) and NBe-peptide specific (C, D) specific titers. For determination of virus-specific (E, F) antibody titers, ELISA plates 
were coated with 25ng/well inactivated B/Hong Kong/5/72 or B/Memphis/12/97 virus. To detect anti-BM2e reactivity, 
cellular ELISAs were performed using fixed monolayers of B/Memphis/12/97 infected MDCK cells (MOI 3; MDCK-B/Mem) or 
HEK cells transfected with a BM2-Flag expressing construct (HEK – BM2-Flag). Shown is the absorbance at 450nm for pooled 
sera of mice immunized with BM2e-tGCN4 (BG) or PBS. Both IgG1-specific (A, C, E, G) and IgG2a-specific (B, D, F, H) titers 
were assessed. ND = not determined (no surviving mice). 
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from mice immunized with inactivated B/Memphis/12/97 was tested in ELISA using plates coated 
with heat-inactivated B/Memphis/12/97 and B/Hong Kong/5/72 as antigens. Prechallenge sera 
clearly react stronger with B/Memphis/12/97 virus, but do show cross-reactivity with B/Hong 
Kong/5/72 virus (Fig. 4.9E, F). To detect anti-BM2e antibody responses, cellular ELISAs were 
performed using B/Memphis/12/97 infected MDCK cells or BM2-Flag transfected HEK cells (Fig. 4.9G, 
H). Relatively high background levels did not allow clear determination of anti-BM2e endpoint titers, 
but absorbance levels measured in ELISA do show an increasing reactivity with the BM2-expressing 
cells with increasing numbers of immunizations. Even more, after challenge, a boost-effect can be 
observed, as indicated by higher reactivity with BM2-Flag expressing HEK cells. Similar set-ups using 
serum from NBe-tGCN4-Flag immunized mice did not show any specific reactivity or boost-effect 
(data not shown). 
Morbidity and mortality after a potentially lethal (4LD50) IBV/Hong Kong/5/72 challenge is illustrated 
in Figure 4.10. Mice immunized with Alhydrogel adjuvanted BM2e-tGCN4 protein were significantly 
protected against mortality compared to the PBS group (p<0.05; Kaplan-Meier analysis). 
Immunization with inactivated B/Memphis/12/97 does not induce protective immunity against 
infection with the distinct B/Hong Kong/5/72 virus, despite the presence of cross-reactive antibodies 
as detected in the anti-virion ELISAs (Fig. 4.9E, F). Again, this indicates lack of cross-lineage 
protection, as observed before (Fig. 4.3). Morbidity, measured by relative body weight, was 
significantly reduced in BM2e-tGCN4 mice on days 8 and 9 post-infection compared to the three 
other groups (Fig. 4.10B).  
Subcutaneous immunizations with Montanide ISA-720 as adjuvant gives a different result (Fig. 4.10C, 
D). In this set-up, NBe-tGCN4-Flag immunization can provide significant protection compared to PBS 
immunization (p<0.05; Kaplan-Meier analysis), whereas BM2e-tGCN4 gives the same survival rate as 
in combination with Alhydrogel (33%). Also here, no cross-lineage protection provided by inactivated 
B/Memphis/12/97 immunization is detected, and morbidity is similar in all groups (Fig. 4.10D). 
In each group of mice, three additional mice were infected with a sublethal dose (0.4LD50) of B/Hong 
Kong/5/72 for analysis of viral replication in the lung three days after the challenge (Fig. 4.10E, F). 
Irrespective of the adjuvant used, NBe- or BM2e-based tGCN4-protein immunization led to a 
significant drop in pulmonary virus titer compared to PBS-treated mice (p<0.05, one-way Anova). 
Noteworthy, immunization with inactivated B/Memphis/12/97 did not induce any inhibitory effect 
on viral replication, reflecting the morbidity and mortality results. 
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Figure 4.10. Protection of mice vaccinated with different tGCN4-constructs after a potentially lethal infection with 
B/Hong Kong/5/72 virus. Mice (n = 9 for all groups except inMem, n = 5) were treated as described in Figure 4.8. A-D. 
Challenge results after a potentially lethal infection (4LD50) with B/Memphis/12/97 virus. Shown are the relative survival 
rate (A) and relative body weight of mice immunized with Alhydrogel-adjuvanted vaccines after challenge (B), and the 
relative survival rate (C) and relative body weight of mice immunized with Montanide ISA-720 adjuvanted vaccines after 
challenge (D). For survival, significant differences as determined by Kaplan-Maier analysis are indicated; *, p<0.05. For 
relative body weights, group averages are shown +SD; *, p<0.05 (one-way Anova). E-F. Two groups of three mice in each 
group were challenged with a sublethal IBV/Memphis/12/97 dose (0.4LD50). Three days later, mice were sacrificed for 
preparation of lung homogenates and titration of the lung virus dose. Shown is the average TCID50 titer (calculated log-
value) ±SD. 
 
In a follow-up experiment, BM2e(QIL)-tGCN4 and P. pastoris expressed gNBe-tGCN4 were used 
alongside BM2e-tGCN4, NBe-tGCN4-Flag, and M2e-tGCN4-Flag and PBS buffer as negative controls. 
Inactivated B/Memphis/12/97 virus was used again as immunogen, this time to assess induction of 
homologous protection against a potentially lethal B/Memphis/12/97 challenge. Combined with 
Montanide ISA-720, induction of antibody responses against the tGCN4-carrier, BM2-protein and 
NBe-peptide were similar as in the previous experiment (data not shown). Additionally, 
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immunofluorescence stainings of influenza infected MDCK cells were carried out to assess 
recognition of viral proteins by immune sera. Representative pictures are shown in Figure 4.11. Sera 
raised with BM2e- and NBe-based chimeric proteins react specifically with IBV infected cells, albeit 
with low intensity, as does M2e-tGCN4 serum with IAV infected cells. Strong staining is achieved with 
antiviral serum raised with inactivated B/Memphis/12/97, as would be expected.  
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Figure 4.11. Immunofluorescence staining of IBV infected MDCK cells shows specific reactivity with tGCN4-protein raised 
mouse serum. MDCK cells were infected with A/PuertoRico/8/34 (MOI 3; A) or B/Memphis/12/97 (MOI 3; B) overnight, 
fixed and permeabilized. Staining was done with immune sera, taken after the third immunization, raised with the indicated 
immunogens (1/300 dilution) and with goat anti-IBV M1 antiserum. Representative pictures for each condition are shown. 
Control stainings using non-infected cells were negative. 
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Figure 4.11. Continued. 
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Challenge results are depicted in Figure 4.12. Immunization with inactivated B/Memphis/12/97 virus 
protects mice from a potentially lethal homologous challenge, leading to only minor morbidity 
shortly after infection. Both BM2e-based tGCN4-vaccines show significant protection from mortality 
compared to M2e-tGCN4 (p<0.05, Kaplan-Meier analysis). Compared to NBe-tGCN4-Flag, gNBe-
tGCN4 and BM2e-tGCN4 provide significant protection (p<0.05, Kaplan-Meier analysis); BM2e(QIL)-
tGCN4 does not reach significance (p=0.051). It should be clearly noted that in this instance, 
mortalitity results are highly influenced by the exclusion of mice losing over 30% of body weight. 
Additionally, on the level of morbidity, no differences are seen between the different tGCN4-
immunized groups. Hence, for BM2e- and gNBe-based proteins showing significant protection from 
mortality, morbidity remains very high but simply does not exceed 30% weight loss for mice depicted 
in the mortality curve. This reflects the need for further improvement regarding the IBV mouse 
model in general and the induction of protective immunity by conserved antigens described here. 
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Figure 4.12. Protection of mice vaccinated with different tGCN4-constructs after a potentially lethal infection with 
B/Memphis/12/97 virus. Groups of mice were immunized three times, three weeks apart, with 10µg Montanide ISA-720 
adjuvanted BM2e-tGCN4, BM2e(QIL)-tGCN4, NBe-tGCN4-Flag, gNBe-tGCN4-Flag or M2e-tGCN4-Flag (n = 9 for each group) 
protein, PBS buffer alone (n = 9) or 1µg inactivated B/Memphis/1/97 (n = 5). Three weeks after the last immunization, mice 
were challenged with a potential lethal (4LD50) dose of B/Memphis/12/97 virus. A. Relative survival for each group, with 
indication of statistical significant differences, as determined by Kaplan-Meier analysis, *, p<0.05; **, p<0.01. B. Relative 
body weight after challenge. Shown are the group averages +SD. 
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4.2.4 Immunogenicity and protective efficacy of chimeric transmembrane NBe-protein 
expressing cells 
 
The second tGCN4-based vaccination experiment indicated a superior effect of the glycosylated 
gNBe-tGCN4 immunogen compared to bacterial expressed NBe-tGCN4-Flag. Hence, we thought it 
appealing to further assess the protective capacity of glycosylated NBe-species. With a lack of good 
expression systems yielding appreciable amounts of soluble glycosylated NBe-proteins next to P. 
pastoris, we employed cellular-vaccine immunizations using mammalian cells transiently transfected 
with constructs expressing transmembrane chimeric NBe-proteins. In this set-up, three consecutive 
immunizations were given, three weeks apart, using HEK293T cells transfected with different 
pCAGGS-based plasmids through calcium phosphate precipitation. As a final heterologous boost (i.e. 
with a distinct cell line transfected with the same constructs), mice were immunized eight weeks 
after the third HEK-immunization with polyethylene-imide transfected NIH3T3 cells. The cell-
expressed antigens used include NBe(WT)-M2-Flag, with the wild type NBe-sequence containing its 
two glycosylation sites, and NBe(Mut)-M2-Flag, with the mutant NBe-sequence lacking the two 
glycosylation sites (N3Q and N7Q mutations). An additional test-group was immunized with BM2-
Flag expressing cells. As controls, M2-Flag expressing cells were included, alongside mock-transfected 
(GFP-expressing vector) cells. A representative Western blot analysis of expression levels in 
transfected cells used for immunization is shown in Figure 4.13A. All immunizations were done with 
appr. 2-4x10
6
 cells per vaccination per mouse, suspended in PBS without an adjuvant. It should be 
noted that the high glycosylation level of NBe(WT)-M2-Flag (nearly 100% fully glycosylated species, 
as seen in Fig. 4.13A) was comparable for each immunization. 
To analyze humoral responses, a number of assays were performed. In peptide ELISA, no anti-NBe 
responses were detected (data not shown). For the M2-Flag immunized group, low anti-M2e serum 
IgG responses were recorded, with endpoint titers just under 10
5
 for both IgG1 and IgG2a (data not 
shown). To assess interaction of antisera with total Flag-tagged proteins or glycosylated NBe, cellular 
stainings were performed. In a first set-up, lysates of NBe(WT)-M2-Flag expressing HEK293T cells 
were analyzed on SDS-PAGE and transferred to Western blot. Using pooled sera of immunized mice 
(after the third HEK-immunization), the blot was detected to reveal anti-cellular and NBe(WT)-M2-
Flag specific responses. As can be deduced from Figure 4.13B, antisera react with a number of 
cellular proteins. Immunization with cells expressing any of the M2-Flag based proteins elicits 
antibodies against the common M2-Flag transmembrane and cytoplasmic domain, indicating release 
and processing of the entire transmembrane protein. This might be due to disruption of transfected 
cells during vaccine preparation and injection, or might happen in vivo after immunization.  
A second, similar analysis was based on detection of virion-associated antigens on Western blot (Fig. 
4.13C). With the AM2, NB and BM2 content of viral particles being relatively low, loading a large 
amount of A/PuertoRico/8/34 and B/Memphis/12/97 pfu (app. 10
7
-10
8
 pfu per lane) on gel allowed 
for detection of minor reactivity. All antisera raised through M2-based immunization reacted with 
the M2-protein, while BM2-specific antisera revealed an influenza B specific protein with a MW 
corresponding to that of BM2. No NB-specific reaction was detected. Overall, using transfected cells 
as immunogens, viral protein specific antibodies can be elicited reactive with full-length proteins in 
Western blot. 
 
125 In vivo validation of cross-reactive IBV vaccine candidates 
 
1 2 3 4 5 6 2 3 4 5 6 1 2 3 4 5 6
1
2 3 4 5 6
a  ba  ba  ba  ba  b
A
B
 
Actin
GFP
Flag-tagged 
proteins
UG
G1/2
G1+2
 
Cellular 
proteins
 
M2-Flag 
proteins
50
37
25
20
15
10
50
37
25
20
15
10
50
37
25
20
15
10
C
1 2 3 4 5 6
A  B A  B A  B A  B A  B A  B
7
A  B
M
AM2
BM2
AM1
 
Figure 4.13. Expression levels in and immunogenicity of cells transfected with different constructs expressing influenza-
derived transmembrane proteins. A. Analysis of cell lysates, showing the expression level of Flag-tagged proteins after 
transfection of HEK293T cells with pCAGGS-based vectors coding for the different proteins. Western blot analyzed with 
rabbit anti-Flag (red) and mouse anti-actine and anti-GFP (green), visualized with the Odyssey imaging system. 1 = gel 
marker (MW in kDa), 2 = mock transfected cells expressing GFP, 3 = pCAGGS-BM2-Flag, 4 = pCAGGS-M2-Flag, 5 = pCAGGS-
NBe(WT)-M2-Flag, 6 = pCAGGS-NBe(Mut)-M2-Flag; a = supernatant after lysis, b = pellet after lysis. B. Reaction of pooled 
antisera of mice, immunized three times with transfected HEK cells expressing NBe(WT)-M2-Flag on Western blot. As 
internal control, the blot was detected with rabbit anti-Flag (red; left panel), showing expression of non-glycosylated (UG), 
single glycosylated (G1/2) and mainly double glycosylated (G1+2) NBe(WT)-M2-Flag. The middle panel shows reactivity of 
antisera with NBe(WT)-M2-Flag lysates, revealing reactivity with both cellular and M2-Flag based proteins. The right panel is 
an overlay of the left and middle panel. 1 = gel marker (MW in kDa), 2 = antiserum against mock-transfected cells, 3 = 
antiserum against BM2-Flag expressing cells, 4 = antiserum against M2-Flag expressing cells, 5 = antiserum against NBe(WT) 
M2-Flag expressing cells, 6 = antiserum against NBe(Mut)-M2-Flag expressing cells. C. Reaction of pooled antisera of mice 
after the fourth immunization with virion-associated proteins. Approximately 10
7
-10
8
 pfu of A/PuertoRico/8/34 (lanes A) or 
B/Memphis/12/97 (lanes B) were loaded on gel for Western blot analysis. Detection of viral proteins was done with 
immune sera (1/300 diluted). The expected location of bands corresponding to AM1, AM2 and BM2 protein are indicated 
by arrows. M = gel marker (MW in kDa), 1 = detection with NBe-specific 15G5mAb, 2 = M1- and M2e-specific 148mAb, 3 = 
antiserum against mock-transfected cells, 4 = antiserum against BM2-Flag expressing cells, 5 = antiserum against M2-Flag 
expressing cells, 6 = antiserum against NBe(WT) M2-Flag expressing cells, 7 = antiserum against NBe(Mut)-M2-Flag 
expressing cells. 
 
Immunofluorescence staining of transfected NIH3T3-cells is a second approach used here to evaluate 
humoral responses elicited by cell-based immunizations. To be able to detect the potential presence 
of antibodies against glycosylated NBe, cells were transfected with BM2-Flag based constructs and 
used for staining after fixation and permeabilization (since the majority of BM2-based proteins is not 
surface-expressed). Background staining of endogenous cellular proteins was largely avoided by a 
pre-clearing step with incubation of immune sera with untransfected NIH3T3 cells before staining of 
transfected cells. Representative pictures of stainings with antiserum (from the final NIH3T3 cell-
based boost) raised against NBe(WT)-M2-Flag are shown in Figure 4.14. In general, little background 
staining is visible because of the pre-clearing step, as evidenced by staining of mock (empty pCAGGS-
vector) transfected cells (top panel). Staining of NBe(WT)- and NBe(Mut)-BM2-Flag expressing cells 
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shows the presence of cross-reactive antibodies, which might be specific for (glycosylated) NBe. 
Staining of BM2-Flag expressing cells however also shows some staining with antiserum, suggesting 
the presence of anti-Flag antibodies. Binding of M2-Flag expressing cells gives a very clear staining of 
the M2-protein, corresponding to the presence of anti-M2 antibodies as detected in Western blot 
stainings (Fig. 4.13). Corresponding stainings with NBe(Mut)-M2-Flag specific antiserum gave similar 
results (data not shown). 
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Figure 4.14. Immunofluorescence staining of transfected cells with pooled antisera raised against cells expressing 
influenza-derived transmembrane proteins. NIH3T3-cells were transfected with empty pCAGGS vector (top row) or 
pCAGGS-based vectors encoding BM2-Flag (second row), NB(WT)-Flag (third row), NBe(WT)-BM2-Flag (fourth row), 
NBe(Mut)-BM2-Flag (fifth row) or M2-Flag (bottom row). 16h after transfection, cells were fixed and permeabilized and 
stained with rabbit anti-Flag (red) and pooled antiserum (1/250 diluted; green) raised against NBe(WT)-M2-Flag by 
immunizing mice with cells transiently expressing this protein. Representative pictures for each setting are shown. 
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In control settings, transfected cells were stained with pooled antiserum raised against mock (GFP-
expressing plasmid), BM2-Flag or M2-Flag transfected cells (Fig. 4.15). Staining of NBe(WT)-BM2-Flag 
expressing cells with M2-Flag specific antiserum revealed staining of Flag-tagged proteins, affirming 
the presence of anti-Flag antibodies in the serum providing cross-reactivity. The corresponding 
staining with BM2-Flag antiserum however shows a more intense binding of the antiserum, 
demonstrating the induction of BM2-protein reactive antibodies. Corresponding stainings of NB-Flag, 
NBe(Mut)-BM2-Flag and BM2-Flag expressing cells fall in line with discussed results (data not shown).  
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Figure 4.15. Immunofluorescence staining of transfected cells with pooled antisera raised against cells expressing 
influenza-derived transmembrane proteins. NIH3T3-ells were transfected with empty pCAGGS vector (top row of each 
panel) or pCAGGS-based vectors encoding NBe(WT)-BM2-Flag (middle row of each panel) or M2-Flag (bottom row of each 
panel). 16h after transfection, cells were fixed and permeabilized and stained with rabbit anti-Flag (red) and pooled 
antiserum (1/250 dilution; green) raised against M2-Flag (A), BM2-Flag (B) or mock transfected cells (C). Representative 
pictures for each setting are shown. 
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Figure 4.15. Continued.  
 
Four weeks after the fourth (heterologous) immunization, mice were challenged with a 2.5LD50 
IBV/Memphis/12/97 dose. With this slightly lower dose compared to previous challenge 
experiments, it was anticipated that protective immunity would be more evident, while still retaining 
potential lethality. For the analysis of viral replication in the lungs of infected mice, a 0.025LD50 dose 
was administered (appr. 3x10
4
 pfu). Challenge results are shown in Figure 4.16. NBe(WT)-M2-Flag 
and BM2-Flag immunized mice show 43% and 29% survival, respectively, although morbidity, as 
determined by body weight measurement, is high. Compared to mock and M2-Flag transfected cells, 
NBe(WT)-M2-Flag can bestow significant protection (p<0.05, Kaplan-Meier analysis).  
Day 3 and day 5 after the sublethal challenge (0.025LD50), lung homogenates were prepared for virus 
titration. For unclear reasons, the titers on day 3 postchallenge for the mock-transfected cell 
immunized group are significantly lower compared to other groups (p<0.05; one-way Anova). 
However, only in this group do titers incline on day 5 compared to day 3 postchallenge. For all the 
M2-Flag based immunized groups, titers are lower on day 5 after infection. More interestingly, titers 
in NBe(Mut)-M2-Flag immunized mice are very low on day 5 postchallenge, and even undetectable in 
the NBe(WT)-M2-Flag immunized group. For the latter group, day 5 titers are statistically lower 
compared to mock- and M2-Flag transfected cell immunized mice (p<0.01 and p<0.05, resp.; two-
sided t-test).  
Combined with significant protection from mortality, absence of lung virus titers shows that 
immunization of mice with a glycosylated NBe-based vaccine has a beneficial effect on the induction 
of IBV antiviral immunity compared to control settings. The mutant counterpart, lacking glycosylation 
sites through mutation of the Asn-residues to Gln (N3Q and N7Q), can induce inhibitory effects on 
viral replication but fails to protect mice from mortality. These results indicate an additional 
advantage of glycosylation of the NBe-sequence in vaccine design in inducing protective immunity 
towards IBV infection. 
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Figure 4.16. Protection of mice vaccinated with transfected cells, expressing transmembrane influenza-derived proteins, 
after a potential lethal infection with B/Memphis/12/97 virus. Groups of seven mice were immunized three times, three 
weeks apart, with transfected HEK293T cells and boosted eight weeks later with transfected NIH3T3 cells. For transfection, 
pCAGGS-based vectors were used encoding BM2-Flag, M2-Flag, NBe(WT)-M2-Flag or NBe(Mut)-M2-Flag. Mock 
transfections were performed with a GFP-expressing vector combined with empty pCAGGS. Three weeks after the last 
immunization, mice were challenged with a potential lethal (2.5LD50) dose of B/Memphis/12/97 virus. A. Relative survival 
for each group, with indication of statistical significant differences, as determined by Kaplan-Meier analysis, *, p<0.05. B. 
Relative body weight after challenge. Shown are the group averages +SD. C. Two additional groups of three mice in each 
group were challenged with a sublethal IBV/Memphis/12/97 dose (0.025LD50). Three and five days later, mice were 
sacrificed for preparation of lung homogenates and titration of the lung virus dose. Shown is the average TCID50 titer 
(calculated log-value) ±SD. *, p<0.05; **, p<0.01; ***, p<0.001. 
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4.2.5 Passive immunization of mice using NBe-specific monoclonal antibodies 
 
Experiments described above indicate that bacterial produced NBe-tGCN4-Flag can provide some 
protection, but that glycosylated NBe-based vaccine candidates (gNBe-tGCN4, NBe(WT)-M2-Flag) 
have superior effects compared to their non-glycosylated counterparts. To further assess the 
protective capacity of non-glycosylated NBe-bases vaccines in an indirect manner, passive 
immunization experiments were performed using the in-house developed NBe-specific monoclonal 
antibody (mAb) 15G5 (see section 3.2.5). Compared to other selected NBe-specific mAbs, 15G5 
shows the highest affinity for its epitope. As controls, the simultaneously selected HBc-specific mAb 
20C3 was used, alongside buffer only (PBS) and polyclonal post-challenge serum of 
B/Memphis/12/97 virus infected mice as positive controls. Passive immunizations was performed 
with 150µg mAbs or 50µL post-challenge serum. One day after transfer, blood was drawn to assess 
the presence of the transferred immune agents before mice were challenged with 2.5LD50 of 
B/Memphis/12/97.  
Serology and challenge results are shown in Figure 4.17. All immune agents transferred are detected 
in sera collected the next day (Fig. 4.17A). Subsequent infection with a potentially lethal dose of 
B/Memphis/12/97 virus induced a high degree of morbidity and mortality in all mouse groups, 
including mice who received the homologous anti-viral serum. Only this latter group showed survival 
(42%), giving a significant difference with other groups (p<0.05, Kaplan-Meier analysis). Similar 
results are seen when analyzing lung viral titers, determined three and four days after a sublethal 
(0.1LD50) challenge. Titers in mice receiving anti-viral serum are significantly lower on both days 
compared to other groups (p<0.05, one-way Anova). In conclusion, the NBe-specific mAb 15G5 is 
unable to convey protection in passive immunization, despite showing binding of infected cells in 
immune-fluorescence assays (see chapter 3, Figure 3.22). 
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Figure 4.17. Passive immunization of mice with NBe-specific mAbs is unable to protect against a potential lethal 
IBV/Memphis/12/97 challenge. Groups of mice were passively immunized by i.p. injection with 150µg NBe- (15G5; n = 8) 
or HBc-specific (20C3; n = 8) monoclonal antibody, 50µL B/Memphis/12/97-specific postchallenge serum (aVir; n = 7) or PBS 
(n = 7). 16h after passive transfer, blood was drawn for serum analysis. 20h after transfer, mice were challenged with a 
potentially lethal (2.5LD50) dose of B/Memphis/12/97 virus. A. Endpoint titers as determined in NBe-, HBc- or virus-specific 
(aVir) ELISA. For the latter, ELISA plates were coated with inactivated B/Memphis/12/97 virus. B. Relative survival for each 
group, with indication of statistical significant differences, as determined by Kaplan-Meier analysis, *, p<0.05.  
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Figure 4.17. Continued. C. Relative body weight after challenge. Shown are the group averages +SD. D. Two additional 
groups of three mice in each group were challenged with a sublethal IBV/Memphis/12/97 dose (0.1LD50). Three and four 
days later, mice were sacrificed for preparation of lung homogenates and titration of the lung virus dose. Shown is the 
average TCID50 titer (calculated log-value) ±SD. 
 
 
4.3. Discussion 
The current epidemic situation of IBV is problematic. Co-circulation of two antigenically distinct 
lineages enables the virus to easily circumvent natural or vaccine-induced immunity by switching 
between strains of both lineages. Additionally, it provides a basis for recombination of genes or gene 
constellations, adding on to intragenic antigenic evolution based on mutation and immune 
selection
15,22-24
. Hence, new strategies are needed to combat future epidemics. Apart from 
implementation of quadrivalent vaccines, containing two IAV (H1N1 and H3N2) and two IBV (of both 
lineages) strains 
25
, recombinant vaccines can provide a basis for a broad, cross-lineage IBV vaccine. 
On these premises, the immunogenic and protective potential of a number of conserved IBV domains 
were scrutinized in this study. 
The main obstruction in this and related work, is the lack of a good, small animal model for IBV. The 
mouse as model is an obvious choice, as for IAV this works well and mice, in general, are easy to 
handle and manipulate. However, compared to IAV, IBV is a ‘humanized‘ form of the virus, with a 
very restricted host range. This entails results obtained in mouse models should not be taken for 
granted. The difficulties with this model were also apparent in our immunization-challenge 
experiments. Initial attempts to adapt a number of IBV to the murine host failed. To overcome this, 
mouse-adapted IBV strains were obtained from other research groups 
7,8
. The dose needed to 
achieve lethality with these mouse-adapted strains however exemplifies the difficulties with the 
model. On average, the LD50 dose for IBV is over 4log values higher than for IAV. Such amounts of 
virus needed for lethality induce an enormous strain on the model as such. This is e.g. illustrated in 
the passive immunization experiment, where administration of homologous antiserum (with an 
endpoint anti-virion ELISA titer of appr. 10
5
/50µL, equivalent to an HI titer of 160) can only protect 
42% of treated mice, a set-up shown to protect mice from excessive IAV induced morbidity and 
mortality 
26
. 
Despite the challenging IBV model, encouraging effects of our vaccine candidates were detected. A 
summary of the immunogenic and protective characteristics of proteins tested here is given in Table 
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4.1. Protection of mice against a potentially lethal IBV infection through immunization with HBc-
based broad IBV vaccine candidates is only evident when using an NBe-HBc particle displaying the 
NBe-sequence N-terminally (1651). In contrast however, 1646 immunized mice show higher anti-NBe 
responses than 1651 immunized mice, as measured in peptide-ELISA (Fig. 4.2A, B), not indicating any 
correlation between protection and anti-NBe titers. A qualitative difference however might explain 
the results, in that the presentation of NBe at the N-terminal end of the chimeric protein might be 
superior to insertion of the NBe-sequence in the loop of HBc. Specific pools of antibody reactive with 
the free N-terminal end of (unglycosylated) NBe could have better access to virally expressed NB 
protein, providing protection through Fc-mediated downstream effects or direct activity on IBV 
infectivity. Also noteworthy in this regard, in this set-up mice were challenged with B/Hong 
Kong/05/72 virus, for which the NBe-sequence shows quite some disparity with that of the vaccine 
construct, but specifically towards the C-terminal end of the sequence (Fig. 4.1). Is should be stated 
however, that no clear specific staining of IBV infected cells was observed using sera raised with any 
of the NBe-HBc fusions reported here (data not shown). 
NM2H-protein immunization has a clear effect on influenza A/X47 infection, subsiding morbidity, 
mortality and pulmonary virus replication compared to HBc- and PBS-treated groups. This protein is 
able to elicit anti-M2e IgG responses to a similar extent as its non-NBe bearing particulate 
counterpart 1817, albeit with a slight skewing towards a higher Th2-biased response. Despite 
induction of high anti-NBe titers, encompassing those evoked by 1646 and 1651, no clear-cut result 
was seen when challenging immunized mice with B/Memphis/12/97. The 3004 particle, displaying 
the cleavage loop op B/HA0 in an immunogenic manner, also failed to induce protection, even 
though specific antibody levels were readily detected in cellular ELISA, and it has been reported that 
the conserved B/HA0 cleavage loop can be used as an immuno-protective antigen in mouse 
27
, 
although certain aspects in the experimental set-up do differ strongly. Here, 4LD50 was given in a 
volume of 50µL, penetrating deep into the lungs, while Bianchi et al. administered 1LD90 in a volume 
of 20µL. Nonetheless, the lack of a significant effect on IBV challenge in these instances further 
emphasizes the demanding aspects of the IBV mouse model, requiring high doses of virus to achieve 
mortality and measurable levels of morbidity. 
The tGCN4-based proteins are expected to display the NBe- and BM2e-epitopes in a tetrameric 
fashion, mimicking their natural conformation 
28-32
. Hence, immune serum raised with these is 
expected to recognize cell-expressed NB and BM2 proteins, as has been shown for M2e-tGCN4 and 
M2 protein recognition 
21
. Cellular assays here show that anti-BM2e immune sera can react with 
BM2-expressing transfected or infected cells in ELISA, albeit at low intensity. Likewise, antisera 
directed towards glycosylated and non-glycosylated NBe can clearly stain transfected cells expressing 
NBe-chimeric transmembrane proteins. However, levels of reactive antibodies might not reach levels 
needed for full protection, resulting in high morbidity and mortality, as detected in described 
experiments. 
The outcome of challenge with potentially lethal doses of IBV after immunizations seems to correlate 
with reactivity of antisera towards infected cells. BM2e-based immunogens can convey protection 
against IBV of both lineages, regardless of the length of the BM2e-sequence used. This is to some 
extent in line with recent data showing a direct in vitro antiviral effect of BM2e-specific antibodies 
33
. 
In vivo data presented here enforce the value of the very short but highly conserved BM2 
ectodomain in broad IBV vaccine development. For NBe, non-glycosylated immunogens might not 
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induce antibody pools able to react sufficiently with glycosylated viral expressed NB. In this regard, 
gNBe-tGCN4 vaccination seems superior to NBe-tGCN4-Flag immunization. Specific subpopulations 
of antibody, recognizing glycosylated NBe or epitopes outside the glycosylated domain, can 
theoretically provide antiviral immunity. 
To supplement data generated using gNBe-tGCN4, whole-cell based vaccination using transfected 
cells expressing glycosylated NBe(WT)-M2-Flag was performed. This less elegant method of 
immunization was used to ascertain the influence of glycosylation of NBe, since in these 
immunizations nearly all of the protein was fully glycosylated (as compared to small-scale 
transfection tests, where non-, mono- and double glycosylated species are clearly distinguishable, cf. 
Fig. 3.16). Antisera raised this way react with the ectodomain, cytoplasmic domain and Flag-tag of 
the expressed proteins, indicating these are liberated during vaccine preparation or injection or 
through in vivo mechanisms. Quite strongly, the NBe(WT)-M2-Flag chimer can evoke protective 
immunity, lowering mortality rates in a significant manner and rendering lung of infected mice 
completely virus-free by day 5 postchallenge. Additionally, NBe(Mut)-M2-Flag, lacking glycosylation, 
also has a significant effect on pulmonary virus titers. With the only common denominator with IBV 
being the NB ectodomain, this set-up further endorsed the merit of glycosylated NBe-based 
vaccination in IBV vaccine development. The method of immunization could lead to the induction of 
specific T cells, conveying anti-IBV activity. However, no NBe-specific T cells are induced in the H2
d
-
background of Balb/c mice (see Chapter 5). 
In conclusion, we have shown a beneficiary effect of BM2e- and glycosylated NBe-based (gNBe-) 
immunization on the outcome of IBV infection. Protection afforded by BM2e-tGCN4 is cross-reactive, 
thwarting infection with both a Yamagata-like IBV strain (B/Memphis/12/97) and a Victoria-like IBV 
strain (B/Hong Kong/5/72). Although no virus neutralizing effects were observed, BM2e- and gNBe-
based immunogens can convey a restriction on pulmonary virus replication and infection-induced 
mortality. We feel these results contribute significantly to research on cross-protective IBV vaccine 
development. 
  
 
Type Immunogen 
Reactivity of antiserum In vivo 
protective 
effect 
Challenge 
virus 
Figure 
towards transfected cells Figure towards infected cells Figure 
HBc 
proteins 
NBe-HBc (1646, 1651) ND - ND - + (1651) B/HK 4.3 
NBe-M2e2-HBc 
ND - ++ (ELISA) 4.6 +++ A/X47 4.5 
ND - - 4.6 - B/Mem 4.8 
B/HA0-HBc (3004) ND - ++ (ELISA, IF) 4.6, 4.7 - B/Mem 4.8 
tGCN4 
proteins 
BM2e-tGCN4 /             
BM2(QIL)-tGCN4 
+ (ELISA) 4.9 + (ELISA, IF) 
4.9, 
4.11 
++ B/HK 4.10 
++ B/Mem 4.12 
NBe-tGCN4-Flag ++ (IF) 
3.17, 
3.18 
+/- (IF) 4.11 
+/- B/HK 4.10 
- B/Mem 4.12 
gNBe-tGCN4 +/- DNS + (IF) 4.11 + B/Mem 4.12 
Full-length 
TM 
proteins 
NBe(WT)-M2-Flag ++ (WB, IF) 
4.13, 
4.14 
+ (WB) 4.13 ++ B/Mem 4.16 
NBe(Mut)-M2-Flag ++ (IF) DNS + (WB) 4.13 +/- B/Mem 4.16 
BM2-Flag ++ (IF) 4.15 + (WB) 4.13 +/- B/Mem 4.16 
mAb 15G5mAb + (PD) 3.21 + (IF) 3.22 - B/Mem 4.17 
 
Table 4.1. Overview of in vitro serological and in vivo antiviral characteristics of broad influenza B vaccine candidates. IF = immunofluorescence, WB = Western blot, PD = pull-
down, ND = not determined, DNS = data not shown; B/HK = B/Hong Kong/5/72, B/Mem = B/Memphis/12/97. 
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4.4. Material and methods 
Mice, viruses and influenza challenges 
For all in vivo studies, 6-8 week old female Balb/c (Charles River, Italy) mice were used. Mice were housed 
under specific pathogen free conditions and fed ad libitum. All infection experiments were conducted under 
BSL-2 containment and were approved by the local Institutional Ethics Committee on Experimental Animals of 
Ghent University. 
IBV infections were performed using mouse-adapted B/Hong Kong/05/72, received from Dr. Robert Sidwell 
7
, 
or B/Memphis/12/97, received from Dr. Jonathan McCullers 
8
. In our model, the LD50 dose of B/Hong 
Kong/05/72 corresponds to 8x10
6
 pfu, and 2.5 x 10
5
 pfu for B/Memphis/12/97. For potential lethal infection, a 
4LD50 or 2.5LD50 dose was administered, as indicated in the test; sublethal infections were done with 0.4LD50 or 
0.025LD50 as mentioned in the text. For IAV infections, mouse-adapted X47 was used, with 1LD50 corresponding 
to appr. 50-100 pfu. For potential lethal infection, a 4LD50 dose was used. All infections were done by instilling 
virus diluted in 50µL phosphate-buffered saline (PBS) into the nostrils of ketamine (50mg/kg) + xylazin 
(7.5mg/kg) anaesthetized mice. Following infection, mice were monitored for weight loss as a measurement of 
morbidity. If mice lost more than 30% of their initial weight, they were regarded as not protected and 
euthanized. All experiments were approved by the Local Ethical Committee. 
 
Immunizations and experimental set-ups 
All protein immunizations were done using 10µg of protein. Intraperitoneal (i.p.) vaccinations using Alhydrogel 
(Brenntag Biosector A/S) as adjuvant were done as described previously 
21
. For i.p. immunization adjuvanted 
with LTR192G 
18
, proteins were diluted in PBS and combined with 1µg LTR192G to a final volume of 100µL. 
Subcutaneous vaccinations were given in a volume of 100µL, consisting of 26µL PBS containing the tGCN4-
protein and 74µL Montanide ISA-720 (Seppic). For immunization with transfected cells, cells were harvested in 
PBS and diluted to appr. 2-4x10
7
 cells/mL. 100µL of cell suspension was injected i.p. as such per mouse per 
vaccination. Passive immunizations were performed by injecting 150µg of antibody or 50µL polyclonal post-
infection serum i.p. in a volume of 100µL PBS. For each experiment, the number of mice per group is indicated 
in the figure legends. 
In active immunization experiments, one week before the first immunization and two weeks after every next 
immunization and infection, blood was drawn from the lateral tail veins for serological analysis. Subsequent 
immunizations had an interval of three weeks; the number of immunizations are mentioned with each 
experiment. Unless stated otherwise, challenge of mice was performed three weeks after the last 
immunization. In passive immunization, blood was drawn one day after transfer of antibodies to determine the 
serum titer of administered antibodies. The same day (i.e. one day after transfer), mice were challenged. In all 
follow-up studies, body weight of challenged mice was determined on a daily or two-daily basis. Lung 
homogenates were prepared on indicated days by tissue homogenization in 1mL PBS using a Heidolph RZR 
2020 homogenizer. Viral titers were determined through TCID50 titration on MDCK cells in quadruplicate 
according to the method of Reed and Muench 
34
. 
  
ELISA procedure 
To analyze antibody responses evoked by active vaccination or presence of antibodies after passive transfer, 
ELISAs were performed. For peptide-specific ELISA (NBe, M2e), Maxisorp immune-plates (Nunc) were coated 
overnight at 37°C with 50µL of a 2µg/mL peptide-solution in 100mM sodium carbonate buffer, pH 9.6. Anti-
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tGCN4-Flag titers were determined using plates coated overnight at 4°C with 2µg/mL tGCN4-Flag in carbonate 
buffer. Anti-viral ELISAs using inactivated viruses as coating antigen were done using plates coated with 50µL 
0.5µg/mL inactivated virus per well. For detection of anti-HBc titers, ELISA plates were coated with 50µL of 
0.5µg/mL rabbit anti-HBc (Serotec) overnight at 4°C. After coating, plates were washed three times with PBS + 
0.1% Tween20 and blocked with PBS + 3% Milk. For HBc-ELISAs, plates were incubated with 50µL 1µg/mL HBc-
protein for 1.5h at room temperature before washing again. Sera from immunized mice were diluted (1/3 
dilution series) in PBS + 0.05% Tween20 + 1.5% Milk and incubated on the ELISA plates for 1.5h at room 
temperature. After washing three times, subtype-specific HRP-linked goat anti-mouse secondary antibodies 
(Bio-Connect) were incubated on the plates for a further 1.5h at room temperature. Following a final wash 
step, titers were detected using TMB substrate (Pharmingen, BD). The reaction was stopped after 10min by 
adding an equal amount of 1M H2SO4. Plates were read at 450nm, with background measurement at 655nm. 
Endpoint titers are determined as the last dilution of immune serum giving an ELISA signal at least twice as high 
as pre-immune serum. 
 
Cellular assays and vaccines 
HEK293T cells were maintained in complete DMEM (DMEM + 10% FCS + L-Gln + sodium pyruvate + non-
essential amino acids + penicillin/streptomycin); MDCK cells in complete DMEM without sodium pyruvate. 
NIH3T3 cells were cultivated in complete RPMI (RPMI + 10% FCS + L-Gln + sodium pyruvate + non-essential 
amino acids + penicillin/streptomycin).  
For cellular ELISAs, MDCK cells were seeded in 96well tissue culture plates (BD) at 2x10
4
 cells per well. 24h 
later, cells were washed with serum-free DMEM and infected with indicated viruses at a multiplicity of 
infection (MOI) of 3. 16h later, cells were washed, fixed with 4% paraformaldehyde in PBS for 30min at room 
temperature and permeabilized for 5min with 0.05% Triton X100 + 20mM Glycine in PBS. After blocking with 
PBS + 3% milk, plates were further processed as described above. 
For cellular immunizations, HEK293T or NIH3T3 cells were seeded in 175cm
2
 flasks (BD) at a density of 4x10
6
 
cells/flask. 24h later, when cells reached 50-70% density, cells were washed once and transfected with 20µg 
pCAGGS-based vectors encoding the indicated proteins through calcium phosphate precipitation (for HEK293T 
cells) or using 120µg polyethylene imide (for NIH3T3 cells). 16h later, cells were washed once, collected using 
non-enzymatic dissociation buffer (Gibco) and washed three further times with PBS. Finally, cells were 
resuspenden in PBS at a concentration of 2-4x10
7
 cells/mL. 
To analyze reaction of antisera with influenza-specific proteins, Western blots and immunofluorescence assays 
were used. For Western blots, the indicated proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membranes. Blots were cut into strips and each strip was incubated with antiserum 1/100 
diluted in PBS + 1.5% Milk + 0.05% Tween-20. Binding of antisera was revealed using anti-mouse-HRP antibody 
or using the Odyssey imaging system (Li-Cor Biosciences). For immunofluorescence assays, NIH3T3 cells were 
seeded on aceton-treated coverslips in 24well plates at a density of 2 x 10
4
 cells/well in complete RPMI. 16h 
later, cells were transfected with 250ng pCAGGS-based constructs using 1.5µg polyethylene imide. 24h later, 
cells were fixed with 4% paraformaldehyde and permeabilized for 5min using 0.05% Triton X-100 in PBS + 
20mM Glycine. After blocking for 1h using a 1% PBS-based BSA solution, cells were stained with rabbit anti-Flag 
and murine antiserum (diluted 1/300). Secondary staining was done using goat anti-rabbit Alexa-fluor-647 
conjugated antibody and goat anti-mouse Alexa-fluor-488 antibody (Invitrogen). Cells were mounted with 
Vectashield containing DAPI for nuclear counterstain before acquiring microscopic pictures. 
 
 
 
137 In vivo validation of cross-reactive IBV vaccine candidates 
4.5. Acknowledgements 
We are grateful to Dr. McCullers (St. Jude Children's Research Hospital, Memphis, TN, USA) for providing the 
influenza B/Memphis/12/97 virus strains and to Dr. Sidwell (Utah State University, Logan, UT, USA) for 
providing the influenza B/Hong Kong/05/72 virus strain. We thank Dr. John Clements (Department of 
Microbiology and Immunology, Tulane University Medical Centre, New Orleans, USA) for providing LTR129G 
enterotoxin. 
 
4.6. References 
1. Sridharan, H., Zhao, C. & Krug, R.M. Species Specificity of the NS1 Protein of Influenza B Virus. Journal 
of Biological Chemistry 285, 7852 (2010). 
2. Versteeg, G.A., et al. Species-specific antagonism of host ISGylation by the influenza B virus NS1 
protein. Journal of virology 84, 5423 (2010). 
3. Ledinko, N. & Perry, B. Studies with Influenza Virus B of Recent Human Origin. The Journal of 
Immunology 74, 371 (1955). 
4. Ledinko, N. An analysis of the process of adaptation of influenza virus B of recent human origin to the 
mouse lung. Journal of General Microbiology 15, 47 (1956). 
5. Reading, P.C., Morey, L.S., Crouch, E.C. & Anders, E.M. Collectin-mediated antiviral host defense of the 
lung: evidence from influenza virus infection of mice. Journal of virology 71, 8204 (1997). 
6. Smee, D.F., Wandersee, M.K., Wong, M.H., Bailey, K.W. & Sidwell, R.W. Treatment of mannan-
enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine. Antiviral 
Chemistry and Chemotherapy 15, 261-268 (2004). 
7. Sidwell, R.W., et al. Inhibitory effects of recombinant manganese superoxide dismutase on influenza 
virus infections in mice. Antimicrobial agents and chemotherapy 40, 2626 (1996). 
8. McCullers, J.A., Hoffmann, E., Huber, V.C. & Nickerson, A.D. A single amino acid change in the C-
terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and 
virulence. Virology 336, 318-326 (2005). 
9. Biere, B., Bauer, B. & Schweiger, B. Distinction of Influenza B virus lineages Yamagata and Victoria by 
real-time PCR. Journal of clinical microbiology 48, 1425-1427 (2010). 
10. Wang, Q., Cheng, F., Lu, M., Tian, X. & Ma, J. Crystal structure of unliganded influenza B virus 
hemagglutinin. Journal of virology 82, 3011 (2008). 
11. Rivera, K., et al. Probing the structure of influenza B hemagglutinin using site-directed mutagenesis. 
Virology 206, 787-795 (1995). 
12. Nakagawa, N., et al. Characterization of new epidemic strains of influenza B virus by using neutralizing 
monoclonal antibodies. Journal of medical virology 65, 745-750 (2001). 
13. Lugovtsev, V.Y., Vodeiko, G.M., Strupczewski, C.M., Ye, Z. & Levandowski, R.A. Generation of the 
influenza B viruses with improved growth phenotype by substitution of specific amino acids of 
hemagglutinin. Virology 365, 315-323 (2007). 
14. Nakagawa, N., Suzuoki, J., Kubota, R., Kobatake, S. & Okuno, Y. Discovery of the neutralizing epitope 
common to influenza B virus Victoria group isolates in Japan. Journal of clinical microbiology 44, 1564 
(2006). 
15. McCullers, J.A., Wang, G.C., He, S. & Webster, R.G. Reassortment and insertion-deletion are strategies 
for the evolution of influenza B viruses in nature. Journal of virology 73, 7343 (1999). 
16. Nakagawa, N., Kubota, R., Maeda, A., Nakagawa, T. & Okuno, Y. Heterogeneity of influenza B virus 
strains in one epidemic season differentiated by monoclonal antibodies and nucleotide sequences. 
Journal of clinical microbiology 38, 3467 (2000). 
17. Nakagawa, N., Kubota, R., Maeda, A. & Okuno, Y. Influenza B virus Victoria group with a new 
glycosylation site was epidemic in Japan in the 2002-2003 season. Journal of clinical microbiology 42, 
3295 (2004). 
18. Dickinson, B.L. & Clements, J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity 
from ADP-ribosyltransferase activity. Infection and immunity 63, 1617 (1995). 
19. Lawrence, G.W., Saul, A., Giddy, A.J., Kemp, R. & Pye, D. Phase I trial in humans of an oil-based 
adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15, 176-178 (1997). 
 
138 Chapter 4 
20. Harbury, P.B., Zhang, T., Kim, P.S. & Alber, T. A switch between two-, three-, and four-stranded coiled 
coils in GCN4 leucine zipper mutants. Science 262, 1401 (1993). 
21. De Filette, M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. 
Journal of Biological Chemistry 283, 11382 (2008). 
22. McCullers, J.A., Saito, T. & Iverson, A.R. Multiple genotypes of influenza B virus circulated between 
1979 and 2003. Journal of virology 78, 12817 (2004). 
23. Chi, X.S., et al. Detection and characterization of new influenza B virus variants in 2002. Journal of 
clinical microbiology 43, 2345 (2005). 
24. Jian, J.W., et al. Genetic analysis and evaluation of the reassortment of influenza B viruses isolated in 
Taiwan during the 2004-2005 and 2006-2007 epidemics. Virus research 131, 243-249 (2008). 
25. Belshe, R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 28, D45-D53 (2010). 
26. Kistner, O., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and 
protective in active immunization and passive protection mouse models. PLoS One 5, e9349 (2010). 
27. Bianchi, E., et al. Universal influenza B vaccine based on the maturational cleavage site of the 
hemagglutinin precursor. Journal of virology 79, 7380 (2005). 
28. Williams, M.A. & Lamb, R.A. Determination of the orientation of an integral membrane protein and 
sites of glycosylation by oligonucleotide-directed mutagenesis: influenza B virus NB glycoprotein lacks 
a cleavable signal sequence and has an extracellular NH2-terminal region. Molecular and Cellular 
Biology 6, 4317 (1986). 
29. Betakova, T., Nermut, M.V. & Hay, A.J. The NB protein is an integral component of the membrane of 
influenza B virus. Journal of general virology 77, 2689 (1996). 
30. Paterson, R.G., Takeda, M., Ohigashi, Y., Pinto, L.H. & Lamb, R.A. Influenza B virus BM2 protein is an 
oligomeric integral membrane protein expressed at the cell surface. Virology 306, 7-17 (2003). 
31. Wang, J., Pielak, R.M., McClintock, M.A. & Chou, J.J. Solution structure and functional analysis of the 
influenza B proton channel. Nature Structural & Molecular Biology 16, 1267-1271 (2009). 
32. Harbury, P.B., Zhang, T., Kim, P.S. & Alber, T. A switch between two-, three-, and four-stranded coiled 
coils in GCN4 leucine zipper mutants. Science (New York, NY) 262, 1401 (1993). 
33. Wang, Y., et al. Monoclonal antibody, but not synthetic peptide, targeting the ectodomain of influenza 
B virus M2 proton channel has antiviral activity. New Microbiologica 33, 311-317 (2010). 
34. Reed, L.J. & Muench, H. A simple method of estimating fifty per cent endpoints. American Journal of 
Epidemiology 27, 493 (1938). 
 
 
  
 
 
 
 
Chapter 5 
T cell based immunity provided by the  
conserved NB ectodomain of influenza B virus 
A potent cytotoxic T cell epitope in the extracellular domain of influenza B 
virus NB promotes virus clearance 
  
Kenny Roose
1,2
, Michael Schotsaert
1,2
, Bert Schepens
1,2
, Anouk Smet
1,2
, Tine Ysenbaert
1,2
, Walter Fiers
1,2
, Xavier 
Saelens
1,2*
  
 
1 Department for Molecular Biomedical Research, VIB, Ghent, Belgium 
2 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium 
* E-mail: Xavier.saelens@dmbr.vib-ugent.be 
 
Running title 
 T cell based immunity provided by the conserved NB ectodomain of influenza B virus  
 
Manuscript ready for submission 
 
 
  
 
141 T cell based immunity provided by the conserved NB ectodomain of influenza B virus 
The extracellular domain of influenza B virus NB harbors a potent cytotoxic T 
cell epitope 
Kenny Roose
1,2
, Michael Schotsaert
1,2
, Bert Schepens
1,2
, Anouk Smet
1,2
, Tine Ysenbaert
1,2
, Walter Fiers
1,2
, Xavier 
Saelens
1,2*
  
1 Department for Molecular Biomedical Research, VIB, Ghent, Belgium, 2 Department of Biomedical Molecular 
Biology, Ghent University, Ghent, Belgium 
 
Abstract 
Influenza B viruses represent a considerable threat to human health as they are responsible for 
about 1 out of 3 influenza epidemics. Like influenza A, they drift easily. Furthermore, the co-
circulation of two antigenically different lineages, necessitates frequent update of vaccines. Hence, 
we explored the potential broad protection provided by the conserved ectodomain of the NB 
transmembrane protein (NBe) of influenza B virus. To mimic its natural quaternary structure, we 
used a scaffold as fusion partner resulting in production of soluble tetrameric NBe. Surprisingly, 
immunization with this NBe-fusion protein induced strong NBe-specific cytotoxic T cell responses, 
which upon challenge enhanced influenza B virus clearance from the lung compartment. Such 
specific T cell responses were also observed following infection of naïve mice with influenza B virus. 
These cellular responses were specific for the CD8+ T cell compartment and mapped to a highly 
conserved, membrane-distal T cell epitope in NBe. In vivo killing assays confirmed the induction of 
strong cytotoxic activity following immunization with NBe-fusion proteins, even when alum, a Th2-
directing immune potentiator, was used as an adjuvant. This is the first identification of immune 
protection provided by the ectodomain of the NB-protein, and the first record of a protective CD8+ T 
cell epitope for influenza B in the mouse. 
 
Author summary 
Influenza A and B viruses cause seasonal epidemics. Every three to four years, a drifted influenza B 
strain spreads globally in the human population leaving epidemics in its track. Most currently 
approved vaccines contain purified hemagglutinin subunits derived from virus strains predicted to 
circulate in the upcoming season. Hence, unexpected drift of the virus will invalidate predictions and 
derail influenza vaccination campaigns. Using conserved regions of viral proteins as vaccine 
components allows to avoid these and other uncertainties. Our aim was to develop an influenza B 
vaccine based on the conserved ectodomain of the NB protein (NBe). Remarkably, irrespective of the 
route or adjuvant used, immunizations with this vaccine led to induction of high numbers of NBe-
specific CD8+ cytotoxic T cells, specific for the H2b-background of C57Bl/6 mice. Following challenge, 
this T cell immunity was responsible for strong anti-influenza B activity, as evidenced by rapid 
clearance of pulmonary influenza B virus. This cellular immune response is surprisingly strong and 
was observed following different NBe-based immunization strategies as well as upon infection by 
influenza B virus. We document here the opportunity of NBe-based immunization with a protein-only 
vaccine to establish cellular immunity protection in an appropriate MHC-mouse model.  
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Introduction 
Influenza B virus is an important respiratory pathogen in humans. Influenza viruses belong to the 
family of Orthomyxoviridae, which are characterized by a segmented negative-stranded RNA 
genome. While influenza B and C infection occurs almost exclusively in humans, influenza A viruses 
also circulate in a much larger animal reservoir including aquatic and migratory birds, pigs, horses 
and some other mammals. This creates a genetic pool from which new influenza strains can emerge 
through processes of mutation, reassortment and recombination. This antigenic drift and shift is 
responsible for yearly epidemics and occasional pandemics in the human population 1-3. The surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA) are the major antigenic determinants of 
influenza A and B viruses. To date, 16 different HA subtypes and 9 NA subtypes have been classified 
for influenza A viruses, all present in the avian reservoir 4. In contrast, influenza B viruses do not 
circulate in an animal reservoir. As a result influenza B viruses display antigenic drift, coerced mainly 
by antibody-based selection pressure induced by vaccination and previous infection 5,6. Even though 
no subtypes of influenza B viruses are distinguished, two separate lineages are acknowledged, 
denoted by their prototypical parental strains B/Victoria/2/87 and B/Yamagata/16/88 7,8, although 
lineage separation occurred already in the early 70s 8. These two lineages co-circulate within the 
human population and cause alternate epidemics. Moreover, frequent genetic reassortment 
between Victoria and Yamagata lineage viruses occurs, creating new epidemic strains with altered 
antigenic and biological properties 5,9,10. There is little or no natural cross-reactive immunity between 
the two influenza B virus lineages, supporting the claim to include both strains in seasonal influenza 
vaccines 11. Indeed, in some instances a mismatch has been observed between the vaccine B-strain 
and circulating strains, resulting in failed vaccination campaigns and excessive morbidity in high risk 
target populations 12-15.  
A number of research groups have attempted to identify cross-protective epitopes present in 
influenza viruses and develop vaccines that induce broader protection based on these 16,17. For 
influenza A, one such an approach has focused on the conserved ectodomain (M2e) of the matrix 
protein 2 ion channel 18,19. Alternatively, conserved regions within the HA2 domain of the HA 
molecule have been proposed as antigenic components of broad spectrum vaccines 20-22. Also for 
influenza B, at least one reported broad-spectrum vaccination strategy was based on conserved 
regions of HA 23. Immunity induced by these cross-protective vaccine relies on antibodies 17,24. In 
addition to these approaches eliciting humoral immunity, broad protection can also be achieved by 
induction of cellular immunity. A number of T cell epitopes, mainly present in internal influenza 
proteins, have been shown to be responsible for broadly protective cellular immunity 16,25,26. 
We previously reported that M2e of influenza A can be rendered immunogenic by using a 
tetramerizing scaffold protein. This is based on a mutant form of the leucine zipper of the yeast 
transcription factor GCN4 (tGCN4) 27,28. We tried to extend these observations to a conserved 
influenza B virus antigen based on the ectodomain (NBe) of the NB protein 29.The NB protein is a 
homotetrameric, viroporin-like type III membrane protein and is encoded by segment 6 along with 
NA from overlapping reading frames 30,31. NB is present on infected cells and in virions, and contains 
an N-terminal ectodomain of 18 amino acid residues in length with two N-glycosylation sites 31-33. 
These are used for addition of poly-N-lactosaminoglycan structures, although low levels of 
unglycosylated NB protein can be found on infected cells 34. The high conservation of NBe, 
irrespective of the influenza B lineage, encouraged us to explore the protective efficacy of a 
  
 
143 T cell based immunity provided by the conserved NB ectodomain of influenza B virus 
tetramerized NBe-based vaccine. Surprisingly, high levels of NBe-specific CD8+ cytotoxic T cells could 
be induced by protein vaccination with the NBe-tGCN4 construct, regardless of the route of 
vaccination or the adjuvant used. A similar strong NBe-specific CD8+ T cell response was induced 
upon influenza B infection. The NBe- directed T cells were able to eliminate NBe-peptide pulsed cells 
in vivo, cleared influenza B virus from the lung of challenged mice and protected mice from influenza 
B virus induced morbidity. To our knowledge, this is the first report showing NBe-based protection 
against influenza B infection and the first identification of a murine-specific T cell epitope for 
influenza B. 
 
Results 
NB vaccine antigen design  
To obtain a cross-reactive influenza B vaccine antigen, we focused on NBe, the ectodomain of the 
tetrameric NB protein. NBe comprises 18 amino acid residues, which are conserved across influenza 
B viruses (Figure 1A). We genetically fused NBe to the tetramerizing leucine zipper tGCN4, in order to 
obtain a soluble vaccine that mimics the natural conformation of NBe 27,28. Increased solubility was 
obtained by addition of a Flag-tag at the C-terminus, resulting in NBe-tGCN4-Flag (Figure 1B). 
 
A
B
MNNATFNYTNVNPISHIR GG KQ EDK EE LSK YH ENE AR KKLLGE GG MDYKDHDGDYKDHDIDYKDDDDKL I L I L I L I
MNKLCEYNVFHNKTFELPRARVNT GG KQ EDK EE LSK YH ENE AR KKLLGE GG MDYKDHDGDYKDHDIDYKDDDDKL I L I L I L I
M I L I L I L IKQ EDK EE LSK YH ENE AR KKLLGE GG MDYKDHDGDYKDHDIDYKDDDDK
 
Figure 1. NBe-based vaccine design. A. Graphical representation of the conservation of the NBe-sequence (A) and vaccine 
design (B).  A. For the sequence analysis, all available NBe-sequences (n = 854, from 1940 up until March 2011) were 
aligned and conservation of the consensus amino acids was calculated.  Sequences were obtained from the Influenza 
Research Database at www.fludb.org. B. Overview of NBe-based vaccine design  and control constructs.  Shown are the 
tGCN4-Flag carrier only vaccine (top), the NBe-tGCN4-Flag vaccine (middle) and the irrelevant epitope-carrier fusion Irr-
tGCN4-Flag (bottom). The different domains of the constructs are boxed and include the N-terminal NBe or irrelevant 
epitope, the central tetramerizing tGCN4 domain and the C-terminal triple Flag-tag.  For the tGCN4-part, amino acids 
involved in tetramerization are shown in red. 
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The chimeric protein was purified by sonication of the resuspended bacterial pellet, heat-treatment, 
followed by anion exchange chromatography and size-exclusion by gel filtration. This last step 
yielded two distinct peaks containing NBe-tGCN4-Flag (Figure S1A). The first peak contains NBe-
tGCN4-Flag in a higher molecular weight (MW) complex, possibly corresponding to NBe-tGCN4-Flag 
oligomers or a complex with bacterial contaminants 28. The second peak corresponds to a protein 
with an estimated MW of approximately 40kDa, close to the expected MW of tetrameric NBe-tGCN4-
Flag (35.2kDa) (Figure S1B). The latter fraction was used in all experiments, and these NBe-tGCN4-
Flag preparations contained negligible amounts of LPS (data not shown).  
The tetrameric assembly of NBe-tGCN4-Flag was confirmed by cross-linking experiments using 
different homobifunctional chemical cross-linkers: BS3 and reducible DSP. M2e-tGCN4 and BM2e-
tGCN4, displaying the M2-ectodomains of influenza A and influenza B in a tetrameric fashion 28, were 
included as controls. Under denaturing, non-reducing conditions BM2e-tGCN4 and NBe-tGCN4-Flag 
migrate with a relative MW corresponding to that of the monomeric proteins (4.68kDa and 8.81kDa, 
respectively), while M2e-tGCN4 (predicted MW of 6.45kDa) migrates predominantly as a dimer, with 
minor bands corresponding to trimers and tetramers (Fig S1C). Cross-linking results in a predominant 
fraction of proteins that migrates in SDS-PAGE with an electrophoretic mobility corresponding to that 
of the respective tetramers. Under reducing conditions uncrosslinked and BS3-crosslinked proteins 
migrate as monomeric proteins (Figure S1D). Overall, these results demonstrate that the purified 
NBe-tGCN4-Flag vaccine is a tetramer. 
 
Immunization with NBe-fusion protein promotes pulmonary virus clearance 
To evaluate the protective efficacy of the NBe-tGCN4-Flag vaccine, we immunized mouse strains of 
different genetic backgrounds, namely BALB/c (H2d), C57Bl/6 (H2b) and C3H/HeN (H2k). This allowed 
us to evaluate the influence of the haplotype on the NBe-specific immune response and compare 
strain-dependent protection against influenza B virus challenge. The importance of the genetic 
background of laboratory mice for susceptibility to influenza A virus infection and M2e-specific 
immune responses has already been reported 35,36. 
Figure S2 depicts the serum antibody titers after immunization with NBe-tGCN4-Flag or carrier only. 
Immunized C57Bl/6 seroconverted weakly to NBe, whereas C3H/HeN mice displayed high NBe-
specific titers and BALB/c mice responded intermediately. In contrast, anti-tGCN4-Flag (the carrier) 
serum IgG titers were high overall, but are completely lacking in C57Bl/6 and C3H/HeN mice that had 
been immunized with tGCN4-Flag (Figure S2 C,D). The latter observation suggests a lack of T helper 
epitope in tGCN4-Flag within the H2b and H2k background that is compensated for by the fusion to 
NBe. Challenge of immunized mice with a strain-matching potentially lethal dose (2.5LD50) of mouse-
adapted influenza B virus revealed no NBe-specific protection in any of the three inbred mouse 
strains (Figure 2A), indicating that NBe-specific serum IgG either does not contribute to immune-
protection or is unable to protect against a high challenge inoculum in our model.  
We therefore decided to determine the extent of lung virus clearance in NBe-tGCN4-Flag immunized 
mice as a more subtle readout for protection, using a sublethal (0.075LD50; 7.5 x 10
4 pfu) challenge 
dose. NBe-immunized mice of all three mouse strains had a significantly lower lung virus titer on day 
4 after challenge compared to control immunized mice (Figure 2B). From this, we concluded that 
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immunization with NBe-tGCN4-Flag enhances influenza B virus clearance from the lungs, but is 
overwhelmed by a high virus titer. 
 
A
*
**
**
B * **
 
Figure 2. NBe-tGCN4-Flag vaccination fails to induce protective humoral immunity in mice. Mice from different genetic 
backgrounds, Balb/c (H2
d
), C57Bl/6 (H2
b
) and C3H/HeN (H2
k
), were immunized three times with carrier only or NBe-tGCN4-
Flag in combination with Alhydrogel. A. Three weeks after the second boost, mice were challenged with 2.5 LD50 of mouse-
adapted IBV virus. Shown are the relative survival level during follow-up, taking a 30% weight loss limit in account. n=6-8 
mice for all groups. B. Three and four day after a sublethal IBV challenge (0.1 LD50) lung homogenates were made for 
titration of viral titers in a TCID50 assay. Asterisks above bars indicate significant differences with the titer for the carrier 
only group determined on the same day. n=3 for all groups. *, p<0.05; **, p<0.01. 
 
Pre-existing NBe-specific CD8 T cell responses correlate with enhanced pulmonary virus clearance 
The reduced influenza B virus replication in the lung of NBe-immunized mice encouraged us to look 
for adaptive T cell responses potentially elicited by NBe-based immunization. Because tGCN4-Flag 
carrier did not induce serum IgG responses in C57Bl/6 (H2b background) and C3H/HeN (H2k 
background) mice, whereas immunization with NBe-tGCN4-Flag induced both NBe-specific as well as 
carrier-specific antibodies (Figure S2), we included a tGCN4-Flag fusion construct displaying an 
irrelevant (Irr) human Respiratory Syncytial virus (RSV) derived peptide as an additional negative 
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control (Irr-tGCN4-Flag). Mice immunized with NBe-tGCN4-Flag or Irr-tGCN4-Flag in the presence of 
alum seroconverted, with clear induction of anti-tGCN4-Flag antibodies in both groups (Figure S3). As 
controls for the induction of cellular antiviral responses, mice that had recovered from a sublethal 
influenza A or B virus infection were used. In addition, a DNA-vaccine construct was generated by 
genetically grafting NBe onto the influenza A M2 transmembrane and cytoplasmic domain, in a 
mammalian expression plasmid. We found that this NBe-containing DNA vaccine construct allowed 
the expression of NBe-M2 chimeras with a higher expression level compared to full-length NB (Figure 
S4). Although it is controversial whether NB possesses ion-gating activity, it is possible that 
constitutive expression of NB is toxic to cells. In contrast, it has been shown that replacement of the 
M2e ectodomain by NBe is expected to abolish the ion channel activity (and associated cytotoxicity) 
of M2 37.  
IFN-specific ELISPOT assays and intracellular cytokine staining (ICS) were performed on splenocytes 
from immunized and convalescent mice. Full-length NBe-peptide (18 amino acids) and haplotype-
matching influenza A virus nucleoprotein peptides (A/NP-peptide) were used for in vitro 
restimulation. ELISPOT analysis revealed clear NBe-specific cellular responses in splenocytes from 
NBe-immunized (NBe-tGCN4-Flag, NBe-M2 DNA and IBV infection) mice of H2b-background (Figure 
3A). Smaller, but still detectable spot counts were also observed in H2d-background mice. Using ICS 
and differential staining for CD4+ and CD8+ cells, the NBe-specific cellular responses could be 
attributed to CD8+ T cells (Figure 3B and C). In summary, NBe-based immunization in the H2b-
haplotype background elicited strong NBe-specific T cell responses that were mainly restricted to the 
CD8+ T cell compartment. Furthermore, we also conclude that influenza B virus infection induces an 
H2b-restricted NBe-specific CD8+ T cell response. 
 
A
 
Figure 3. Ex vivo restimulation of splenocytes from immunized mice reveals the presence of NBe-restricted T-cell 
responses specific for the H2b-haplotype. Balb/c (H2
d
), C57Bl/6 (H2
b
) and C3H/HeN (H2
k
) were immunized with the 
indicated immunogens twice, three weeks apart. Four weeks after the second immunization, induction of cellular responses 
was evaluated. A. IFN-specific elispot analysis detecting cellular responses. Splenocytes from immunized mice were 
restimulated in elispot plates using NBe-peptide or haplotype-specific A/NP peptides as positive controls. (Continues next 
page) 
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Figure 3. Continued. B and C. ICS analysis detecting cellular responses.  Here, splenocytes were restimulated overnight with 
the same peptides as in the elispot assay and were stained for intracellular IFN-upregulation. The analysis was done for 
CD4+ T-cells (B) and CD8+ T-cells (C). For all peptide restimulations, n=3; control setting were only tested once.  
 
 
To further evaluate the protective efficacy of the NBe- T cell response induced by immunization with 
NBe-tGCN4-Flag, C57Bl/6 mice were immunized three times with this NBe-fusion protein, Irr-tGCN4-
Flag or tGCN4-Flag. Figure S5 shows pooled serum antibody titers against NBe-peptide, Irr-peptide 
and tGCN4-Flag carrier for all groups. As seen before, tGCN4-Flag immunized mice do not 
seroconvert, while NBe- or Irr-substituted tGCN4-Flag does evoke an anti-carrier response. Three 
weeks after the third immunization, mice were challenged with 0.075LD50 of influenza 
B/Memphis/12/97 virus. Lung homogenates were prepared on day three, four and five after 
infection, a window encompassing the likely timing for a specific T cell memory response, to evaluate 
antiviral activity 38-40. As shown in Figure 4, immunization with NBe-tGCN4-Flag was associated with a 
significantly enhanced influenza B virus clearance from the lungs of challenged mice. In conclusion, 
the enhanced reduction of influenza B virus titers in the lungs of NBe-immune C57Bl/6 mice 
correlates with the presence of NBe-specific CD8+ T cells.  
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Figure 4. The NBe-tGCN4-Flag vaccine is able to induce anti-IBV immunity in C57Bl/6 mice. C57Bl/6 mice were immunized 
with tGCN4-Flag, NBe-tGCN4-Flag or the Irr-tGCN4-Flag vaccine. Viral lung titers were determined in TCID50 titration at the 
indicated time points after a sublethal (0.1 LD50) IBV challenge three weeks after the third immunization. Asterisks above 
bars indicate significant differences with the titer of both control groups determined on the same day. For tGCN4-Flag and 
NBe-tGCN4-Flag groups, n=6 on all days; for Irr-tGCN4-Flag, n=5 on day 3 and n=4 on day 5 and 6. Shown are averages ± SD.  
***, p<0.001. 
 
Primed NBe-specific CD8 T cells are heterologously boosted by influenza B virus infection 
Influenza B viruses circulate globally as epidemic strains. Therefore, we were interested in the effects 
of prior vaccination or infection on the magnitude of NBe-specific CD8+ T cell responses upon 
subsequent vaccination or infection. Naïve C57Bl/6 mice were primed with NBe-tGCN4-Flag 
vaccination or exposed to a sublethal influenza B virus infection and 3 weeks later boosted 
homologously (i.e. with the same immunogen as for the priming) or heterologously (i.e. with the 
other immunogen as used for the priming). Cellular responses primed by NBe-vaccine were 
significantly boosted by a repeat vaccination (homologous boost). Strikingly, boosting with influenza 
B virus infection elicited a much higher NBe-specific cellular response as determined by ELISPOT 
(Figure 5A). This cellular booster effect was confirmed for NBe-tGCN4-Flag primed mice in an IFN-
specific ICS assay. This experiment also confirmed that CD8+ but not CD4+ T cells are the main 
responders to NBe (Figure 5B). No NBe-peptide-specific boosting effect was observed by a double 
infection with influenza B virus, presumably due to the sterilizing immunity evoked by the primary 
infection. In contrast, NBe-tGCN4-Flag vaccination boosted infection-induced cellular responses of 
CD8+ T cells. A polyclonal, influenza B virus-based restimulation analyzed by ICS, also showed clear 
CD4+ T cell responses, mainly detectable when assayed on splenocytes from influenza B immunized 
mice (Figure 5B).  
To further evaluate the breadth of the cellular anti-NBe response, the effect of different 
immunization routes and adjuvants on NBe-tGCN4-Flag vaccination was investigated. The NBe-
immunogen was combined with the LTR192G, a detoxified mutant of the heat-labile E. coli 
enterotoxin 41, and administered intranasally or emulsified in Montanide ISA-720, a metabolisable, 
oil-based adjuvant 42, and injected subcutaneously. Alum-adjuvanted intraperitoneal and 
subcutaneous vaccination induced similar NBe-specific cellular responses, as measured in ELISPOT 
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(Figure 5C). Intranasal immunization with NBe-tGCN4-Flag in the presence of LTR192G however 
induced a higher level of splenocyte responses compared to either of the other immunization routes. 
Following heterologous boost with influenza B virus infection, both intraperitoneally and 
subcutaneously primed mice responded strongly (Figure 5C). Strikingly though, cellular immunity 
induced by intranasal priming was boosted more moderately by a subsequent influenza B virus 
infection. These results reveal that NBe-tGCN4-Flag immunization induces strong anti-NBe immune 
responses independent of the adjuvant or route of immunization used. In addition, heterologous 
boosting by influenza B virus infection strongly augments the vaccine-induced anti-NBe responses. 
 
A
C
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Figure 5. Homologous and heterologous prime-boost settings induce different levels of NBe-specific cellular responses. 
Mice were immunized once with NBe-tGCN4-Flag or IBV-infection or primed with NBe-tGCN4-Flag vaccination or IBV-
infection and boosted homologously or heterologously with vaccination or infection. A. IFN-specific ex vivo elispot analysis 
through NBe-peptide restimulation of splenocytes. Vaccines were adjuvanted with alhydrogel, infections were done with a 
sublethal influenza B dose (0.1 LD50). B. IFN-specific ICS of splenocytes from the same mice restimulated with NBe-peptide 
or IBV virus. C. IFN-specific ex vivo elispot analysis of splenocytes from homologously and heterologously immunized mice. 
For vaccine primings, NBe-tGCN4-Flag protein was mixed with different adjuvants as indicated and administered in 
appropriate ways. For the heterologous boost, 0.1 LD50 influenza B was used. IP = intraperitoneal, IN = intranasal, SC = 
subcutaneous. n=3 for all settings; controls were only measured once. 
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In vivo killing assays reveal strong NBe-specific cytotoxic effects 
To functionally analyze the NBe-specific CD8+ T cell responses, in vivo killing assays 43 were performed 
using differentially CFSE-labeled and peptide-pulsed splenocytes as targets in immunized recipient 
mice. In a first setup, mice were immunized twice with tGCN4-Flag carrier, NBe-tGCN4-Flag or were 
infected with a sublethal (0.075LD50) dose of influenza B/Memphis/12/97 virus. NBe-directed 
cytotoxicity was assessed at four weeks and three months after the second immunization (Figure 6A 
and Figure S6A). In both instances, a clear shift in ratio between NBe-peptide and irrelevant peptide 
uploaded splenocytes was observed. This translates in specific NBe-directed killing when compared 
to the carrier only vaccinated groups (Figure 6A) and this specific cell killing activity is sustained over 
time. In a second setup, mice were infected twice with influenza A or influenza B virus or primed with 
NBe-tGCN4-Flag and heterologously boosted with influenza B virus, a protocol that results in very 
strong NBe-specific CD8+ T cell levels (Figure 5B and 5C). Compared to naive mice, high NBe-directed 
in vivo killing was observed in the influenza B virus infected group (30% specific killing) and the 
heterologuosly boosted group (80% specific killing) (Figure 6B). In summary, these in vivo killing 
assays confirm the induction of NBe-directed cytotoxic responses in NBe-immune C57Bl/6 mice, 
either by vaccination or by sublethal influenza B virus infection, and these responses were sustained 
for at least three months post-immunization. 
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Figure 6. In vivo killing assays reveal strong anti-NBe cytotoxic effects of vaccine or infection induced T-cells. C57Bl/6 
mice were prime-boost immunized as indicated. In vivo killing assays were performed by transfer of differentially CFSE-
labelled peptide-pulsed splenocytes  and FACS-analysis of the presence of CFSE-positive population in the spleen of 
recipient mice 24h post-transfer. Percent specific killing was calculated based on a control group. Shown are the averages 
for at least 4 mice per group ± SD. A. Mice were immunized twice with NBe-tGCN4-Flag or infected twice with a sublethal 
influenza B dose (0.1 LD50). In vivo killing assays were performed 4 weeks or three months post-boost. The control group 
consisted of carrier only immunized mice (Figure S6). ***, p<0.001. B. Mice were infected twice with a sublethal dose (0.1 
LD50) of influenza A or B virus or NBe-tGCN4-Flag primed and boosted with influenza B infection. In vivo killing assays were 
performed 4 weeks post-boost using naïve mice as control group. n = 5 for all groups. **, p<0.01; ***, p<0.001. 
 
 
CD8+ T cell epitope mapping in NBe 
Using the NetMHC 3.2 Server 44,45, NBe-derived peptides capable of binding H2b, H2d and H2k alleles 
were predicted (Table 1). To assess if the predicted H2b-restricted epitopes of NBe are generated in 
vivo, C57Bl/6 mice were immunized using different regimens. Homologously prime-boosted tGCN4-
Flag, NBe-tGCN4-Flag, influenza A virus and influenza B virus infected mice were used. In an 
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additional group, NBe-tGCN4-Flag primed mice were subsequently boosted by a sublethal 
(0.075LD50) influenza B virus infection. Controls for this set-up included carrier primed and influenza 
B boosted and NBe-tGCN4-Flag primed and influenza A virus boosted mice. This allowed us to 
ascertain the specificity of the heterologous boosting effect for NBe. 
 
Table 1. Overview of predicted MHCI-restricted epitopes present in the NBe-sequence of influenza B. Predictions were 
made using the NetMHC 3.2 Server application. 
Peptide length H2b H2d H2k 
8mer 3-ATFNYTNV-12 4-NYTNVNPI-13  
9mer 5-FNYTNVNPI-15  5-FNYTNVNPI-15 
10mer    
11mer  4-NYTNVNPISHI-16  
 
 
 
As can be deduced from the ELISPOT results in Figure 7A, both the full-length NBe-peptide and the 
H2-Kb-restricted ATFNYTNV octameric peptide induce in vitro recall responses in splenocytes from 
NBe-immune mice. The outcome of the two control groups employing non-specific heterologous 
boosts (i.e. carrier only – influenza B virus infection and NBe-tGCN4-Flag – IAV infection) indicate that 
the boosting effect is NBe-specific, since the number of IFN-positive spots from this setting does not 
reach the level of the NBe-heterologous boost (NBe-tGCN4-Flag – IBV infection) group. From these 
data, we conclude that ATFNYTNV corresponds to the NBe-derived peptide that is presented by H2b 
MHC-I class molecules, following immunization with NBe-tGCN4-Flag or influenza B virus infection. 
To identify the specific T cell players involved in NBe-based immunity, we performed a combination 
of in vivo killing assays with specific T cell depletions. For this, mice were primed with carrier only or 
NBe-tGCN4-Flag, and boosted homologously with the respective vaccine or heterologously by 
influenza B virus infection. Four weeks after the boost, mice were treated with PBS, anti-CD4 or anti-
CD8 depleting antibody to achieve specific T cell depletion (Figure S7). Subsequently, an in vivo killing 
assay was performed to evaluate the effect of deletion of CD4+ or CD8+ T cell population on NBe-
directed cytotoxicity. As depicted in Figure 7B, carrier only vaccinated mice did not show any baseline 
in vivo killing effect. In the homologously boosted NBe-tGCN4-Flag group, depletion of CD8+ T cells 
strongly reduced the NBe-directed cytotoxicity compared to PBS-treated mice (p<0.001). Strikingly, 
CD4+ T cell depletion also had an effect, shifting specific killing from 61.8% to 32.7% (p<0.01). For the 
carrier-only primed group that was subsequently boosted with influenza B virus infection, the effect 
of depletion of both CD4+ and CD8+ T cell population completely abrogated in vivo NBe-specific 
killing (p<0.001). In contrast, CD4+ T cell depletion in NBe-tGCN4 primed mice that were boosted by 
an influenza B virus infection had no significant effect compared to PBS-treated mice (p=0.082), while 
CD8+ T cell deletion completely abolished specific cytotoxic effects (p<0.001). 
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Figure 7. Identification of the NBe-specific H2
b
-restricted epitope and the T-cell players involved. A. C57Bl/6 mice were 
immunized twice three weeks apart as indicated. Three weeks post-boost splenocytes were used for ex vivo elispot assays 
using the full-length NBe peptide, the octameric H2-K
b
 peptide or the nonameric H2-D
b
 peptide for restimulation. B. 
C57Bl/6 mice were immunized twice as indicated. Three weeks post-boost the mice were treated with PBS, 500µg anti-CD4 
or 500µg anti-CD8 depleting antibody. 24 hours later, an in vivo killing assay was performed. Shown are the specific killing 
rates, analyzed 24 hours later by FACS, as compared to naïve recipient mice. Asterisks indicate significant differences 
compared to PBS treated mice. n=5 for all groups. **, p<0.01; ***, p<0.001. 
 
 In conclusion, the CD8+ T cell restricted NBe-specific epitope maps to the more membrane distal 
ATFNYTNV peptide sequence in NB. In addition, depletion of CD8+ T cells completely abolished the 
killing of targe T cells that had been uploaded with this octameric NBe peptide, while an auxiliary role 
for CD4+ T cells was revealed in single and homologous immunization settings, possibly because 
these CD4+ T cells provided help to CD8+ T cells in killing NBe-uploaded targets.  
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Local immunity induced towards NBe is strongly protective 
We noticed that heterologous immunization (by exposure to influenza B virus infection) after 
intranasal priming with LTR192G-adjuvanted NBe-tGCN4-Flag resulted in a more limited cellular NBe-
specific boosting effect compared to intraperitoneal or subcutaneous priming (Figure 5C). Therefore, 
we immunized C57Bl/6 mice twice intranasally with NBe-tGCN4-Flag or tGCN4-Flag only, both in 
presence of LTR192G adjuvant. Mice that were mock-immunized with PBS only were included as 
additional controls to exclude an antiviral adjuvant effect, as has been reported for related molecules 
46,47. Four weeks after the boost immunization, cellular responses were analyzed in different lymph 
nodes and organs. In all lymph nodes tested, strong vaccine-induced NBe-specific responses were 
detected in ELISPOT. Strikingly, NBe-specific cellular responses in cells derived from the lung were 
remarkably high (Figure S8A), indicative of a powerful local adaptive cellular immune response.  
The animals were challenged eight weeks after the booster immunization. A sublethal dose of 
0.3LD50 influenza B virus was used to evaluate morbidity, while a 0.075LD50 dose was administered 
for analysis of pulmonary virus replication,. NBe-tGCN4-Flag vaccination significantly reduced 
morbidity following infection (Figure 8A). During the recovery phase, a small adjuvant effect was 
detectable, as PBS immunized mice recovered more slowly than the two adjuvanted groups. 
Quantification of the viral lung titers revealed that NBe-specific immunity inhibited viral replication in 
the lungs (Figure 8B). At all three time points evaluated, viral titers in the NBe-tGCN4-Flag group 
were significantly lower than in both control groups, and the challenge infection was cleared totally 
by day 6 post-challenge.  
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Figure 8. Mucosal immunization of mice with LTR192G adjuvanted NBe-tGCN4-Flag affords strong anti-influenza B 
immunity. C57Bl/6 mice were immunized with PBS, adjuvanted carrier only or adjuvanted NBe-tGCN4-Flag twice three 
weeks apart. Eight weeks post-boost, the mice were challenged with sublethal influenza B doses. A. Morbidity following 
sublethal challenge (0.3 LD50), illustrated by relative weight. Asterisks indicate significant differences compared to both 
other groups. n=5 for PBS and carrier only groups, n=6 for NBe-tGCN4-Flag group. *, p<0.05; **, p<0.01; ***, p<0.001. B. 
Viral lung titers determined at the indicated timepoints following a sublethal challenge (0.067 LD50). Asterisks indicate 
significant differences compared to both other groups. n=5 for all groups. **, p<0.01; ***, p<0.001. 
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Figure 8. Continued. 
 
As a final control, the challenged mice were used for an in vivo killing assay two weeks after 
challenge. Adoptively transferred CFSE-labeled peptide-pulsed splenocytes were not only detected in 
the spleen of recipient mice, but also in the inguinal lymph nodes (ILN) and lungs. As shown in Figure 
S8B, specific killing was comparable in the three immune compartments analyzed, within each group. 
NBe-directed cytotoxicity was similar in both PBS and adjuvanted carrier only groups, reflecting anti-
NBe immunity induced by the single infection. However, the NBe-tGCN4-Flag immunized mice 
showed a higher specific killing activity, reaching over 90%, reflecting the heterologous boosting 
effect observed above following intraperitoneal priming (Figure 6B).  
Taken together, these data show that the adjuvanted NBe-tGCN4-Flag vaccine induces strong local 
NBe-directed cellular immunity, inhibiting viral replication in the lung and improving the clinical 
outcome of the infection.  
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Discussion 
Even without an animal reservoir feeding novel genetic reassortments, the epidemic burden of 
influenza B viruses is quite substantial. The co-circulation of two antigenically distinct lineages in the 
human population offers a basis for gene shuffling, creating influenza B virus strains with improved 
fitness or a difficult to predict antigenic make-up 5,9,10. Additionally, vaccination- or infection-induced 
immune pressure will cause the virus to drift and contributes to evasion of existing immunological 
memory 6. Surveillance data scrutinizing a number of sequential influenza seasons has revealed that 
vaccine mismatches occur fairly frequently 48-51. Co-circulation of viruses belonging to either of the 
influenza B lineages will lead to diminished vaccine efficacy and supports the drift of influenza B 
viruses 48. Vaccine mismatch puts the (vaccinated) high-risk populations in a vulnerable position and 
increases the risk of potential hospitalization or death 14,15,48,49. To avoid hurdles faced with classical 
vaccines, we approached influenza B vaccination from a different angle. We focused on the 
conserved ectodomain (NBe) of the NB protein in an attemt to induce cross-reactive immunity 
against influenza B virus infection in an experimental model. Within the H2b-background of C57Bl/6 
mice, NBe-based immunization induced strong NBe-specific CD8+ T cell responses that were 
associated with enhanced lung virus clearance and reduced morbidity. Furthermore, and although a 
number of human CTL epitopes of influenza B viruses have been identified 52,53, to our knowledge, 
the NBe-CTL epitope is the first murine-specific influenza B epitope identified.  
Using a tetramerizing mutant of the leucine zipper of the GCN4 transcription factor 27,28, we initially 
aimed to develop an antibody-inducing vaccine. Surprisingly though, vaccination with NBe-tGCN4-
Flag protein, even in the presence of a Th2-skewing adjuvant like Alhydrogel 54, induced strong 
cellular responses directed to NBe. In recent years, many studies have been performed to elucidate 
the mechanism by which aluminum salt, which have a track-record of over 80 years, exert their 
adjuvancy 55-60. Aluminum adjuvantation is largely based on its crystalline structure, leading to 
lysosomal destabilization upon lipid membrane binding and uptake by dendritic cells (DCs), inducing 
the release of PGE2, a Th2-mediator 
57. Aluminum salts also induce cell death, leading to the release 
of uric acid and host DNA, endogenous danger signals amplifying the crystalline aluminum signal 58,60. 
Additionally, cytokines induced during immunization will stimulate a Th2-driven immune response. 
Nonetheless, NBe-tGCN4-Flag combined with Alhydrogel induces strong cellular responses, indicating 
effective cross-presentation upon vaccination. For this, soluble antigen has to be taken up by DCs 
through phagocytosis and processed for MHCI-presentation 61. However, membrane binding of DCs 
by aluminum salts will usually not lead to productive endocytosis, disfavoring cross-presentation 56,61. 
One way to overcome aluminum salt induced Th2-skewing, is the addition of pro-inflammatory 
proteins such as TLR agonists, as is the case with the ASO4 adjuvant system 62. The specific 
mechanism by which NBe-tGCN4-Flag protein vaccination promotes a strong CD8+ T cell response 
however, remains uncertain. Clearly though, the NBe-epitope on its own appears to be strong and 
naturally processed, irrespective of its way of presentation. The combination with the tGCN4-Flag 
motif may further strengthen the immunological properties of the NBe-epitope. The specific role of 
tGCN4 in potential immune modulation is under further scrutiny. 
For respiratory diseases like influenza, mucosal immunization might serve as a preferred mode of 
vaccination. Not only local immune responses are induced, providing a first line of defense at the site 
of entry, but also systemic immunity is generated. Intranasal immunization with NBe-tGCN4-Flag 
induced enhanced protection compared to the intraperitoneal route. High local cellular responses 
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are induced, and two immunizations (with an eight week period between boost and infection) show 
stronger inhibitory effects on influenza B virus replication than three i.p. immunizations (Figure 4 and 
8B). In the homologous and heterologous prime-boost setting we were initially surprised that 
intranasal priming is only boosted moderately by influenza B virus infection (Figure 5C). The higher 
(systemic) response that homologous intranasal boosting induced points to a stronger anti-NBe 
response during priming compared to other vaccination routes, which might be strong enough to 
neutralize the low-dose influenza B boost to a certain extent 63. Although residual adjuvant effects of 
LTR192G limiting boosting cannot be excluded, clearly, intranasal NBe-based immunization 
significantly restrains pulmonary replication of influenza B virus. 
Protective immunity against influenza A virus induced by M2e-fusion constructs is largely dependent 
on the induction of M2e-specific IgG 24,64. However, the initial vaccination experiment with NBe-
tGCN4-Flag using different mouse strains revealed no correlation between NBe-specific serum IgG 
and protection from morbidity and death following a potential lethal challenge with 2.5LD50 influenza 
B virus. It is important to note that in the mouse model for influenza B virus infection the challenge 
dose needed to obtain a lethal outcome is orders of magnitudes larger than the dose required for 
most mouse-adapted influenza A virus strains. We used mouse-adapted B/Memphis/12/97 29 as 
challenge virus, for which, under our conditions, 1 LD50 corresponds to 10
6 pfu for C57Bl/6 mice, a 
dose up to 4-logs higher than required for influenza A viruses. The lack of protection seen in an initial 
challenge experiment (Figure 2), despite the induction of NBe-specific T cells with anti-influenza B 
activity (Figure 3 and 4), might be linked to the levels of T cell induction and viral dose used for 
infection. Using lower infectious doses of 0.075LD50, clear effects on viral replication can be seen 
(Figure 2B and 4). Moreover, two mucosal immunizations, inducing higher relative numbers of NBe-
specific T cells (Figure 5C) and strong local immunity (Figure S8), reduced disease manifestation 
significantly after a 0.3LD50 sublethal influenza B infection in NBe-tGCN4-Flag immunized mice (Figure 
8). A too low ratio between T cell level and viral dose might mask protective efficacy of induced T 
cells, an observation also made in adoptive transfer experiments using different levels of transferred 
T cells 65. 
To identify the specific T cell players involved in NBe-directed immunity, we combined depletion of 
specific T cell populations with an in vivo killing assay. Based on intracellular cytokine staining assays, 
it was apparent that CD8+ T cells are the prime NBe-reactive induced species (Figure 3). However, 
minor NBe-specific CD4+ T cell contribution was consistently detected. The depletion assay did reveal 
a role for CD4+ T cells in (non-infectious) NBe-directed killing. Single prime or homologous prime-
boost immunizations clearly need CD4+ T cell help to obtain maximal effect. This is in agreement with 
studies showing the influence of helper T cells on CD8+ memory expansion and responsiveness 66,67. 
For the heterologous boost setting, however, the cytotoxic NBe-directed killing response appears to 
operate without the help from CD4 T cells. The robust T cell induction that heterologous prime-boost 
immunizations evoke apparently circumvents the need for help for a recall response when 
encountering antigen. CD4+ T cells specifically assist in the expansion and survival of memory CD8+ T 
cells 68,69; the high levels of CD8+ T cells generated by the heterologous boosting scheme, and 
potentially their phenotype, might avoid the need for CD4+ T cell induced expansion 70. 
The finding that heterologous boosting schemes are so efficient in inducing cellular immune 
responses is encouraging. Evidently, many research groups have uncovered the power of 
heterologous prime-boost regimens in inducing T-cell and antibody responses to combat diseases 
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such as influenza, HIV and malaria 71,72. Classically though, the prime immunization consists of a viral 
vector or a DNA vaccination, followed by a different viral vector or protein boost. There are only a 
limited number of studies involving a protein to achieve priming 73. In our setting, boosting vaccine-
induced responses by a sublethal influenza B virus dose is robust. NBe-tGCN4-Flag vaccination on its 
own elicits strong responses, inhibiting viral replication and reducing excessive morbidity. A following 
influenza B infection however boosts cellular immunity considerably. Translated to an epidemic 
setting, this implies that seasonal infection would boost immunity induced by the (infection-
permissive) NBe-based vaccination. Hence, influenza B virus exposure would serve as a natural 
booster immunization, extending protection induced by the conserved NB ectodomain. This opens 
prospects for general influenza vaccination strategies, based on non-neutralizing, infection-
permissive vaccines 74. Additional candidates for this are the M2-ectodomain of influenza A, the LAH 
of influenza A/H3 viruses which induce non-neutralizing antibodies, and validated cytotoxic T cell 
epitopes. Immunity induced by these vaccine candidates would be boosted with every infection, 
which may not be completely blocked but might subside to subclinical levels. 
Our results provide new insights into the potential of inducing effective cytotoxic T cell responses to 
combat infectious diseases. While exploring the value of a novel influenza B restricted H2b-restricted 
epitope, we uncovered the strength of this epitope in depressing influenza B virus infection and the 
potential power of our carrier protein in inducing T cell responses. Moreover, the heterologous viral 
boosting effects add further evidence for the advantageous nature of infection-permissive vaccines.  
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Material and methods 
Mice, viruses and influenza challenges 
For all in vivo studies, 6-8 week old female mice were used. BALB/c mice were obtained from Charles River 
(Italy), C57Bl/6J mice from The Jackson Laboratory (France) and C3H/HeN mice from Harlan (The Netherlands). 
Mice were housed under specific pathogen-free conditions and fed ad libitum. All infection experiments were 
conducted under BSL-2 containment and were approved by the local Institutional Ethics Committee on 
Experimental Animals of Ghent University. 
All influenza B infections were performed using the mouse-adapted M15-strain of B/Memphis/12/97 
29
. In our 
model, one LD50 dose corresponds to 10
6
 pfu for C57Bl/6J mice, 1.25 x 10
6
 pfu for Balb/c mice and 6 x 10
5
 pfu 
for C3H/HeN mice. For potential lethal infection, a 2.5LD50 dose was administered; sublethal infections were 
done with 0.075 or 0.3 LD50 as indicated in the text. For influenza A virus infections, mouse-adapted A/Puerto 
Rico/8/34 was used, with 1LD50 corresponding to approximately 50-100 pfu. Sublethal infections as form of 
immunization were performed with 0.075 LD50. All infections were done by instilling virus diluted in 50µL 
phosphate-buffered saline (PBS) into the nostrils of ketamine (50mg/kg) + xylazin (7.5mg/kg) anaesthetized 
mice. Following infection, mice were monitored for weight loss as a measurement of morbidity. Mice that had 
lost more than 30% of their initial weight, were euthanized, as demanded by the approved protocol, and 
regarded as not-protected . 
 
Construction, purification and cross-linking of NBe-tGCN4-Flag 
Construction of tGCN4-Flag and NBe-tGCN4-Flag expressing vectors was done as previously described 
28
. 
Briefly, overlapping oligonucleotides (Invitrogen) were used to create the coding sequences for the 
tetramerizing tGCN4 leucine zipper variant 
27
, the NB ectodomain and the triple Flag-tag. Using classical cloning 
techniques based on restriction enzyme digestion and PCR, the three domains were fused in frame and 
inserted in the pLT32H expression vector using the NdeI and HindIII restriction sites 
75
, leading to pL-promotor 
driven expression in bacterial systems.  
For expression, BL21 CodonPlus (Stratagene) bacteria, bearing the pICA2 repression plasmid 
28
, were 
transformed with the tGCN4-protein expressing pLT32H vectors. Inductions were done by diluting a 40mL 
bacterial culture, grown overnight at 28°C in Luria Broth (LB), 1/50 in 2L of LB. Cultures were grown further at 
28°C until they reached an optical density at 600nm of 0.5-0.8. At this point, the cultivation temperature was 
raised to 42°C, leading to denaturation of the temperature-sensitive cI
ts
-repressor 
76
, expressed by pICA2, 
liberating the pL-promotor and leading to expression of the chimeric tGCN4-proteins. After 4h of induction, 
bacteria were collected by pelleting the culture through centrifugation (10 min, 4°C, 6000g). If needed, 
bacterial pellets were stored dry at -20°C until use. 
To purify the chimeric tGCN4-proteins, bacterial pellets were resuspended in 1/10 of the original volume using 
50mM Tris/HCl pH8.0 + 150mM NaCl (4°C). Bacteria were disrupted by sonication and immediately treated for 
30min at 65°C to precipitate contaminating bacterial proteins, relying on the heat-resistant properties of the 
tGCN4 leucin zipper 
27
. Next, denatured proteins and bacterial debris were removed by centrifugation (1h, 4°C, 
20.000g) and filtered through a 0.45µm filter. Using an Akta purification station, cleared lysates were applied 
on a SourceQ anion exchange column, followed by a linear gradient elution using 50mM Tris pH8.0 + 1M NaCl, 
going from 0% to 100% elution buffer. Elution fractions were analyzed through SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE); fractions containing the protein of interest were pooled and concentrated using 
Vivaspin columns (GE Healthcare) with a 5 kDa cut-off. Samples were loaded on a calibrated Superdex 75 prep-
grade gel filtration column and eluted with PBS. Fractions containing tGCN4-proteins of the desired size and 
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purity (Figure S1) were pooled and concentrated using Vivaspin columns (5 kDa cut-off) to concentration of 1-
30 mg/mL without losing solubility. Protein solutions were batched out and stored at -80°C. 
Purified NBe-tGCN4-Flag, M2e-tGCN4 and BM2e-tGCN4 were used for cross-linking experiments 
28
. Briefly, 
stock solutions of 50mM BS
3
 (bis(sulfosuccinimidyl)suberate; Pierce) in water and 25mM DSP 
(dithiobis(succinimidylpropionate); Pierce) in DMSO were prepared freshly prior to use. These were diluted to 5 
mM final concentration in PBS containing 10µg of the different tGCN4-proteins. Cross-linking reaction was 
allowed to continue for 1h at room temperature, after which the reactions were stopped by adding 50 mM 
Tris, pH 6.8. Samples were divided in two and boiled in non-reducing (50 mM Tris pH 6.8, 10% Glycerol) or 
reducing (50 mM Tris pH 6.8, 10% Glycerol, 20mM β-mercapto-ethanol) sample buffer, followed by analysis on 
SDS-PAGE and Coomassie-staining. 
 
Construction and expression of NBe-M2 chimeras 
The cDNA coding for M2 and NB was obtained by reverse transcription using RNA prepared from A/Puerto 
Rico/8/34 or B/Memphis/12/97 virus-infected MDCK cells. Exchange of the two ectodomains was done by 
fusion PCR, using oligonucleotides spanning the NBe and the M2 transmembrane region. All coding sequences 
were cloned into the pCAGGS vector, allowing constitutive expression driven by the chicken β-actin/rabbit β-
globin hybrid promoter. A single Flag-tag was introduced C-terminally to allow detection. 
For transfections tests, HEK293 T cells were seeded at 2 x 10
5
 cells in a 6-well plate in complete DMEM medium 
(DMEM + 10% FCS + L-Gln + sodium pyruvate + penicillin/streptomycin). 16h later, cells were transfected with 
1µg plasmid DNA using calcium phosphate precipitation. 24h later, cells were lysed and analyzed by SDS-PAGE 
followed by Western blotting. Flag-tagged proteins were visualized using rabbit anti-Flag antibody detection, 
combined with alkaline phosphatase labeled goat anti-rabbit-AP secondary antibody and NBT/BCIP substrate 
(Roche) for detection. 
For immunofluorescence assays, HEK293T cells were seeded on aceton-treated coverslips in 24-well plates at a 
density of 2 x 10
4
 cells/well in complete DMEM. 16h later, cells were transfected with 250 ng pCAGGS-based 
constructs. 24h later, cells were fixed with 4% paraformaldehyde and permeabilized for 5 min using 0.05% 
Triton X-100 in PBS + 20 mM Glycine. After blocking for 1 h using a 1% PBS-based BSA solution, cells were 
stained with rabbit anti-Flag and murine antiserum raised against M2e-tGCN4 (diluted 1/500) and NBe-tGCN4-
Flag (diluted 1/50). Secondary staining was done using goat anti-rabbit Alexa-fluor-647 conjugated antibody 
and goat anti-mouse Alexa-fluor-488 antibody (Invitrogen). Cells were mounted with Vectashield containing 
DAPI for nuclear counterstain before microscopic analysis. 
 
Immunization methods and challenge experiments 
All protein immunizations were with 5 µg of protein per dose. Intraperitoneal vaccinations using Alhydrogel 
(Brenntag Biosector A/S) as adjuvant were performed as described 
28
. For intranasal immunization, proteins 
were diluted in 50 µL PBS and adjuvanted with 1 µg LTR192G. The vaccine preparation was instilled into the 
nostrils of ketamine/xylazine anaesthetized mice. Subcutaneous vaccinations were given in a volume of 100 µL, 
consisting of 26 µL PBS containing the tGCN4-protein and 74 µL Montanide ISA-720 (Seppic). DNA 
immunizations were administered intramuscularly, using 100 µg LPS-free plasmid DNA in a volume of 100 µL 
PBS. 
One week before the first immunization and two weeks after every subsequent immunization, blood was 
drawn from the lateral tail veins for serological analysis. Subsequent immunizations had an interval of three 
 
160 Chapter 5 
weeks; the number of immunizations is mentioned in the legends. Unless stated otherwise, challenge of mice 
was performed three weeks after the last immunization. For follow-up studies, body weight of challenged mice 
was determined on a daily basis. Lung homogenates were prepared on different days after challenge by tissue 
homogenization in 1 mL PBS using a Heidolph RZR 2020 homogenizer. Viral titers were determined by TCID50 
titration on MDCK cells in quadruplicate and calculated according to the method of Reed and Muench 
77
. 
 
ELISA procedure 
Antibody responses induced by vaccination were quantitated by ELISA. For peptide-specific ELISA (NBe, Irr), 
Maxisorp immune-plates (Nunc) were coated overnight at 37°C with 50 µL of a 2 µg/mL peptide-solution in 100 
mM sodium carbonate buffer, pH 9.6. Anti-tGCN4-Flag titers were determined using plates coated overnight at 
4°C with 2 µg/mL tGCN4-Flag in carbonate buffer. After coating, plates were washed three times with PBS + 
0.1% Tween-20 and blocked with PBS + 3% milk. Sera from immunized mice were diluted (1/3 dilution series) in 
PBS + 0.05% Tween-20 + 1.5% milk and incubated on the ELISA plates for 1.5 h at room temperature. After 
washing three times, subtype-specific HRP-linked goat anti-mouse secondary antibodies (Bio-Connect) were 
incubated on the plates for a further 1.5 h at room temperature. Following a final wash step, titers were 
detected using TMB substrate (Pharmingen, BD). The reaction was stopped after 10 min by adding an equal 
amount of 1 M H2SO4. Plates were read at 450 nm, with background measurement at 655nm. Endpoint titers 
are determined as the last dilution of immune serum giving an ELISA signal at least twice as high as pre-
immune serum. 
 
ELISPOT and intracellular cytokine stainings (ICS) 
Murine IFNɣ-specific ELISPOT assays (U-Cytech Biosciences) were performed according to the manufacturer’s 
instructions. Briefly, Maxisorp immune-plates were coated with monoclonal anti-IFNɣ antibodies overnight at 
4°C. Splenocytes were isolated from mice three weeks after the last immunization by gentle homogenization of 
the spleen in PBS, followed by red blood cell lysis using hypotonic ammonium chloride buffer. Cells were 
seeded at densities of 1-3 x 10
5
 cells per well and restimulated overnight with 2 µg/mL of the described 
peptides (synthetized by Pepscan, The Netherlands). Cells were flicked out of the wells and plates were washed 
with PBS + 0.1% Tween-20. Next, plates were incubated for 1.5 h with biotinylated polyclonal anti-IFNɣ 
antibodies, followed by a wash step and incubation with GABA anti-biotin antibodies. Spots were detected with 
specific reagent leading to silver staining. Spots were manually counted using an inverted light microscope. 
Control set-ups use restimulation with DMSO only, irrelevant Ova-peptide, and the polyclonal concanavalin A 
(ConA) stimulus. 
For ICS, splenocytes were prepared and restimulated as for the ELISPOT assays. Restimulations however were 
performed in 12-well suspension plates using 1 mL cell-suspension at 3 x 10
6
 cells per well. Further processing 
was done using the CytoFix/Perm kit (BD) according to the manufacturer’s protocol. In short, after 4-6 h of 
incubation with peptides (2 µg/mL), 1 µg of Brefeldin A was added to stop secretion of cytokines. After a 
further incubation of 8-12 h, cells were collected, washed in PBS + 1 % BSA and incubated for 30 min at room 
temperature with anti-CD3ε-PE, anti-CD4-FITC and anti-CD8-PerCP.Cy5 (all from BD) for staining of surface 
markers. After a further wash, cells were fixed, permeabilized, and stained for intracellular IFNɣ. Cells were 
washed and subsequently analyzed on a FACS Calibur or LSRII cytometer using CelQuestPro (BD) software. 
Positive (ConA) and negative (irrelevant peptide) restimulations were included as controls as well as antibody-
staining controls (i.e. single antigen stains, isotype controls). were included. 
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In vivo killing assays 
The in vivo killing assays are based on the protocol of Barber et al. 
43
. Briefly, splenocytes were prepared, as 
described above, from naive mice and resuspended in complete RPMI (RPMI + 10% FCS + L-Gln + sodium 
pyruvate + penicillin/streptomycin) to a final density of 3-5 x 10
6
 cells per mL. One half of the cell population 
was pulsed with a specific NBe-related peptide (full-length NBe-peptide or octameric ATFNYTNV, as indicated) 
and the other half with an unrelated Ova-peptide (SIINFEKL). Peptides were added at a concentration of 10 
µg/mL, followed by incubation for 1-2 h at 37°C in a CO2-incubator. After this, peptide-pulsed cells were 
washed and stained differentially with 5 µM or 0.5 µM CFSE (carboxyfluorescein diacetate succinimidyl ester; 
Invitrogen) according to the manufacturer’s protocol. Subsequently, cell populations were mixed in equicellular 
amounts and adoptively transferred to immunized mice at the indicated time points by intravenous injection of 
approximately 5 x 10
6
 cells. Twenty four h later, spleens (or other immune organs, as indicated) were isolated 
and cells were prepared and analyzed on a FACS Calibur using CelQuestPro (BD) software. To calculate specific 
killing rates, ratios of CFSE (high) and CFSE (low) cell numbers were compared in test groups with an irrelevant 
(naive) mouse group or negative control, using the equation 100-100*[ratio (test setting) / ratio (control 
setting)]. 
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Supplementary Figures 
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Figure S1. The NBe-tGCN4-Flag protein behaves as a tetrameric protein. A-B. Gel filtration profile of the final purification 
step of NBe-tGCN4-Flag (A), overlayed with a calibration run using proteins of different sizes. Analysis of fractions 
corresponding to the NBe-tGCN4-Flag gel filtration on polyacrylamide gel shows the protein of interest (indicated by the 
arrow) to be present  in two distinct peaks (B). Peak 2 corresponds to NBe-tGCN4-Flag protein with the expected molecular 
weight (35,24kDa), while peak 1 contains aggregated chimeric NBe-protein, or protein associated with bacterial 
contaminants. The purest fractions of this peak were further used throughout this study. M = gel marker (mass in kDa), S = 
starting material for the gel filtration. C-D. Cross-linking experiment using two homobifunctional cross-linkers with similar 
reactivity, DSP and BS
3
, of which DSP contains a reducable disulfide bridge in its spacer arm. Validated tGCN4-based 
tetrameric proteins were taken along as controls 
28
. Analysis was done on polyacrylamide gel under non-reducing (C) and 
reducing (D) conditions. M = gel marker (mass in kDa), BG = BM2e-tGCN4, MG = M2e-tGCN4, NGF = NBe-tGCN4-Flag; U = 
uncross-linked, B = BS
3
-cross-linked, D = DSP-cross-linked. 
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Figure S2. Mice of different genetic backgrounds react differently to NBe-tGCN4-Flag and carrier only vaccination. Mice 
from different genetic backgrounds, Balb/c (H2
d
), C57Bl/6 (H2
b
) and C3H/HeN (H2
k
), were immunized three times with 
carrier only or NBe-tGCN4-Flag in combination with Alhydrogel. Serum endpoint titers of pooled sera determined two 
weeks after each immunization in NBe-peptide (A & B) or tGCN4-Flag-specific (C & D) ELISA.  Both IgG1 (A & C) and IgG2a or 
IgG2c (B & D) specific titers were analyzed. 
 
A B
 
Figure S3. Irr-tGCN4-Flag immunization evokes anti-Irr and anti-tGCN4-Flag responses in mice of different genetic 
backgrounds. Mice from different genetic backgrounds, Balb/c (H2
d
), C57Bl/6 (H2
b
) and C3H/HeN (H2
k
), were immunized 
twice with carrier only, Irr-tGCN4-Flag or NBe-tGCN4-Flag in combination with Alhydrogel. Serum endpoint titers of pooled 
sera determined two weeks after each immunization in NBe-peptide (A & B), tGCN4-Flag (C & D) or Irr-peptide specific 
ELISA.  Both IgG1 (A, C, E) and IgG2a or IgG2c (B, D, E) specific titers were analyzed. 
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Figure S3. Continued. 
 
1
2
S   P
2'
S   P
3
S   P
4
S   P
A
1
2 
S   P
3
S   P
4
S   P
B
20
15
10
25
37
50
20
15
10
25
37
50
 
Figure S4. Eukaryotic expression of chimeric NBe-M2-Flag protein after transient transfection. A. Western blot analysis of 
lysates of HEK cells transiently transfected with pCAGGS-based constructs expressing Flag-tagged full-length influenza ion 
channels, showing nice expression of M2 and BM2, but no detectable levels of NB. 1 = protein gel marker (mass in kDa), 2, 
2’ = M2-Flag, 3 = BM2-Flag, 4 = NB-Flag; S = supernatant after cell lysis, P = pellet after cell lysis. B. Expression of chimeric 
Flag-tagged NBe-M2-Flag, in which the M2-ectodomain is replaced by NBe. 1 = protein gel marker (mass in kDa), 2 = mock 
transfection (empty pCAGGS), 3 = M2-Flag, 4 = NBe-M2-Flag; S = supernatant after cell lysis, P = pellet after cell lysis. C. 
Immunofluorescense staining of HEK cells transiently transfected with pCAGGS vectors expressing NB-Flag (top), M2-Flag 
(bottom) or NBe-M2-Flag (middle). Staining was done with immune serum raised using M2e-tGCN4 (Balb/c mice) and NBe-
tGCN4-Flag (C3H/HeN mice). As control rabbit anti-Flag staining was used, showing clear expression of all three proteins in 
this set-up. Note immune serum from mice immunized with NBe-tGCN4-Flag, carrying a triple Flag-tag, does not cross-react 
with the single Flag-tag of M2-Flag, indicating staining of NBe with this serum is specific. 
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Figure S4. Continued. 
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Figure S5. Induction of antibody titers using different carrier-based immunogens in C57Bl/6 mice. C57Bl/6 mice were 
immunized three times with tGCN4-Flag carrier only, NBe-tGCN4-Flag or Irr-tGCN4-Flag, as depicted in Figure 1, in the 
presence of alum. Serum endpoint titers of pooled sera were determined two weeks after each immunization in NBe-
peptide (A & B), irrelevant peptide (C & D) or tGCN4-Flag-specific (E & F) ELISA. Both IgG1 (A, C, E) and IgG2c (B, D, F) 
specific titers were analyzed. 
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Figure S6. Short- and long-term in vivo killing assays reveal strong and long-lasting NBe-directed cytotoxicity. C57Bl/6 
mice were immunized twice as indicated. In vivo killing assays were performed by transfer of differentially CFSE-labelled 
peptide-pulsed splenocytes  4 weeks (A) or three months (B) post-boost. The presence of CFSE-positive population in the 
spleen of recipient mice was determined through FACS-analysis 24h post-transfer. Shown are the ratios of Ova-peptide 
pulsed cells labeled with 0.5mM CFSE (low) and NBe-peptide pulsed cells labeled with 5mM CFSE (high). The number of 
mice in each group is indicated in the bars. **, p<0.01; ***, p<0.001. 
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Figure S7. CD4- and CD8-specific T cell depletion. A-C. FACS profiles of splenocytes stained for CD3 (A), CD4 (B) or CD8 (C) 
after treatment with PBS (yellow graph), anti-CD4 (blue graph) or anti-CD8 (black graph). The gray filled profile corresponds 
to the staining of splenocytes from untreated naive mice. D. Relative positivity for CD3 within the total splenocyte 
population and for CD4 and CD8 within the CD3
+
-population, determined by FACS for naive untreated mice and PBS-, anti-
CD4- and anti-CD8-treated heterologous NBe-based prime-boosted mice.  
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Figure S8. Mucosal immunization with LTR192G adjuvanted NBe-tGCN4-Flag vaccine induces strong local immunity. 
C57Bl/6 mice were immunized with PBS, adjuvanted carrier only or adjuvanted NBe-tGCN4-Flag twice three weeks apart. A. 
Four weeks post-boost, cellular responses were evaluated in an ex vivo elispot assay using the indicated lymph nodes and 
organs. For restimulation, the H2-K
b
 restricted octameric ATFNYTNV NBe-peptide was used. n=3 for all groups. B. Eight 
weeks post-boost, mice were challenged with a sublethal influenza B dose (0.3 LD50) for follow-up of morbidity (Figure 7). 
Two weeks post-challenge, mice were subjected to an in vivo killing assay using irrelevant peptide and the H2-K
b
 restricted 
octameric ATFNYTNV NBe-peptide. Shown are the specific killing rates compared to a naïve mouse group. Asterisks indicate 
significant differences compared to both other groups. n=5 for PBS and carrier only groups, n=6 for NBe-tGCN4-Flag group. 
***, p<0.001. 
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Additional data 
 
Correlation between viral lung titers and post-challenge cellular responses 
Next to intranasal NBe-tGCN4-Flag immunization, ip. vaccination with the tetrameric protein is able 
to inhibit IBV replication in the mouse lung (cf. Figure 4 and Figure 8). In an attempt to repeat the 
results of the initial experiment (Figure 4), C57Bl/6 mice were immunized ip. with tGCN4-Flag or NBe-
tGCN4-Flag in combination with Alhydrogel. In this instance however, only two immunizations were 
given instead of three, to assess whether this also yields protective levels of NBe-directed cellular 
responses against IBV infection. As positive control, mice were sublethally pre-challenged twice with 
homologous IBV/Memphis/12/97 virus, further controlled by a sublethal influenza A infected mouse 
group. Three weeks after the second immunization or infection, mice were challenged with a 
0.067LD50 dose of B/Memphis/12/97. On day 5 post-challenge, lung homogenates were made for 
determination of the lung virus titer. As can be deduced from Figure A1, NBe-tGCN4-Flag 
immunization had little effect on IBV replication in the lung compared to tGCN4-Flag immunization. 
As expected, IBV pre-challenged mice did not show any pulmonary viral load. Surprisingly though, 
also influenza A pre-infected mice were almost completely devoid of IBV as well. This is most likely 
caused by so-called non-specific temporary immunity induced by a previous unrelated influenza 
infection 1.  
 
 
Figure A1. Intraperitoneal NBe-tGCN4-Flag immunization does not provide confiding protection against IBV infection. 
Mice were immunized twice three weeks apart with tGCN4-Flag or NBe- tGCN4-Flag, or infected twice with a sublethal 
influenza A or IBV dose. Three weeks after the second immunization, mice were challenged with a 0.067LD50 dose of IBV. 
On day 5 post-challenge, viral lung titers were determined in a TCID50 titration. n = 6 for all groups.  
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Concomitantly with lung virus titer determination, NBe-specific cellular responses were ascertained 
using splenocytes of the infected mice. All groups reacted strongly towards NBe-peptide 
restimulation in ELISPOT analysis, including non-NBe immunized mice (Fig. A2A). Such strong 
immediate post-challenge induction of NBe-specific cellular responses was seen in other instances as 
well (data not shown). When comparing viral lung titers with NBe-specific cellular responses (Fig. 
A2B-D), striking correlations can be found. Both for tGCN4-Flag immuned and influenza A virus (IAV) 
pre-infected mice, higher pulmonary virus titers correspond to higher NBe-specific cellular responses 
detected in ELISPOT. For the NBe-tGCN4-Flag immunized mice however, higher virus titers correlate 
with a lower number of cellular responses. This indicates NBe-directed cellular responses do provide 
a certain degree of protection in NBe-tGCN4-Flag mice, limiting viral replication in an apparent dose-
dependent manner. In non-NBe immune mice, higher viral loads simply induce higher levels of NBe-
responsive T cells.  
Although non-protective in this instance, NBe-directed cellular responses do correlate with anti-IBV 
activity. This is reminiscent of the study of McMichael et al. 2, which showed for the first time a 
correlation between virus-directed cytotoxicity and viral shedding in the absence of cross-reactive 
antibodies. With antisera containing undetectable amounts of anti-IBV titers and not showing any 
neutralization effect in vitro (data not shown), conditions here are similar. 
 
A B
DC
***
 
Figure A2. Correlation between pulmonary viral load and NBe-specific immune responses in NBe-tGCN4-Flag immunized 
mice. Splenocytes from mice used for the determination of IBV replication in the lungs day 5 post-challenge (Fig. A2), were 
restimulated with NBe-peptide to asses cellular responses in an IFN-specific ELISPOT. A. Number of spots for each 
immunized mouse group. n = 6 for all groups. ***, p<0.001 (Two-way ANOVA). B-D. Correlation between number of spots 
induced by NBe-peptide restimulation and viral lung titer, assessed on the same day (day 5) after a sublethal IBV challenge, 
for tGCN4-Flag (B), NBe-tGCN4-Flag (C) and influenza A virus (IAV) pre-infected (D) mice. Indicated are the Pearson’s 
coefficients of correlation with their respective p-value. 
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NBe-vaccination based on different carriers can induce NBe-specific T cells 
Using NBe-tGCN4-Flag, cytotoxic NBe-specific T cell responses can be induced using different 
adjuvants and immunization routes. Additionally, IBV infection and NBe-based DNA immunization 
also evokes such responses. To evaluate the value of other NBe-carrier fusion proteins, mice were 
immunized ip. with a number of proteins combined with Alhydrogel. Next to validated NBe-tGCN4-
Flag and NBe-M2 DNA immunization, three different HBc-based vectors were used 3,4. In 1646 and 
1651, a single copy of the NB ectodomain is fused to the N-terminus (1651) or inserted into the 
immunodominant loop (1646) of the short version of HBc, lacking the nucleic acid binding protamine 
region. In NBe-2M2e-HBc, a single NBe-copy is fused N-terminally to two M2e-copies coupled a 
short-version HBc-particle. The 2M2e-HBc particle has been validated in influenza A based challenges 
5, and provides a more soluble basis for carrying the NBe-sequence. To check the influence of the 
highly-charged Flag-tag on induction of cellular responses, tag-less P. pastoris NBe-tGCN4 was used, 
produced by both wild type (PpWT) and glyco-engineered yeast producing only glycoproteins bearing 
mannose5-structures (PpM5) 
6,7. IFNg-specific ELISPOT revealed all NBe-based immunization methods 
induce specific cellular responses, albeit to a different extent, both in homologous (two protein 
immunizations, Fig. A3A) and heterologous (protein immunization boosted by a sublethal IBV 
infection, Fig. A3B) setting. In general, it can be concluded that, in addition to using different 
adjuvants and immunization routes in combination with NBe-tGCN4-Flag, different carriers can lead 
to the induction of cellular responses directed towards the coupled NB ectodomain. 
 
A
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Figure A3. NBe-specific cellular responses can be induced by different NBe-carrier fusions. Mice were immunized 
intraperitoneally in combination with Alhydrogel using the indicated immunogens, except for NBe-M2 given intramuscularly 
as a DNA vaccine. Three weeks after the first immunization, mice were boosted homologously with the same immunogen 
(A) or heterologously with IBV infection (B). Cellular anti-NBe responses were assessed three weeks after the boost in IFN-
specific ELISPOT. 
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The tGCN4-carrier can induce T cells against different epitopes 
Even with the NBe-epitope being a strong natural antigen, and different carrier systems being able to 
induce NBe-directed cellular responses, we wondered what the applicability of the tGCN4-carrier is. 
The ease of construction and purification of epitope-tGCN4 fusions, combined with the high yield in 
the prokaryotic expression system is extremely inviting for a broad T cell inducing vaccine basis. To 
assess this, a number of validated cytotoxic T cell epitopes were genetically fused to the tGCN4-Flag 
carrier (Table A1). These include H2b-, H2d- and H2k-restricted influenza A-derived NP epitopes 8-10, 
alone or fused together into one construct, and the well-known H2b-restricted OVA epitope 11,12.  
 
Table A1. Overview of epitopes and their sequences fused to tGCN4-Flag used for immunization. The sequences shown 
include the epitope (underlined) flanked by three amino acids on either side derived from the natural context. These 
sequences are fused together or the tGCN4-Flag carrier using a Gly-Gly (GG) linker. 
Epitope Sequence 
H2
b
-specific NP-epitope [NP(b)] MVQIASNENMETMESS-GG-[tGCN4-Flag] 
H2
d
-specific NP-epitope [NP(d)] MNDATYQRTRALVRTG-GG-[tGCN4-Flag] 
H2
k
-specific NP-epitope [NP(k)] MLKLSDYEGRLIQNS-GG-[tGCN4-Flag] 
Combined NP-epitopes [NPc] NP(k)-GG-NP(d)-GG-NP(b)-GG-[tGCN4-Flag] 
H2
b
-specific OVA-epitope [Ova] MQLESIINFEKLTEW-GG-[tGCN4-Flag] 
 
 
For initial testing, small-scale purification were done, based on pull-down using the Flag-tag. Bacterial 
pellets from low-volume inductions (giving high relative yields) were sonicated, followed by 
immunoprecipitation of the Flag-tagged product using mouse anti-Flag. As internal control, both for 
purification and immunization, NBe-tGCN4-Flag (NGF) was used. Figure A4 shows the purification 
results. Most of the protein remains unbound to Protein G beads, mainly due to a low antibody-
antigen ratio. However, for each protein, a small amount is detectable in the eluate. Also note, 
because of the non-covalent association of beads and antibody, the elution fractions contain both 
antigen and anti-Flag antibody. 
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Figure A4. Small-scale purifications of chimeric tGCN4-Flag proteins. Analysis of fractions after anti-Flag pull-down using 
Protein G agarose beads of tGCN4-Flag based proteins on Coomassie-stained polyacrylamide gels. The highly intense 
stained bands correspond to the protein of interest. The different fractions are indicated as input (I), unbound (U) and 
eluted (E). The eluates also contain the anti-Flag antibody used for the pull-down of the tGCN4-Flag proteins, as indicated 
by the presence of heavy (IgH) and light (IgL) antibody chains. 
 
To test the immunogenicity of the chimeric proteins, mice with genetic backgrounds responsive to 
the epitopes used were immunized twice three weeks apart ip. with the eluted proteins, mixed with 
Alhydrogel as adjuvant. This entails Balb/c mice were immunized with NP(d)-tGCN4-Flag and NPc-
tGCN4-Flag, C3H/HeN mice with NP(k)-tGCN4-Flag and NPc-tGCN4-Flag and C57Bl/6 mice with NP(b)-
tGCN4-Flag, NPc-tGCN4-Flag, OVA-tGCN4-Flag and NBe-tGCN4-Flag.  
As a first analysis, tGCN4-Flag specific antibody responses after the second immunization were 
determined in ELISA (Fig. A5A). IgG2a/c titers (in comparison to IgG1 titers) are higher than would be 
expected from aluminum salt adjuvanted vaccination. The most likely cause for this is the presence 
of mouse anti-Flag antibodies together with the eluted protein provides a complexed vaccine 
preparation, leading to a more pronounced immune response 13. This would also explain the 
reasonably high antibody response directed towards the small amount of protein.  
Cellular responses were ascertained in IFN-specific ELISPOT. NP-based immunization resulted in 
epitope-specific and haplotype-restricted responses in each of the mouse strains (Fig. A5B). In the 
control set-up, using immunoprecipitated NBe-tGCN4-Flag, cellular responses were high and specific 
for the octameric peptide (Fig. A5C). The tGCN4-Flag protein bearing the H2b-restricted Ova-peptide 
also induced epitope-specific cellular responses (Fig. A5C). In conclusion, the tGCN4-Flag carrier 
protein is able to induce epitope-specific cellular responses in different genetic murine backgrounds 
when immune-complexed with anti-Flag antibody. Future experimental settings using tGCN4-based 
proteins purified through conventional chromatographic methods should provide additional 
evidence for the broad immunogenicity of such chimeric proteins. 
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Figure A5. Immunogenicity of tGCN4-Flag proteins bearing validated T cell epitopes in different mouse strains. Mice were 
immunized twice ip. with Alhydrogel adjuvanted tGCN4-Flag proteins bearing different influenza A/NP-epitopes, the H2
b
-
restricted SIINFEKL Ova-peptide, or the NBe-ectodomein, purified through immunoprecipitation with mouse anti-Flag (Fig. 
4). A. Antibody titers (IgG1 and IgG2a/c) two weeks after the second immunization, detected in tGCN4-Flag specific ELISA. 
B-C. Detection of cellular responses, through IFN-specific ELISPOT. NP-specific responses were assessed, showing 
haplotype-dependent reactivity (B). Ova- and NBe-restricted responses, as determined in C57Bl/6 immunized mice (C). 
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Viruses with a deviating NBe-sequence confirm the defined consensus epitope sequence 
 As shown in Figure 1, a number of NBe-sequences contain mutations specifically in the mapped 
ATFNYTNV T cell epitope. The H2-Kb  MHC molecule, responsible for binding the peptide, imparts a 
number of restrictions on its ligand. The major anchor residues for octameric peptides are located at 
position 5, with a preference for Tyr or Phe, and position 8, with a preference for residues with a 
hydrophobic side chain, such as Leu, Met, Ile or Val 14. Table A2 describes all alternative NBe-
sequences found in the influenza database (www.fludb.org), with a sequence deviating from the 
consensus epitope sequence. A total of 66 sequences containing a mutation can be identified. Based 
on predictions using the NetMHC 3.2 server, only 6 of these will cause a drastic drop in affinity, with 
half of those responsible for complete abolishment of binding. 
 
Table A2. NBe-sequences with deviating H2-K
b
-restricted epitope sequence. All NBe-sequences available in the influenza 
sequence database (www.fludb.org; n = 854, from 1940 till March 2011) were aligned to identify all possible sequences 
corresponding to the identified H2-K
b
 restricted T cell epitope. In 788 instances (92.3%), the consensus sequence was found 
back. For all other situations, the H2-K
b
 binding was predicted using the NetMHC 3.2 server and ordered according to 
affinity (+++, very strong binding; ++, strong binding; +, relative strong binding; +/-, weak binding; -, no binding predicted). 
For sequences with weak or no predicted binding, the lineage to which the corresponding virus belongs is indicated (V = 
B/Victoria/02/87 lineages, Y = B/Yamagata/16/88 lineage, P = virus pre-dates lineages separation, ND = not determined). 
Sequence Occurrence H2-Kb binding Lineage 
ATFNYTNV 788/854 +++ ND 
ATFDYTNV 1/854 ++ V 
ATFNYTNI 10/854 ++ V(5) / Y(5) 
ATLNYTNV 48/854 ++ V(22) / Y(26) 
ATLNYTNI 1/854 + V 
ATFNHTNV 1/854 +/- V 
ATFNYTNA 2/854 +/- V(1) / Y(1) 
ATINHTNV 1/854 - V 
ATFNCTNI 2/854 - V(1) / P(1) 
 
 
To assess the influence of mutation of the NBe-restricted epitope, groups of C57Bl/6 mice were 
infected with a number of different IBVes (Fig. A6A). Of these, the B/Hong Kong/05/72 virus contains 
three residues deviating from the consensus NBe-sequence, with two of them residing in the T cell 
epitope. Specifically, the mutation of Tyr at position 8 (Y8C) is predicted to completely abolish MHCI-
restricted binding 14. Cellular responses were assessed through IFN-specific ELISPOT; results are 
shown in Figure A6B. Clearly, while B/Memphis/12/97, B/Harbin/07/94 and B/Yamagata/16/88 virus, 
all with consensus sequence, induce NBe-specific cellular responses, B/Hong Kong/05/72 is unable to 
do so.  
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A
B
Strain Nucleotide sequence (HA) amino acid sequence (NBe)
B/Yamagata/16/88
B/Harbin/07/94
B/Memphis/12/97
B/
B/
GTTACCAGTAGAAACGGATTT
GCTACCAGTAGAAGCGGATTT
GCTACCAGTAGAAGCGGATTT
GTTACCAATGGAAACGGATTT
GTTACCAATGGAAACGGATTT
MNNATFNYTNVNPISHIR
MNNATFNYTNVNPI HIR
MNNATFNYTNVNPISHIR
MNNATFN TN NPI HIR
Victoria/02/87
Hong Kong/05/72
MNNATFNYTNVNPISHIR
P
C I T
 
Figure A6. Mutation of the NBe-specific T cell epitope abolishes induction of cellular responses. Groups of three mice 
were infected twice, three weeks apart with buffer only (naive) or with 7.5x10
4
 pfu IBV/Memphis/12/97 (0.075LD50), 
B/Harbin/04/94, B/Yamagata/12/88 or B/Hong Kong/05/72 or with 0.075LD50 A/Puerto Rico/08/34 virus. Three weeks after 
the second immunization, NBe-specific cellular responses were assessed in IFN-specific ELISPOT using the octameric 
ATFNYTNV peptide for restimulation. A. Classification of viruses can be done according to a specific stretch of nucleotides in 
the hemagglutinin (HA) sequence (nucleotides 481-501), assigning them to one of either IBV lineage (B/Yamagata/16/88 or 
B/Victoria/02/87 lineage) 
15
. The corresponding amino acid sequence of the NB ectodomain of each virus is also shown. 
Residues deviating from the consensus sequence are shown bold in red. B. IFN-specific ELISPOT results after restimulation 
with the ATFNYTNV peptide. Shown is the average of the response of the three mice, each measured in triplicates, ±SD. 
 
It should be noted that the occurrence of specific mutations of the Y8 anchor residue is very low. One 
of the viruses with this feature is the first isolated IBV (B/Lee/40), passaged numerous times in in 
vitro systems, and a single primary isolate (B/Mississippi/UR06_0345/2007). However, the two other 
viruses with deviating NBe-sequence established themselves as epidemic strains and were included 
in the trivalent vaccines for the 1974-1979 seasons (B/Hong Kong/05/72 virus) and the 1984-1986 
seasons (B/USSR/100/83 virus). 
The consequences of these observations cannot be ignored. Using predictive online tools (NetMHC 
3.2 server; IEDB predictions), a substantial number of hits were identified showing high affinity of 
NBe-derived epitopes for a number of human HLA alleles (data not shown). Several of these hits 
correspond to the octameric ATFNYTNV murine H2-Kb specific epitope and are predicted to bind HLA-
molecules of the quite common A2-supertype. The identification of mutations in the NBe-sequence 
in epidemic strains interfere with this exciting finding. The potential natural occurrence of human 
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NBe-specific T cell responses in the population and influence of (common) NBe-mutations is under 
further scrutiny. The mere fact epidemic IBV strains, establishing themselves for a long period of time 
in the human population, contain mutations abolishing theoretical T cell recognition of the NB 
ectodomain, could reflect natural NBe-specific immunity. After all, for IAV, a number of strains have 
been identified bearing mutations in validated human NP epitopes, which have been linked to 
immune escape 16-18. 
Generally, any prophylactic or therapeutic strategy based on induction of cytotoxic T cells is 
restricted by the stringent characteristics imposed by the peptide-MHC-TCR interaction. In some 
instances, naturally presented epitopes have a low affinity for MHC binding, thus suboptimally 
inducing T cells. Using peptides with a high (predicted) affinity for their cognate MHC molecule as a 
replacement for epitopes naturally present in the target protein, so-called heteroclitic peptides, is a 
common approach used in e.g. cancer treatments 19. The main alterations introduced in heteroclitic 
compared to natural peptides are replacing anchor residues with those predicted to have a higher 
affinity for MHC binding. It is anticipated that using such a strategy will induce high number of T cells 
able to react both the inducing (high affinity) and the natural (low affinity) epitope. However, recent 
studies have shown that both in vitro and in vivo T cell repertoires induced by heteroclitic epitope 
based immunizations can differentiate between natural and sequence-optimized peptides 18,20,21. 
Hence, although predicted, the use of the consensus NBe-sequence might not induce T cells reactive 
to e.g. the alternative ATLNYTNV (5.6% prevalence, between 1999 and 2005) or ATFNYTNA 
sequences. Careful selection of cross-reactive or novel immune-dominant epitopes is warranted in 
such vaccination strategies18. 
 
Material and methods 
Mice, viruses and influenza challenges 
For all in vivo studies, 6-8 week old female mice were used. BALB/c mice were obtained from Charles River 
(Italy), C57Bl/6J mice from The Jackson Laboratory (France) and C3H/HeN mice from Harlan (The Netherlands). 
Mice were housed under specific pathogen-free conditions and fed ad libitum. All infection experiments were 
conducted under BSL-2 containment and were approved by the local Institutional Ethics Committee on 
Experimental Animals of Ghent University. 
Influenza virus infections were performed as described in the main text. Next to A/PuertoRico/08/34 and 
B/Memphis/12/97, other non-mouse-adapted influenza viruses used here include B/HongKong/05/72, received 
from Dr. Robert Sidwell 
22
, B/Harbin/04/97 and B/Yamagata/16/88. For sublethal infections with these, 7.5x10
4
 
pfu was inoculated, the equivalent of 0.075LD50 mouse-adapted B/Memphis/12/97. 
 
Construction and small-scale purification of tGCN4-based proteins 
Chimeric tGCN4-based proteins were constructed by PCR methods using primer sets containing the sequence 
of the epitope to be linked to tGCN4 and a sequence homologous to the N-terminal tGCN4 coding sequence. 
Upon amplification of epitope and tGCN4-Flag coding sequences, both were fused in frame through PCR. Fused 
sequences were cloned into pLT32H, as described in the main text. For protein expression, small-scale 
inductions (3mL) were performed based on the method described in the main text.  
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Purifications were done on a small-scale level. Briefly, 50µL of bacterial lysate after sonication (corresponding 
to 500µL bacterial culture) was incubated with 10µg mouse anti-Flag (Sigma) overnight in 500µL 
immunoprecipication (IP) buffer (10mM Tris/HCl pH7.4 + 150mM NaCl + 0.5% NP40 + 0.5% Triton X-100). 20µL 
of washed Protein G beads (GE Healthcare) was added to the antigen-antibody mixture and incubated for three 
hours. Next, beads were collected, washed three times with IP buffer and treated with 300µL 100mM sodium 
citrate pH3.0 for 30min at room temperature to elute the antibody-antigen complexes. Immediately after 
pelleting of the beads, the supernatant was collected and neutralized using 30µL 1M Tris pH8.8. The IP was 
analyzed on SDS-PAGE by loading 1/10 of each fraction (i.e. the input material, the unbound fraction and the 
eluted fraction) on gel. 
 
Immunization procedures 
Immunizations using NBe-HBc and P. pastoris produced NBe-tGCN4 (described in Chapter 3) were done with 
5µg of protein per immunization given i.p. in combination with Alhydrogel, as described in the main text. NBe-
M2 DNA was administered as a DNA vaccine by injecting 100µg LPS-free plasmid in 100µL PBS intramuscularly. 
For the heterologous boost, 0.075LD50 of IBV/Memphis/12/97 was given. Novel tGCN4-based proteins 
administered after IP purification were given ip. in combination with Alhydrogel in a volume of 300µL, using 
30µL eluted sample (appr. 1/10 of the eluate) diluted with PBS to 150µL and combined with 150µL diluted 
Alhydrogel. 
 
ELISA and IFN-specific ELISPOT procedure 
As described in the main text. 
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General discussion and perspectives 
 
Cross-protection induced by B/HA0-, BM2e- and NBe-based IBV vaccine candidates 
The current situation of influenza vaccination needs to be addressed urgently. Licensed trivalent 
vaccines, consisting of inactivated or life-attenuated viruses of influenza B (IBV) and the influenza A 
(IAV) A/H1N1 and A/H3N2 subtype, do provide strong sterilizing immunity to homologous or closely 
related strains. However, with influenza viruses constantly diversifying under vaccine or infection 
induced immunity, selection of an inappropriate seed strain to prepare vaccines will fail to induce 
protective immunity in vaccinated people 1. Specifically for IBV this is a contemporary problem. For 
IAV, two strains are included in vaccines, covering both H1N1 and H3N2 subtypes currently 
circulating in the population as seasonal viruses. IBV is not characterized by subtypes, but is 
subdivided in lineages (Victoria and Yamagata lineage) which are antigenically distinct 2-4. Inclusion of 
a single IBV strain in the vaccine, belonging to one of both lineages, entails a failure to choose a 
strain of the circulating lineage will lead to a vaccine mismatch. Indeed, the past decade, nearly one 
in two seasons has been characterized by a lineage mismatch between circulating and vaccine IBV 
strain, resulting in vaccine failure. This is particularly troublesome for people more sensitive to IBV 
infection and related complications, such as children and the elderly 5-7. Moreover, failure to protect 
vaccinees will diminish belief in the merit of influenza vaccination, and will have strong socio-
economic consequences. In this thesis we wanted to address the problem of IBV vaccination by 
exploring the protective efficacy of properly presented conserved features of the virus in a mouse 
model. With this, we wanted to add on to the wealth of information related research with IAV has 
given (Chapter 1) 8 and supplement the few studies into cross-protective IBV vaccine development 
(Chapter 2) 9-13. A general overview of observations made in this study, is given in Figure IV.1. 
We selected three different extravirionic epitopes, presented in high numbers on infected cells, as 
target antigens. The rationale for this was to, in analogy with the M2 ectodomain of IAV 14, develop a 
vaccine capable of inducing humoral immunity. These included the ectodomains of the BM2 and NB 
transmembrane proteins (BM2e and NBe, respectively) and the maturational cleavage loop of HA 
(B/HA0). To mimick their natural conformation as much as possible, specific carrier proteins and 
expression systems were selected. Insertion of B/HA0 in the immunodominant loop of HBc clearly 
induced virus specific antibodies, although challenge of immunized mice did not reveal protection. 
This is in strong contrast with the results of Bianchi et al. 9, who could protect mice with a B/HA0-
OMPC vaccine against challenge with IBV strains of different lineages. Minor differences in the 
antigen dose and challenge model might however explain this discrepancy. The B/HA0-HBc protein 
showed very low solubility, requiring dual expression of unsubstituted HBc and B/HA0-HBc to yield a 
soluble protein (termed 3004) with mixed substitution rate. Hence, while the OMPC vaccine induced 
very high B/HA0-specific titers, as assayed in B/HA0-peptide ELISA, 3004 induced only moderate virus 
specific titers (Fig. 4.6). Our challenge model is based on administering 4LD50 of IBV in a volume of 
50µL, while Bianchi et al. used 1LD90 in a volume of 20µL. The smaller volume and lower infectious 
dose (although a direct comparison of this is not possible), combined with a better immune 
response, might tilt the balance towards stronger protection. 
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The N-terminal NB ectodomain was presented by HBc in three different manners: a direct N-terminal 
fusion (1651), coupled to M2e2-HBc extending the accessibility of NBe (forming NM2H) or inserted in 
the immunodominant loop to improve the immunogenicity and accessibility (1646). Surprisingly, only 
1651 was able to provide protection against a potential lethal IBV infection. Even with the use of 
mouse-adapted B/Hong Kong/5/72 virus, containing a strongly deviating NBe-sequence as compared 
to the consensus sequence used for vaccine construction, NBe-HBc immunization can protect mice 
from excessive lethality. The presentation of NBe, providing a non-ligated free N-terminus, on a 
particulate HBc-protein appears to be superior to the more immunogenic 1646 particle. The NM2H-
protein, forming small aggregates but not particles, can thwart an IAV infection as efficiently as the 
M2e2-HBc particle, but fails to induce protective NBe-responses acting against an IBV infection. From 
the NBe-peptide ELISA is can be deduced the non-particulate NM2H protein elicits lower anti-NBe 
responses than 1651, most likely related to the T-cell independent induction of antibody responses 
by particulate HBc 15. Hence, it seems an immunogenic presentation of N-terminally presented NBe is 
required to provide effective protection against IBV. 
With BM2 and NB forming tetramers, we coupled the BM2e and NBe sequences to a tetramerizing 
variant of the leucine zipper of GCN4 (tGCN4). Four different formats were used: a short (5AA) and a 
long (8AA) BM2e-sequence coupled to tGCN4, NBe coupled to a triple Flag-tag bearing tGCN4 
scaffold and NBe-tGCN4 without tag produced in P. pastoris to achieve glycosylation of NBe (gNBe-
tGCN4), as naturally occurs 16,17. Using size-exclusion chromatography, native PAGE MW 
determination and chemical cross-linking experiments, tetramerization of the proteins was 
confirmed. Immunization of mice with tGCN4-based proteins revealed an extremely immunogenic 
protein format, eliciting carrier-specific antibody titers exceeding 107 endpoint dilution. Both BM2e-
based chimeras show induction of BM2- and IBV-reactive antibodies, protective against a potential 
lethal challenge with both B/Memphis/12/97 (Yamagata-like virus) and B/Hong Kong/5/72 (Victoria-
like virus). NBe-tGCN4-Flag on the other hand induces clear anti-NBe peptide responses, reactive 
with NBe-expressing transfected cells but only slightly with IBV infected cells. The main reason for 
this is most likely the glycosylation state of the three species. Using non-glycosylated NBe-tGCN4-
Flag, antibodies can be elicited reactive with transfected cells expressing NBe-proteins, since these 
display non-, mono- and di-glycosylated NBe (Fig. 3.16). For infected cells, the precise glycosylation 
state of NB within our in vitro system should be addressed, but could be more complex, disfavouring 
anti-NBe detection. Like for N-terminal NBe-HBc fusions, it simply might be a question of quantity. 
When comparing Alhydrogel and Montanide-ISA-720 adjuvanted NBe-tGCN4-Flag immunization, the 
latter induces higher anti-NBe titers and concomitantly provides better protection compared to the 
former. If anti-NBe responses could be boosted further, protection might be even more confiding. 
The observation the NBe-specific 15G5mAb can stain IBV infected cells, but is unable to protect mice, 
might also reflect a difference in accessibility of NBe in vitro and in vivo, something which should be 
investigated within our mouse model. Alternatively, it might reflect a qualitative problem, in that a 
polyclonal response evoked in vivo offers better IBV recognition and protection in vivo. 
The gNBe-tGCN4 protein displays glycosyl-structures less complex as determined on native NB 17, but 
do provide a general glycosylated form of NBe. As vaccine, it offers significant protection against a 
potential lethal B/Memphis/12/97 infection compared to bacterial expressed NBe-tGCN4-Flag, 
highlighting the merit of glycosylated NBe as antigen, even if glycosylation is far for complete. These 
observations were extended with the use of transfected cells as immunogens. In this case, NBe(WT)-
M2-Flag expressing cells induce significant protection compared to NBe(Mut)-M2-Flag expressing 
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cells. Obviously, the introduction of the mutations in the NBe sequence, removing the glycosylation 
sites, can affect the primary recognition of the wild type NBe sequence, although the inverse 
situation (recognition of NBe(Mut) by NBe(WT) antiserum) does not show problems of that sort. 
Nonetheless, NBe(WT)-M2-Flag con evoke significant protection, reinforcing the value of 
glycosylated NBe-vaccine constructs. Development of a cellular expressed and secreted NBe-based 
protein to further evaluate this is therefore warranted. 
In a number of set-ups, heat-inactivated IBV viruses were used as immunogen to assess homologous 
or heterologous protection. In general, no heterologous protection was observed in any of the 
experiments. This is in accordance with other animal studies 18, although under specific vaccination 
conditions the immune response evoked by inactivated IBV can be broadened to be reactive with 
both lineages 19. The method of inactivation used (30min incubation at 56°C) might destroy antigenic 
structures more than formalin or detergent inactivation. In humans, cross-reactive titers have been 
detected in primed individuals 18,20-22. Hence, it deems worthwhile to look for epitopes residing in HA 
responsible for the cross-reactivity. This could be achieved by e.g. reverse vaccinology as has been 
done for the LAH structure of IAV HA 23,24. 
As main conclusion it can be stated both BM2e- and glycosylated NBe-based vaccine candidates can 
offer significant protection against a potential lethal IBV infection. Anti-BM2e responses can afford 
protection against both Yamagata- and Victoria-like strains of IBV, making it a cross-protective 
vaccine basis. However, it should be stated protection seen is based purely on survival of challenged 
mice. When looking at morbidity, none of the cross-reactive vaccine candidates can avoid induction 
of morbidity when using 2.5LD50 or 4LD50 doses of challenge virus. Most likely, this is related to the 
mouse model, requiring high IBV doses (in pfu) for inducing lethality. Indeed, for assaying pulmonary 
virus replication we used appr. ten-fold lower doses, and in many instances this revealed stronger 
antiviral responses compared to controls. Hence, it would be interesting to retest the vaccine 
candidates described here in a low-dose challenge model, utilizing sublethal doses of e.g. 0.3LD50, 
and score protection based on prevention of morbidity.  
 
The NB ectodomain harbours a T cell epitope affording strong IBV protection 
In an attempt to improve NBe-tGCN4-Flag induced immunity, two other inbred mouse strains, 
C3H/HeN and C57Bl/6, were used next to Balb/c mice. Based on a small-level reduction in lung virus 
titers, further research uncovered a strong CD8+ T cell epitope within the NBe-sequence specific for 
the H2b-background of C57Bl/6 mice. We showed this epitope to induce cytotoxic effects towards 
peptide-pulsed cells and induce a strong impairment on virus replication in the lungs of immunized 
mice. Moreover, a sublethal infection with 0.3LD50 showed that NBe-based cellular immunity, 
although not neutralizing, can improve the clinical outcome of infected mice drastically. 
It is quite remarkable parenteral immunization with a soluble antigen (NBe-tGCN4-Flag), adjuvanted 
by aluminum salt, induced such strong cellular responses. Indeed, it is a central paradigm that for 
efficient induction of T cell responses, the intracellular pathway of antigen presentation needs to be 
followed. Known exceptions include the use of cell-penetrating peptides (CPP) or protein 
transduction domains (PTD), allowing direct delivery of the protein in the cytoplasm 25, or use of 
specific adjuvants which exert similar actions or which specifically activate immune cells such as 
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monocytes or dendritic cells (DCs) 26-30. DCs specifically possess the ability to cross-present 
exogenous antigens for the induction of cellular responses 31,32. The specific mechanisms responsible 
for T cell induction here remain unclear. One possibility is the formation of immune complexes (ICs), 
consisting of protein combined with a large amount of antibodies. ICs generally have a negative 
effect on immune responses, leading to exacerbation of disease or induction of autoimmune 
diseases 33-35. However, in some instances, they are used specifically in immunizations to induce 
cellular or humoral responses 36,37. With the tGCN4-Flag moiety of the protein being so immunogenic, 
it is not inconceivable free antigen (be it during priming or with boosting) is coated with antibody. 
Such ICs can be taken up by DCs through FcRI- (CD64-) mediated phagocytosis, leading to cross-
presentation of the antigen 38,39. Some evidence is in line with this theory. First of all, immunization 
of C57Bl/6 mice with NBe-peptide mixed with tGCN4-Flag protein, which is not immunogenic in the 
H2b-background, did not induce T cell responses (data not shown). Second,  other proteinaceous 
NBe-carrier protein fusions, based on the highly immunogenic HBc- or tagless tGCN4-scaffold 
(Chapter 5, Additional data), also induced NBe-specific T cell responses. And third, using a very low 
amount of chimeric proteins consisting of NP-epitopes fused to tGCN4-Flag in combination with 
mouse IgG1 anti-Flag antibodies, relative high T cell responses were evoked. Although circumstantial, 
it thus seems there is a link between high antibody responses and cellular responses. To address this, 
several models could be used. If for instance a chemical coupling of NBe-peptide and tGCN4-Flag is 
not immunogenic in the C57Bl/6, the influence of complexing the chemical conjugate with anti-
tGCN4-Flag antibodies could be assessed. Similarly, immunization of B cell deficient mice (e.g. 
IgMT/MT mice 40) or mice lacking FcRI  (CD64-/- mice) or the common FcR-chain could provide more 
insight. If so, the value of tGCN4-Flag or a highly immunogenic carrier in general in eliciting a broad 
(i.e. humoral and cellular) immune response would be enforced dramatically. 
A second intriguing observation was the fact cellular immunity induced by a single immunization with 
NBe-based immunogens (NBe-tGCN4-Flag, NBe-HBc, NBe-DNA) was boosted drastically by a 
sublethal IBV infection. Such a heterologous boost effect is encouraging, if it can efficiently be 
translated to human immunology. Recent clinical trials with HIV- or malaria-derived immunogens did 
show heterologous boost effects in humans when using DNA vaccines or viral vectors 41-43. The 
concept of ‘original-antigenic-sin’ is well-known, and anecdotic, epidemiological and immunological 
data has shown this concept can also be applied to influenza infections. Examples include data from 
past influenza pandemics 44,45, the IBV vaccination studies mentioned above 18-22 and any reverse 
vaccinology approach identifying cross-reactive antibodies 46. The derived vaccination strategy seems 
extremely appealing: any infection occurring after immunization based on a conserved viral feature 
would boost immunity further. A drawback of such an approach is that the immunity induced by the 
initial vaccination would not or cannot be neutralizing, since it has to allow a boosting effect by 
infection. However, it has become increasingly clear over the past few years that heterologous anti-
influenza immunity is naturally induced by repetitive heterologous infections 47,48. Hence, any 
vaccination strategy aiming at neutralizing infection will completely abrogate such an effect. The 
identification of the first murine CD8+ T cell restricted epitope of IBV in this thesis will allow future 
research to monitor the induction of heterosubtypic immunity against IBV by vaccine-induced non-
sterilizing immunity. Additionally, the cross-protective nature of this epitope, and other NBe- or IBV-
restricted epitopes specific for mouse and man, deserves future attention. 
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Influenza vaccination: The Good, The Bad and The Ugly 
In a sense, influenza vaccination tactics can be coined as ‘The Good, The Bad and The Ugly’. 
Conventional vaccination with inactivated viruses will induce a strong anti-HA response able of 
neutralizing homologous infection completely; The Good. However, a vaccine mismatch will not 
allow protection induced by such a vaccination, leading to a lack of protection of vaccinees: The Bad. 
Using vaccines based on CTL epitopes, certain HA epitopes, M2e of IAV and BM2e or NBe or IBV, 
infection would not be neutralized, inducing some clinical symptoms: The Ugly. However, as 
indicated by animal studies 49-53, these symptoms could be subdued to subclinical levels, and 
immunity towards (other) cross-reactive epitopes would be favored and built up over time. Like 
many other research groups 54, we feel this is the way forward for inducing effective influenza 
immunity, exploiting natural mechanisms for heightening heterologous immunity.  
One main consideration to take into account when using an infection-permissive vaccination 
approach, either antibody or CTL inducing, is the effect this could have on viral antigenic selection 
and evolution. Immunity directed against a single or a select set of epitopes might drive the selection 
of viruses containing specific mutations within these epitopes. This is clear from conventional 
influenza vaccination using TIV vaccines or sequential infection, which drives antigenic mutation of 
HA and NA and selects for CTL epitope variants 55-58. Additionally, sequential infection of mice in the 
presence of M2e-directed antibodies has been shown to induce mutations within the M2e-sequence 
59. However, in many instances, such escape is limited because of ramifications on viral fitness. For 
instance, the M2-escape mutants detected in the study by Zharikova et al. were limited to a single 
residue (P10) 59, a mutation which does not influence its recognition by polyclonal anti-M2e sera 
(unpublished data). CTL escape mutations on the other hand often have detrimental effects on viral 
fitness and require compensatory co-mutations 60-63. This might be more challenging to overcome 
from a vaccination point-of-view, although a certain flexibility in epitope sequence is allowed for 
recognition by CTLs 64,65. 
A more difficult question to address in preclinical settings is the effect infection-permissive vaccines 
could have on general evolution of influenza viruses. Under neutralizing pressure, only viruses able to 
escape immunity before initial infection will be able to generate progeny; when host immunity 
matches circulating seasonal strains, the level of viruses circumventing antiviral immunity will be 
rather low. Under infection-permissive immunity, selection of escape variants will occur both before 
(for antibody-inducing vaccines) and after initial infection. This entails selection of escape mutants 
could occur more rapidly. It is also not inconceivable this will drive evolution of influenza viruses as a 
whole faster than neutralizing immunity will do. Moreover, infection-permissiveness will also allow a 
higher level of progeny virus to be produced, which in turn could lead to higher transmissibility of 
(selected) viruses, fueling selection of escape variants and evolution even further. Theoretically, this 
means infection-permissive vaccines could have more detrimental than beneficial effects on the level 
of viral ecology. It remains unclear if broad immunity induced by infection-permissive vaccines can 
keep up with vaccine-induced viral evolution.  
To date, the use of live attenuated influenza vaccines (LAIV) has not been reported to speed up 
antigenic evolution of seasonal influenza virus. Since such vaccines stimulate both the humoral and 
cellular arm of the immune system, they induce combined strain-specific neutralizing immunity and 
heterosubtypic broad infection-permissive immunity 66,67. For single-epitope based infection-
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permissive vaccines it might also be worthwhile to combine them with a vaccine inducing 
neutralizing immunity, to cover all bases. This has been shown advantageous for M2e-
supplementation of conventional inactivated vaccines 68,69 and hence might be extended to other 
antigenic targets. Future will tell if  such strategies are feasible and achievable for human influenza 
vaccination. 
 
 
HA NA BM2NB
NBe: low-level protection induced by        
N-terminal soluble presentation 
(1651, NBe-tGCN4-Flag)
gNBe: stronger protection, limiting viral 
replication
(gNBe-tGCN4, NBe(WT)-M2-Flag)
NBe-CTL: strong impairment of viral 
replication and protection from 
morbidity, allowing viral boost effect
BM2e: induction of cross-protective (Victoria- and 
Yamagata-strain specific) immunity
BM2: induction of low-protective immunity
Inactivated virus: no induction of cross-
lineage protection
B/HA0: no induction of protective 
immunity
 
Figure IV.1. Overview of  (non-)protective immune responses observed in this thesis. 
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Algemene discussie en perspectieven 
 
Kruisbescherming geïnduceerd door B/HA0-, BM2e- en NBe-gebaseerde IBV kandidaat-vaccins 
De huidige situatie van influenza vaccinatie moet dringen herbekeken worden. Goedgekeurde 
trivalente vaccins, bestaande uit geïnactiveerde of levend verzwakte virussen van influenza B (IBV) en 
de influenza A (IAV) A/H1N1 en A/H3N2 subtypen, geven sterke steriliserende bescherming tegen 
homologe of sterk gerelateerde stammen. Echter, gezien influenza virussen continue diversifiëren 
onder druk van vaccinatie of infectie geïnduceerde immuniteit, zal een verkeerde keuze van stam om 
vaccins aan te maken niet leiden tot inductie van beschermende immuniteit in gevaccineerde 
personen 1. Specifiek voor IBV is dit een hedendaags probleem. Voor IAV worden twee stammen 
ingesloten in vaccins, behorende tot zowel het H1N1 als H3N2 subtype die momenteel circuleren in 
de menselijke populatie als seizoensgebonden stammen. IBV wordt weliswaar niet gekenmerkt door 
virus subtypes, maar er worden wel twee antigenisch verschillende lijnen erkend (de Victoria en de 
Yamagata lijn) 2-4. Inclusie van slechts één IBV stam in het vaccin, behorende tot één van de twee 
lijnen, houdt in dat de keuze van een stam die tot de tegenovergestelde lijn behoort dan deze die 
circuleert zal leiden tot een vaccin mismatch. Het is inderdaad zo dat in het afgelopen decennium 
bijna de helft van de griepseizoenen gekenmerkt werden door een lijn mismatch tussen IBV 
vaccinstam en circulerende stam. Dit is vooral problematische voor personen die extra gevoelig zijn 
voor IBV infectie en afgeleide complicaties, zoals kinderen en ouderen 5-7. Bovendien zal het niet 
beschermen van gevaccineerde personen het geloof in de voordelen van influenza vaccinatie teniet 
doen, wat zware socio-economische gevolgen kan hebben. In deze thesis wilden we probleem 
omtrent IBV vaccinatie aankaarten door het beschermend effect van op gepaste wijze 
gepresenteerde geconserveerde delen van IBV na te gaan in een muismodel. Zodoende wilden we 
bijdragen tot de weelde aan informatie dat gerelateerd onderzoek met IAV heeft opgeleverd 
(Hoofdstuk 1) 8 en de schaarse studies rond kruisbeschermende IBV vaccins te ondersteunen 
(Hoofdstuk 2) 9-13. Een algemeen overzicht van vaststellingen gemaakt in deze studie is gegeven in 
Figuur IV.1. 
We hebben als doelwit antigenen drie verschillende extravirionische epitopen gekozen, in 
aanzienlijke aantallen gepresenteerde door geïnfecteerde cellen. De idee achter dit was om in 
analogie met het M2 ectodomain van IAV 14 een vaccin te ontwikkelen dat humorale immuniteit kan 
opwekken. De gekozen antigenen omvatten het ectodomain van het BM2 en NB 
transmembraaneiwit (respectievelijk BM2e en NBe) en de klievingssequentie van HA (B/HA0). Om 
hun natuurlijke conformatie zo goed mogelijk na te bootsen werden specifieke dragereiwitten en 
expressiesystemen gekozen. Insertie van B/HA0 in de immunodominante lus van HBc kon duidelijk 
virusspecifieke antilichamen induceren, alhoewel infectie van geïmmuniseerde muizen geen 
bescherming kon aantonen. Dit is in schril contrast met de studie van Bianchi et al. 9 die met behulp 
van een B/HA0-OMPC vaccine muizen konden beschermen tegen infectie met IBV stammen van de 
verschillende lijnen. Kleine verschillen in de antigendosis en het infectiemodel kunnen deze 
discrepantie echter verklaren. Het B/HA0-HBc eiwit toonde een lage oplosbaarheid en vroeg om 
dubbelexpressie van zowel vrij HBc als B/HA0-HBc om een oplosbaar product te geven (3004 
genaamd) met gemengde substitutiegraad. Terwijl het OMPC vaccin duidelijke hoge B/HA0-
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specifieke antilichaamtiters kon opwekken, bepaald in B/HA0-peptide specifieke ELISA, kon 3004 
slecht gemiddelde virusspecifieke titers opwekken (Fig. 4.6). Ons infectiemodel is gebaseerd op 
toediening van 4LD50 IBV in een volume van 50µL, terwijl Bianchi et al. een dosis van 1LD50 gebruikten 
in een volume van 20µL. Het kleiner volume en lagere virusdosis (alhoewel een exacte vergelijking 
van dit niet mogelijk is), gecombineerde met een betere immuunrespons de balans kan doen 
overhellen naar robuuste bescherming. 
Het N-terminale NB ectodomain werd met behulp van HBc gepresenteerd op drie manieren: een 
directe N-terminale fusie (1651), gekoppeld aan M2e2-HBc (NM2H) om de bereikbaarheid van NBe te 
verhogen of ingevoegd in de immunodominante lus van HBc om zowel immunogeniciteit als 
bereikbaarheid te verhogen (1646). Verassend genoeg had enkel 1651 de mogelijkheid om 
beschermende immuniteit op te wekken tegen een potentieel letale dosis IBV. Zelfs gebruik 
makende van muisgeadapteerd B/Hong Kong/05/72 virus, met een sterk afwijkende NBe-sequentie 
in vergelijking met de consensus sequentie gebruikt voor vaccin constructie, kon NBe-HBc muizen 
beschermen tegen excessieve letaliteit. De presentatie van NBe, met een vrije N-terminus, op een 
partikelvormend HBc-eiwit blijkt superieur te zijn in vergelijking met het meer immunogene 1646 
partikel. Het NM2H eiwit, dat kleine aggregaten vormt in plaats van partikels, kan weliswaar even 
efficiënt als M2e2-HBc een IAV infectie afzweren, maar kan geen beschermende NBe-responsen 
opwekken effectief tegen een IBV infectie. Uit de NBe-peptide specifieke ELISA kan afgeleid worden 
dat het niet-partikelvormig NM2H eiwit lagere anti-NBe responsen opwekt dan 1651, waarschijnlijk 
gelinkt aan de T cel onafhankelijke inductie van antilichaamresponsen door partikelvormig HBc 15. 
Het blijkt dus dat een immunogene presentatie van N-terminaal gepresenteerd NBe nodig is om 
afdoende bescherming op te wekken tegen IBV. 
Gezien BM2 en NB tetrameren vormen, hebben we BM2e en NBe gekoppeld aan een 
tetrameriserende variant van de leucine zipper van GCN4 (tGCN4). Vier verschillende fusies werden 
gebruikt: een korte (5AA) en een langere (8AA) BM2e-sequentie gekoppeld aan tGCN4, NBe 
gekoppeld aan tGCN4 met een C-terminale driedubbele Flag-sequentie en NBe-tGCN4 geproduceerd 
door P. pastoris om glycosylatie van NBe te bekomen (gNBe-tGCN4), wat tijdens infectie ook gebeurt 
16,17. Door middel van chromatografische analyse, natieve PAGE en chemische cross-linking 
experimenten konden we tetramerisatie van de eiwitten bevestigen. Immunisatie van muizen met de 
tGCN4-gebaseerde eiwitten toonde aan dat het een extreem immunogene eiwitvorm is, met inductie 
van antilichaamtiters die 107 eindpuntsverdunning overschrijden. Beide BM2e-gebaseerde chimeren 
tonen inductie van BM2- en IBV-specifieke antilichamen, die bescherming kunnen bieden tegen een 
potentieel letale infectie met zowel B/Memphis/12/97 (een Yamagata-lijn virus) als 
B/HongKong/5/72 (een Victoria-lijn virus). NBe-tGCN4-Flag op zijn beurt induceert duidelijke anti-
NBe responsen die reageren met NBe-expresserende getranfecteerde cellen, maar slechts lichtjes 
IBV geïnfecteerde cellen. De hoofdreden voor dit verschil is waarschijnlijk de glycosylatiestatus van 
de drie species. Door niet-geglycosyleerd NBe-tGCN4-Flag te gebruiken worden antilichamen 
opgewekt die reageren met getransfecteerde cellen die NBe-eiwitten expresseren, aangezien deze 
zowel niet-, mono- als di-geglycosyleerd NBe dragen (Fig. 3.16). Voor geïnfecteerde cellen is de 
exacte glycosylatiestatus van NB binnen ons in vitro systeem niet gekend maar kan complexer zijn en 
kan zo anti-NBe detectie benadelen. Zoals bij de N-terminale NBe-HBc fusies kan het silpelweg een 
kwestie van hoeveelheid zijn. Wanneer we immunisaties met NBe-tGCN4-Flag geadjuvanteerd met 
Alhydrogel en Montanide-ISA-720 vergelijken kan de laatste hogere anti-NBe titers induceren en 
biedt bijgevolg betere bescherming.  Als anti-NBe responsen verder verhoogd zouden kunnen 
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worden, kan de bescherming nog meer sluitend zijn. De vaststelling dat het NBe-specifieke 15G5mAb 
IBV geïnfecteerde cellen kan kleuren, maar muizen niet kan besschermen, kan ook een verschil in 
beschikbaarheid van NBe in vitro en in vivo reflecteren, iets dat onderzocht zou moeten worden 
binnen ons muismodel. Alternatief kan het ook een kwalitatief probleem voorstellen, waarbij een in 
vivo opgewekte polyklonale respons betere IBV herkenning en bescherming geeft in vivo. 
Het gNBe-tGCN4 eiwit draagt glycosylstructuren die minder complex zijn als op natief NB 17, maar 
geven wel een algemeen geglycosyleerde vorm van NBe. Als vaccin kan het significant meer 
bescherming bieden tegen een mogelijks letale infectie met B/Memphis/12/97 in vergelijking met 
NBe-tGCN4-Flag, wat het voordeel van een geglycosyleerd NBe als antigen verder onderstreept. Deze 
vaststelling werd verder uitgebreid  door het gebruik van getransfecteerde cellen als immunogen. In 
deze opstelling konden NBe(WT)-M2-Flag expresserende cellen significante bescherming opwekken 
in vergelijking met NBe(Mut)-M2-Flag expresserende cellen. De introductie van mutaties in de NBe-
sequentie om glycosylatie te vermijden kan uiteraard herkenning van de wild type NBe-sequentie 
verhinderen, alhoewel de inverse situatie (herkenning van NBe(Mut) door immuunserum opgewekt 
met NBe(WT)) geen gelijkaardige problemen toont. Desalniettemin, NBe(WT)-M2-Flag kan 
significante bescherming opwekken, wat verder het voordeel van een geglycosyleerd NBe-vaccin 
onderstreept. De ontwikkeling van een cellulair geproduceerd en gesecreteerd NBe-eiwit om dit 
verder te evalueren is daarom zeer aangewezen. 
In een aantal opstellingen werden hitte-geïnactiveerde IBV virussen aangewend als immunogen om 
homologe en heterologe bescherming na te gaan. Algemeen gezien kon geen heterologe 
bescherming worden vastgesteld. Dit is in overeenkomst met andere dierstudies 18, alhoewel onder 
specifieke condities van vaccinatie de immuunrespons opgewerkt door geïnactiveerd IBV verbreed 
kan worden om reactief te zijn met beide lijnen 19. De methode voor inactivatie (30min incubatie bij 
56°C) kan antigenische structuren meer vernietigen als formaline of detergens inactivatie. Bij mensen 
kunnen kruisreactieve titers gedetecteerd worden in voorheen geïmmuniseerde personen 18,20-22. Het 
lijkt dus de moeite waard om epitopen te identificeren aanwezig in HA die verantwoordelijk zijn voor 
kruisreactiviteit. Dit kan gerealiseerd worden door bv. reverse vaccinology, zoals uitgevoerd voor 
identificatie van de LAH structuur in IAV HA 23,24. 
Als algemeen besluit kan gesteld worden dat zowel BM2e- als geglycosyleerd NBe-gebaseerde 
kandidaatvaccins aanzienlijke bescherming kunnen bieden tegen een mogelijk letale IBV infectie. 
Anti-BM2e responsen kunnen bovendien bescherming bieden tegen zowel Yamagata- als Victoria-lijn 
IBV stammen, wat het een kruisbeschermende vaccin basis maakt. Het moet echter vermeld worden 
dat de detectie van bescherming gebaseerd is op overleving van geïnfecteerde muizen. Wanneer 
naar morbiditeit wordt gekeken, kan geen enkel kruisbeschermend kandidaatvaccin morbiditeit 
vermijden wanneer dosissen van 2.5LD50 of 4LD50 gebruikt worden. Dit is waarschijnlijk gerelateerd 
aan het muismodel, waarbij hoge dosissen (uitgedrukt in pfu) nodig zijn om letaliteit te induceren. 
Om pulmonaire replicatie van virus na te gaan word een ongeveer 10voudig lagere dosis gebruikt 
voor infectie, en dit toonde in veel gevallen inderdaad sterkere antivirale responsen in vergelijking 
met controles. Het is dus interessant om de vaccinkandidaten hier beschreven te hertesten in een 
lage-dosis infectiemodel, gebruik maken van bv. dosissen van 0.3LD50, en bescherming na te gaan op 
basis van het voorkomen van morbiditeit. 
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Het NB ectodomein bevat een T cel epitoop dat sterke bescherming tegen IBV biedt 
In een poging om immuniteit opgewekt door NBe-tGCN4-Flag te verhogen, werden naast Balb/c 
muizen twee andere inteeltstammen gebruikt, C3H/HeN en C57Bl/6. Vertrekkende van een kleine 
reductie in long virustiters kon verder onderzoek een sterk CD8+ T cel epitoop identificeren binnen de 
NBe-sequentie, specifiek voor de genetische H2b-achtergrond van C57Bl/6 muizen. We konden 
aantonen dat dit epitoop cytotoxische effecten kan opwekken gericht tegen peptide-opgeladen 
cellen en een sterke reductie in virusreplicatie in de longen van geïmmuniseerde muizen kan 
opwekken. Bovendien kon NBe-gebaseerde cellulaire immuniteit, ook al is ze niet neutraliserend, de 
klinische afloop van muizen geïnfecteerd met een subletale dosis van 0.3LD50 drastisch verbeteren. 
Het is opmerkelijk dat parenterale immunisatie met een oplosbaar antigen (NBe-tGCN4-Flag), 
geadjuvanteerd door een aluminiumzout, dergelijke sterke cellulaire responsen kan induceren. Een 
van de centrale paradigma’s voor de efficiënte inductie van T cel responsen stelt immers dat in dit 
geval de intracellulaire weg voor antigenpresentatie gevolgd moet worden. Gekende uitzonderingen 
omvatten het gebruik van celpenetrerende peptiden (CPP) of eiwittransductie domainen (PTD) die 
directe aflevering van het eiwit in het cytoplasma toelaten 25, of het gebruik van specifieke adjuvantia 
met gelijkaardige effecten of die immuuncellen zoals monocyten of dendritische cellen (DCs) kunnen 
activeren 26-30. DCs bezitten specifiek de eigenschap om exogene antigenen te kruispresenteren, 
leidend tot de inductie van cellulaire responsen 31,32. Het specifieke mechanisme verantwoordelijk 
hier voor de inductie van T cellen blijft echter onduidelijk. Eén mogelijkheid is de vorming van zgn. 
immuuncomplexen (ICs), bestaande uit eiwit gebonden door een grote hoeveelheid antilichamen. 
Algemeen gezien hebben ICs een negatief effect op immuunresponsen, leiden tot een ontsporing van 
ziekte of inductie van auto-immuun afwijkingen 33-35. In sommige gevallen echter kunnen ze specifiek 
aangewend worden bij immunisaties om cellulaire en humorale responsen op te wekken 36,37. 
Aangezien het tGCN4-Flag deel van het vaccin zo immunogeen is, is het aannemelijk dat vrij antigen 
(tijdens de initiële immunisatie of bij verdere immunisaties) bedekt wordt door antilichamen. Zo 
gevormde ICs kunnen vervolgens opgenomen worden door DCs via FcRI- (CD64-) gemedieerde 
fagocytose, resulterend in kruispresentatie van het antigen 38,39. Een aantal vaststellingen steunen 
deze theorie. Ten eerste, immunisatie van C57Bl/6 muizen met een mengsel van NBe-peptide en 
tGCN4-Flag, wat niet immunogeen is in deze muizen, kon geen T cel responsen opwekken (data niet 
getoond). Ten tweede, andere NBe-dragereiwit fusies die als proteïne toegediend werden, zijn 
gebaseerd op het sterk immunogene HBc en tGCN4 (Hoofdstuk 5, Additionele data); ook deze 
konden NBe-specifieke T cel responsen opwekken. En ten derde, door gebruik te maken van een lage 
hoeveelheid chimeer eiwit bestaande uit een NP-epitoop gefusioneerd aan tGCN4-Flag in combinatie 
met muis IgG1 anti-Flag antilichamen, konden relatief hoge T cel responsen opgewekt worden. 
Alhoewel indirect duiden deze vaststellingen aan dat er een link is tussen hoge antilichaamresponsen 
en cellulaire responsen. Om dit te bevestigen kunnen verschillende modellen gebruikt worden. Als 
bv. een chemische koppeling van NBe-peptide en tGCN4-Flag niet immunogeen blijkt in C57Bl/6 
muizen, kan het effect van anti-tGCN4-Flag antilichamen op de cellulaire immuunrespons bekeken 
worden. Analoog kan immunisatie van B cel deficiënte muizen (bv. IgMT/MT muizen 40) of muizen 
zonder FcRI (CD64-/- muizen) of de gemeenschappelijke FcR-keten meer inzicht geven. Indien 
aantoonbaar wordt de waarde van tGCN4-Flag, of een gelijkaardige immunogene drager in het 
algemeen, in het induceren van een breed (t.t.z. humoraal en cellulair) immuun antwoord aanzienlijk 
versterkt worden. 
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Een tweede intrigerende vaststelling was het feit dat cellulaire immuniteit opgewekt met een enkele 
vaccinatie met een NBe-gebaseerd immunogen (NBe-tGCN4-Flag, NBe-HBc, NBe-DNA) aanzienlijk 
kon verhoogd worden door een subletale IBV infectie. Een dergelijk heterologe boosteffect is 
stimulerend, als het efficiënt vertaald kan worden naar humane immunologie. Recente klinische 
testen met HIV of malaria afgeleide antigenen konden dergelijke effecten aantonen in mensen, 
wanneer gebruik gemaakt werd van DNA vaccins of virale vectoren 41-43. Het begrip van de ‘originele 
antigenische zonde’ is gekend, en anekdotische, epidemiologische en immunologische data hebben 
aangetoond dat dit begrip ook toepasbaar is op influenza infecties. Voorbeelden omvatten data van 
voorbije influenza pandemieën 44,45, de IBV vaccinatie studies hierboven vermeld 18-22 en elke reverse 
vaccinology benadering die kruisreactieve antilichamen heeft kunnen identificeren 46. De afgeleide 
vaccinatie strategie is aantrekkelijk: elke infectie die plaatsvindt na immunisatie met een 
geconserveerd viraal kenmerk zal immuniteit versterken. Een nadeel van deze aanpak is echter dat 
de immuniteit opgewekt door de initiële vaccinatie niet kan of niet mag neutraliserend zijn, 
aangezien het een boost effect door infectie moet toelaten. De laatste jaren is het echter duidelijk 
geworden dat heterologe anti-influenza immuniteit natuurlijk wordt opgewekt door herhaaldelijke 
heterologe infecties 47,48. Zodoende zal elke vaccinatie strategie die neutraliserende immuniteit 
opwekt een dergelijk effect blokkeren. De identificatie van het eerste muriene CD8+ T cell epitoop 
voor IBV in deze thesis zal verder onderzoek toelaten de inductie van heterologe immuniteit tegen 
IBV door vaccin geïnduceerde niet-steriliserende immuniteit te volgen. Daarnaast verdienen het 
kruisbeschermend potentieel van dit epitoop, en andere NBe- of algemeen IBV-afgeleide epitopen 
specifiek voor de muis en de mans, meer aandacht. 
 
Influenza vaccinatie: The Good, The Bad and The Ugly 
In zekere zin kan influenza vaccinatie omschreven worden met het adagium: “The Good, The Bad and 
The Ugly”. Conventionele vaccinatie met geïnactiveerde virussen zal sterke anti-HA respons 
induceren, die infectie met een homologe virusstam kan neutraliseren: The Good. Een mismatch 
tussen vaccin en circulerende virusstam zal echter geen bescherming kunnen bieden bij 
gevaccineerde personen: The Bad. Wanneer gebruik gemaakt wordt van CTL epitopen, bepaalde HA 
epitopen, M2e van IAV en BM2e of NBe van IAV voor vaccinconstructie, zal infectie niet 
geneutraliseerd worden, waarbij lichte symptomen geïnduceerd zullen worden: The Ugly. Echter, 
deze symptomen kunnen tot subklinisch niveau herleid worden, zoals aangetoond door dierstudies 
49-53, en immuniteit tegenover (andere) kruisbeschermende epitopen zou bevoordeeld worden en 
opgebouwd worden met de tijd. Zoals andere onderzoeksgroepen 54 is het onze mening dat dit de 
juiste aanpak is om effectieve immuniteit op te wekken tegen influenza, gebruik makend van 
natuurlijke mechanismen om heterologe immuniteit op te bouwen.  
Een belangrijke bedenking die gemaakt kan worden betreffende het gebruik van infectiepermissieve 
vaccins, zowel antilichaam als CTL inducerend, is het effect deze kunnen hebben op antigenische 
selectie and evolutie van influenza virus. Immuniteit gericht tegen een enkel of een beperkte groep 
van epitopen zou de selectie van virussen met specifieke mutaties binnen deze epitopen kunnen 
drijven. Dit is zo voor conventionele vaccinatie met geïnactiveerde virussen of sequentiële infectie, 
wat de antigenische variatie van HA en NA beïnvloedt en selecteert voor CTL epitoop mutanten 55-58. 
Bovendien werd aangetoond dat na opeenvolgende rondes van influenza A infectie in muizen in de 
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aanwezigheid van anti-M2e antilichamen, mutaties worden geïnduceerd in de M2e-sequentie 59. 
Echter, meestal is dergelijke omzeiling van immuniteit door mutatie beperkt door weerslag op de 
virale fitness. Zo waren bvb. de M2e-mutanten gedetecteerd in de studie van Zharikova et al. beperkt 
tot een enkel residu 59, een mutatie die geen invloed heeft op de herkenning van M2e door 
polyklonale sera (ongepubliceerde data). CTL-epitoop mutaties op hun beurt hebben vaak een zware 
terugslag op viabiliteit van het virus en vragen om compenserende co-mutaties 60-63. Vanuit een 
vaccinatie standpunt kan dit een uitdaging zijn om te omzeilen en verhelpen, alhoewel een zekere 
flexibiliteit in epitoopsequentie toegelaten is voor herkenning door CTLs 64,65. 
Een moeilijkere vraag om te beantwoorden via preklinische testen is het effect infectiepermissieve 
vaccins zouden kunnen hebben op de algemene evolutie van influenzavirus. Onder neutraliserende 
druk zullen enkel virussen die vóór de initiële infectie immuniteit kunnen omzeilen nageslacht geven; 
wanneer de immuniteit van de gastheer overeenstemt met circulerende virusstammen, zal zo het 
niveau van virussen dat antivirale immuniteit kan ontwijken relatief laag liggen. Onder 
infectiepermissieve immuniteitsdruk zal de selectie van mutante virussen zowel vóór (voor 
antilichaaminducerende vaccins) als na de initiële infectie gebeuren. Dit houdt in dat de selectie van 
virussen die immuniteit omzeilen sterker zal zijn en vlugger kan gebeuren. Het is ook niet 
ondenkbaar dat dit de evolutie van influenzavirussen in het algemeen meer kan leiden dan 
neutraliserende immuniteit dit kan. Bovendien zal infectiepermissiviteit ook toelaten dat er een 
hoger aantal virussen geproduceerd wordt bij infectie, wat kan leiden tot hogere transmissie van 
(geselecteerde) virussen en zo verder selectie en evolutie van virussen kan drijven. Theoretisch kan 
dit inhouden dat infectiepermissieve vaccins meer nadelen dan voordelen kunnen hebben op het 
niveau van virale ecologie. Het blijft onduidelijk of de brede immuniteit geïnduceerd door 
infectiepermissieve vaccins de vaccin-geïnduceerde virale evolutie kan bijbenen. 
Tot nog toe werd niet bericht over een eventuele invloed die levend geattenueerde influenza 
virussen (LAIV) als vaccin hebben op de evolutie van seizoensgriep. Aangezien dergelijke vaccins 
zowel de humorale als de cellulaire arm van het immuunsysteem activeren, induceren ze zowel 
stamspecifieke neutraliserende immuniteit als brede heterosubtypische infectiepermissieve 
immuniteit 66,67. Voor infectiepermissieve vaccins gebaseerd op een enkel epitoop kan het de moeite 
zijn deze te combineren met een vaccin dat neutraliserende immuniteit opwekt, om zo op beide 
paarden te wedden. Dit werd al voordelig aangetoond voor M2e-supplementatie van conventionele 
geïnactiveerde vaccins 68,69 en kan misschien ook toegepast worden op andere antigenen. De 
toekomst zal uitwijzen of een dergelijke aanpak doenbaar en haalbaar is voor influenza vaccinatie 
van de menselijke populatie. 
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HA NA BM2NB
NBe: lage bescherming opgewekt door        
N-terminale oplosbare presentatie 
(1651, NBe-tGCN4-Flag)
gNBe: sterkere bescherming, met limiterend 
effect op virale replicatie in de long
(gNBe-tGCN4, NBe(WT)-M2-Flag)
NBe-CTL: sterke beperking van virale 
replicatie, met bescherming tegen 
morbiditeit en vatbaarheid voor 
boost door infectie
BM2e: inductie van kruisbescherming 
(Victoria- and Yamagata-lijn specifiek) 
BM2: inductie van laag-effectieve bescherming
Geïnactivateerd virus: geen inductie van 
kruisbescherming
B/HA0: geen inductie van beschermende 
immuniteit
 
Figuur IV.1. Overzicht van (niet-)beschermende immuunresponsen vastgesteld in deze thesis. 
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Voila, we zijn er… Na iets meer als zeven jaar zit het erop. Het is uiteindelijk een iets langere reis 
geworden dan voorzien, maar soit! Sommigen betitelen deze laatste hordes van schrijven en 
verdedigen als een formaliteit; ook al is dat in zeker zin wel zo, het voelt in ieder geval niet zo aan. 
Het zijn toch nog serieuze hordes die genomen moeten worden en zelfs mijn ‘immer onbreekbare 
stressbestendigheid’ heeft het op sommige momenten begeven.  
Gezien de lengte van mijn verblijf in het DMBR tot nu toe, moet ik natuurlijk heel wat mensen 
bedanken binnen en buiten het labo. En we beginnen natuurlijk bij de bron. Xavier, bedankt voor de 
wetenschappelijke en soms ook morele steun van de afgelopen jaren. Experimenteel gezien liep het 
niet altijd van een leien dakje, maar desalniettemin heb ik het wetenschappelijk inzicht dat ik bezit 
grotendeels verworven dankzij jou. Zeker ook je inzet de afgelopen maanden om alles rond te krijgen 
kon ik zeker appreciëren; ik heb waarschijnlijk geen totaalbeeld van de moeite die je hebt moeten 
doen, dus zeker bedankt daarvoor. Ik ben ervan overtuigd dat in de komende periode onze 
samenwerking vruchtvol en interessant zal zijn! 
Willy en Marina, jullie waren eigenlijk degene die mij in het labo ingelijfd hebben. Dankzij jullie en 
Elke ben ik (rustig weg) begonnen met het influenza B werk wat mij toch wel enkele jaren heeft zoet 
gehouden…! Jullie lagen ook aan de basis van mijn beginstapjes in de wereld van kloneren en muizen 
hanteren, waarvoor dank! 
Prof. Fiers, ik denk dat iedereen het over eens is dat uw blijvende inzet en interesse in de 
wetenschap uitermate bewonderenswaardig zijn en blijven. Zelfs bij herhaaldelijke tegenslag of 
doodlopende weg blijft u aan alternatieven of oplossingen denken. Uw ongebreideld geloof in 
projecten die u actief opvolgt is inspirerend te noemen. 
Na zeven jaar in het labo heb ik uiteraard heel wat mensen zien komen en gaan. Karim, immer stil en 
rustig, maar met een inzet die tegen alle frustraties en tegenslagen in kan gaan. Jou 
doorzettingsvermogen kan alleen maar stimulerend werken! Els, ook jij was een doorbijter, maar 
vooral kon je goed van jezelf afbijten… Mostafa en Jonas, jullie hebben de hybridoma techniek in ons 
labo binnengebracht; maar misschien interessanter waren de gesprekken die we daarnaast gevoerd 
hebben. En ik zal zeker nooit die ene editie van het VIB seminarie vergeten (ook al herinner ik me 
blijkbaar niet meer alles…); wie erbij was, weet wel waarover het gaat. Wouter, je was erbij van in 
het begin van mijn tijd in het labo (en misschien wel een extra drijfveer om er te blijven ;-)) en hebt 
mij dan ook veel basistechnieken aangebracht en véél geholpen bij mijn eerste eiwitzuiveringen. 
Maar daarbuiten was je vooral een plezanten om mee op stap te gaan en es goe te zeveren! Francis, 
jij hebt er mij toe aangezet zonder veel poespas op de Akta te leren werken; een man die van 
aanpakken weet! Maar ook wel megaschattig als hij ietwat beneveld nog ‘guanidinium 
hydrochloride’ probeert uit te spreken… Kimberly, ook al was je niet direct mijn type, ik vond het een 
supertrieste dag toen je besliste om ons te verlaten. Ook al betreurde ik die keuze, ik bewonder wel 
dat je ze kon maken. Het was even aanpassen aan de stilte die volgde, maar das wel gelukt! Wanneer 
is je trouw nu eigenlijk ook alweer gepland? Veronique, jouw beslissing om het ergens anders te 
proberen kwam nog onverwachter, maar ik vond ze even moedig om te maken. Ik ben er zeker van 
dat wat je ook onderneemt, je het tot een goed einde zal brengen. Itati, till lately the ‘mother’ of the 
 
218 Dankwoord 
lab, I miss your drive and dedication, very inspiring to say the least! And I definitely miss your 
cooking; you can always send me a bag of palitto’s as well! I hope we’ll see each other again in the 
near future. En tenslotte, onze voetballer, Frederik. Om het met een adagium te stellen: I hate to see 
you leave, but I love to see you walking away… Het labo is niet meer hetzelfde sinds je vertrek, en dat 
op zoveel vlakken. Het ga je goed bij de buren; af en toe door het raam zwaaien é! 
En dan zijn we bij de vaste waarden – het meubilair als het ware – beland. En dan beginnen we met 
de oudste van de hoop, ons Anouk. Ik denk dat je niet direct beseft, en dat het je ook niet genoeg 
gemeld wordt, hoe belangrijk je voor het labo bent. In zekere zin ben jij de draaischijf (en soms ook 
schietschijf als het nodig is!) van ons groepje. Zowel praktisch (ik kan nog altijd geen deftig cellulair 
experiment doen zonder je visuele hulp te vragen…) als ondersteunend (koffie, koekskes en de 
gazet!) ben je onmisbaar geworden, maar vooral daarbuiten kon ik altijd op je steun rekenen. Onze 
dagelijkse wandelingen naar Ally’s zijn nog steeds essentieel om ons gezond verstand te behouden 
en onze frustraties te luchten, ook al is het vaak éénrichtingsverkeer… ;-p. Merci voor de voorbije 
zeven jaar, en alvast voor de jaren die nog komen! Michel, zonder introductie van alle cellulaire 
immuniteit gerelateerde know-how door jou ging het labo, en zeker ook mijn doctoraat, op zijn gat 
gezeten hebben. Daarbuiten hebben we héél wat fijne momenten beleefd in het labo en daarbuiten, 
culminerend in een avondje sex on the beach in Hong Kong. Trouwens, nog niet al mijn troeven zijn 
uitgespeeld om je de franse beginselen af te leren…! Nu we toch in de juiste sfeer zitten: Bert, nooit 
gedacht dat ik het zou zeggen van een bioloog, maar jouw praktisch inzicht is soms fenomenaal. 
Gebeten door alle vormen van wetenschap, en geobsedeerd door nog zo veel meer dingen. Samen 
met je buurman ontspruiten er soms vreemde gedachtenkronkels uit jullie hoekje, ik hou mijn hart al 
vast voor een eventueel filmpje… En dan de meisjes! Toen Veronique en Kimberly er nog waren, 
zaten we effectief met een kiekenkot, maar ondertussen is het kliekje uitgedund en is iedereen wat 
volwassener geworden. Sarah (of is het toch Sara?), ooit nog mijn thesisstudentje, toen ik nòg 
minder wist en kon als nu, ik ben ervan overtuigd dat je van je project een prachtig verhaal zal 
kunnen maken, zonder probleem! En van Judith verwacht ik ook niet minder; tussen het loodgieteren 
en dergelijke door supergestructureerd deftige experimenten voeren, chapeau! Ik wens jullie allebei 
nog veel succes de komende tijd bij het afwerken van alles en kijk al uit naar het eindresultaat. En 
dan Tine, het manusje van alles dat zonder problemen verbouwingen, een eigen project, werk van 
meerdere andere en het begeleiden van studenten combineert, en er toch nog zo schitterend blijft 
uitzien, nie normaal! Samen met Anouk ben je het bewijs dat een labo staat of valt met de 
laboranten die erin rondlopen. Merci voor alle hulp die je mij en ons labo al hebt gegeven! And then, 
Mister Mexico: working at times when most people are at home, attending every social function 
there is, showering all the ladies with attention… Now that Itati has gone, I wonder who’s going to 
check up on you? ;-) En tenslotte de ‘nieuwe garde’: Silvie, ik ben er vrij zeker van dat we nog niet 
alles weten en gezien hebben van je, maar dat zal zeker nog gebeuren! Koen, ik wens je vooral succes 
met het in toom houden van de vrouwen daar in je buurt… ;-p Lei, all the best for the coming years, 
I’m sure your dedication will pay off! 
Nu zal ik mijn blik verruimen tot buiten ons labo… Francis, ons dubbelspel vraagt nog een beetje 
sleutelwerk, maar ooit worden we Europees bedrijfsportkampioen, ik voel het! Als je trouwens 
binnenkort es ene wil gaan drinken in den Duvel, let me know; ik ben de perfecte chaperon om naar 
daar te gaan! Kristof (Pluisje voor de vrienden), we moeten meer een kamer in Duitsland delen; de 
volgende keer kruip ik wel in bed met jou in plaats van Francis, beloofd. En geen nood, what happens 
in Hamburg, stays in Hamburg… Katrien, onze stuntdubbel, laten we geregeld toch es gaan eten om 
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‘bij te praten’, belangrijk om op de hoogte te blijven é! Charlotje, immer dartelend door de gang aan 
het bewegen, als je nog es gaat shoppen in Parijs, mag ik dan mee? Thx! ;-p. Bram, Dieter, Annelies, 
Evelyn, Leander, Petra, Mouna, Sylviane, Isabelle en Pieter, merci voor alle technische hulp, maar 
vooral om zulke leuke buren te zijn, nu en in het verleden! 
Tante Ria, nu je een verdiep omhoog bent gekropen zal ons contact vluchtiger en minder frequent 
zijn jammer genoeg… Of misschien beter zo, anders zou er van werken niet veel meer in huis komen. 
Tot 21h staan tetteren (lees: roddelen) met Anouk erbij is ook niet bevorderlijk voor mijn huisvrede, 
dus laten we het vooral bij geplande dinertjes en dergelijke houden, een verse traditie om te 
koesteren! Muriel, nog zo’n bron van waarheidsgetrouwe, pittige informatie, ooit nog studentje 
onder mijn vleugels (meest memorabele practicum tot nu toe!). Blijven komen met alle verhalen! 
Iedereen van Unit 7 die mij getroost heeft als Vanessa weer eens zoek was, thx! 
De mensen van alle core-facilities en technische diensten mag ik zeker niet over het hoofd zien; 
steeds zijn ze actief, vaak op de achtergrond, maar wel onmisbaar! Marita, Veerle, Chantal, Myriam 
en Rik; Didier, Steven en Wim; Nancy, Charly en Geert; Ann en Wilma; Daisy, Thomas, Korneel, Tijl, 
Tim, Natalie, Laetitia en alle andere dierverzorgers; Ann, Carine en Christiane; Eef, Wies, Sam, 
Amanda en Evelien; Chantal en Jannick; Pieter (eerste prijs ook voor de meest herkenbare 
aftershave!); en alle andere die ik hier vergeten ben (sorry!). 
Laten we het DMBR even verlaten nu… De voorbije jaren hebben een groot aantal mensen mij 
gesteund als het nodig was, of op zijn minst mij veel plezier en liefde bezorgt. Een kleine 
waarschuwing wel: het kan melig worden met momenten… Schete, wie had ooit gedacht dat de GB 
zo’n invloed op een mens zijn leven kon hebben! Ik mag er niet aan denken waar ik zou staan moest 
ik je niet leren kennen hebben in Middelkerke en terug tegen het lijf was gelopen in Gent; ik ben je 
oprecht dankbaar voor zóveel zaken. Love ya, hunnybunny, en Seba en Julien ook! Mollie, ik zie je 
nog altijd zwaaien naar me de eerste keer dat we elkaar ontmoet hebben in de Irish Pub en met trots 
declareerde dat je goed was in chemie enzo… De band die we door de jaren heen hebben 
opgebouwd is onbreekbaar, me dunkt; als we al samen naar de ‘CD-winkel’ kunnen gaan, zit het wel 
snor. Prinses Wendy, telkens ik je zie, beeld ik me in dat we terug in Juan-les-pins, Antibes of Monaco 
zitten, you stylisch lady! Katy B, jonglerend tussen verbouwer, gids, dierenoppasser en ambtenaar, 
zelden iemand gekend die een tent op Werchter zo proper kan houden als jij! Wel nog effe oefenen 
met die plastuit zou ik zeggen… Misschien moet je Maarten es een aantal tips vragen. Oh ja, als 
Spencer Tunik nog es in de buurt es, hold the presses, frontpage new on the way! Iiris and Don, good 
luck with the new house but even more with the family addition! I wonder how a Finnish-Irish baby 
will look like… As long as he/she is better behaved than Casper! Marlien, altijd rustig en 
gereserveerd, maar in de R&B hebben we je pas echt leren kennen! And last but least (hèhè), Dididel 
de opperklet, veel noten op je zang maar blaffende hondjes bijten niet. Laten we Londen volgende 
zomer maar es goe onveilig maken! 
Sara, Gert, Jeroen, Ryfka en Pjotr, weekendjes en reisjes met jullie zijn steeds educatief 
(begraafplaatsen, hoezee! Eben-Emael, nice!) maar ook zeker ontspannend (Jungle speed met 
bijbehorende kwetsuren, uren plezier in doolhoven verspreid over gans Europa, …). Vooral de bonte 
avonden zijn memorabel… Tis trouwens nog es dringend tijd dat we een quiz winnen, ik wil toch op 
zijn minst éénmaal in mijn leven in De Serrist terecht komen. De Messalina’s rule! Samen kunnen we 
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ook zonder moeite Anderlecht kunnen verheffen tot de beste ploeg die er is (alsof onze hulp 
daarvoor nodig is…). Ik kijk ook uit naar ons eerste bezoekje aan ‘de Hof van Creve’! 
En dan komen we bij de belangrijkste vermeldingen aan. Om te beginnen, mijn ouders en 
grootmoeder. Mama, papa en mémé, ik wil jullie bedanken om mij ten eerste de kans te geven te 
kunnen studeren in Gent. Het blijft een financiële aderlating, zeker als zoonlief net dat iets duurder 
kot (studio dus) wou huren. Bedankt voor de onvoorwaardelijke steun tijdens mijn studies, daarvoor 
en daarbuiten. Ook bedankt aan Tante Lea voor alle goeie zorgen in het verleden en aan de rest van 
de familie (maar die zijn net te talrijk om allemaal te vernoemen!) 
Schete, hoe zou het labo-leven eruit zien zonder jou? Je bent gewoonweg een deel van mijn dag 
geworden. Hoe het zo ver is kunnen komen weet ik zelfs niet meer, maar eigenlijk maakt het niet 
zoveel uit. Ik denk niet dat ik zonder jou in de buurt het tot een goed einde had kunnen brengen; 
merci voor alle steun en zorg van de voorbije jaren! We gaan er sebiet een spetterend feestje van 
maken! Oh ja, en zeg maar tegen Koen dat ik hem ooit wel zal krijgen… ;-) 
Misschien een klein postuum woordje van dank aan Alan Alexander Milne. Wiedadde, denk je nu? 
Wel, het fantastisch brein waaruit Teigetje en Co zijn ontsproten, toch wel een vaste waarde in mijn 
leven geworden ondertussen. Niets kan mij zo opbeuren als de dubbeldikke-dwarsgestreepte-
superstrakke-stuit (gewoon youtube checken, you’ll see!). 
En dan gaan we eindigen in schoonheid. Zoetje, ik weet, je hebt afgezien de afgelopen maanden (of 
meer?). Ik ga het moeilijk hebben om alle maaltijden, afwasbeurten, winkelsessies, … terug te 
betalen. Zonder de liefde, steun en vooral geduld die je me hebt kunnen geven de voorbije jaren was 
dit alles niet mogelijk geweest. Ook al zijn we nu al effen samen, ik ben er zeker van dat onze reis 
samen nog maar net begonnen is. Niets liever zou ik willen dan nog meer mooie en innige momenten 
met je te beleven, zoals we er al veel hebben beleefd; ik hou van je, mijn lieveling! 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
